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 Preface 
The rapidly increasing incidence of adenocarcinoma of the oesophagus, a cancer which arises in 
Barrett’s oesophagus, has created a flurry of interest in this pre-malignant condition. The cancer 
risk involved in Barrett’s oesophagus was variously reported to be between 0.23 and 2% per 
annum and especially the higher estimates resulted in attempts to control the incidence of 
adenocarcinoma of the oesophagus by endoscopic surveillance. However, this proved to be of 
limited use as only 5% of individuals with adenocarcinoma of the oesophagus were found to 
have been previously identified with Barrett’s oesophagus.   
The gastroenterological community in the old Rotterdam University Hospital had a longstanding 
interest in Barrett’s oesophagus and its associated adenocarcinoma. Jan Dees described one of 
the first large series of patients with adenocarcinoma in Barrett’s oesophagus. He also was able 
to conduct a number of the most extensive observational studies into the incidence of 
adenocarcinoma in Barrett’s oesophagus, which found adenocarcinoma of the oesophagus 
incidence rates in the 0.5% per annum range and, in addition, demonstrated that in practice, only 
a small the percentage of patients with Barrett’s oesophagus actually died from adenocarcinoma 
of the oesophagus. In addition, a number of clinical and basic studies from the departments of 
Surgery and Pathology and lately from the department of Gastroenterology and Hepatology have 
maintained Rotterdam in the forefront of Barrett’s oesophagus research. 
After my retirement a survey of the literature on the epidemiology of Barrett’s oesophagus 
produced surprisingly few items. However, there were a number of publications containing data 
which appeared to offer opportunities for further analysis by an author with more leisure time 
than the original authors. These authors who very generously shared their data with me were Dr. 
Clarisse Böhmer (Haarlem, The Netherlands), Dr. Peter Bytzer (Copenhagen, Denmark) and Dr. 
Christine Caygill (London, UK) with whom I was able to co-author the first 4 publications in this 
thesis.  
These publications set me on the path of the study of the epidemiology of cancer of the 
oesophagus in The Netherlands on the basis of the extensive data provided by the Netherlands 
Cancer Registry in Utrecht. Finally, the study testing the hypothesis of an inverse relationship 
between the incidence of adenocarcinoma of the oesophagus and the prevalence of H. pylori 
infection (MDL laboratory, Erasmus MC Rotterdam), added a small element of do it myself. 
 
Mark van Blankenstein 
Berkel en Rodenrijs, November 2006 
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Chapter 1 
 
GENERAL INTRODUCTION AND AIM OF THE THESIS 
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AIM OF THIS THESIS. 
The fact that the presence of Barrett’s oesophagus is thought to be unknown in at least 90% of 
individuals1 suffering from this pre-malignant condition2 has obviously been the central handicap 
in describing its epidemiology. The well known analogy with an iceberg is very apt. It is in 
principle possible to obtain data on the height, circumference and angle of slope of the iceberg 
from observations of its visible part. Although the number of observers of the visible Barrett 
iceberg has been small, because each viewed different areas, they have tended to come up with a 
variety of answers.    
The submerged edges of the iceberg regularly collide with other objects floating in its vicinity; 
we then speak of adenocarcinoma of the oesophagus. These collisions obviously reveal the 
location of some of the outer edges of the iceberg and should be able to provide data from which 
it may be possible to construct a description of its hidden 90%.  
This thesis comprises a number of studies attempting to gain more insight into the epidemiology 
of Barrett’s oesophagus, on the one hand from observing the visible part of the iceberg from the 
broadest possible viewpoint, i.e. relatively unselected patients referred for endoscopy by general 
practitioners or randomly selected individuals who are part of an isolated population, on the 
other hand, from the palpable results of the collisions, the epidemiology of adenocarcinoma of 
the oesophagus and its companion, adenocarcinoma of the gastric cardia. 
 
Outline of the thesis. 
Chapter 1, a general introduction. After defining and describing Barrett’s oesophagus, it then 
traces the history of its development and its relationship to both its predecessor, reflux 
oesophagitis and to its outcome, adenocarcinoma of the oesophagus.  Next an outlines is given of 
the history of reflux oesophagitis. Finally, it provides a brief overview of current thinking about 
carcinogenesis in Barrett’s oesophagus and its relationship to gastro-oesophageal reflux. 
 
Chapter 2 gives an analysis of the incidence of adenocarcinoma in inhabitants of institutions for 
the severely mentally handicapped, in whom the prevalence of Barrett’s oesophagus had 
previously been determined in a randomly selected, but representative group. This population 
was unique, both in its lack of mobility, its social homogeneity and in not consuming alcohol or 
tobacco. 
 
Chapter 3 describes the prevalence of Barrett’s oesophagus in a population of patients referred 
over a 15-year period by general practitioners for endoscopy to a single endoscopic unit in the 
UK. This relatively unselected patient population hopefully provided the closest possible 
approach to an unselected cross section of the general population. By using the total number of 
endoscopies as the denominator, it was possible to establish Barrett’s oesophagus prevalence 
rates by age and gender.  
 
Chapter 4 describes the calculation of the age and gender specific incidence rates of 
adenocarcinoma of the oesophagus, adenocarcinoma of the gastric cardia and squamous cell 
carcinoma of the oesophagus in Denmark. This material was unique as the always difficult 
distinction between adenocarcinoma of the oesophagus and adenocarcinoma of  
the gastric cardia had been made by a panel of gastroenterologists, using original diagnostic data. 
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Chapter 5 reports the first attempt to deduce the size and composition of the invisible Danish 
population with Barrett’s oesophagus from the incidence data for adenocarcinoma of the 
oesophagus established in chapter 4 by the use of a little known statistical method named 
expectation maximalisation.  
 
Chapter 6 provides an analysis of the time trends in the incidence rates of adenocarcinoma of the 
oesophagus and of adenocarcinoma of the gastric cardia in The Netherlands over the period 
1989-2003. It aimed to establish whether both tumours had been equally involved in the overall 
rise in the incidence of oesophageal adenocarcinomas in The Netherlands over this 15 year 
period. 
 
Chapter 7 comprises the first population based study attempting to explain the considerable 
differences in the incidence rates of adenocarcinoma of the oesophagus in 9 Comprehensive 
Cancer Registration regions of The Netherlands from differences in the prevalence of 
Helicobacter pylori infection in four of these regions with contrasting incidence rates. The 
prevalence of Helicobacter pylori infection was determined in 400 blood donors from each of 
these four regions, divided into 5 ten-year age groups,  
 
Chapter 8 the final chapter, contains a summary and a discussion of the findings presented in 
this thesis. 
 
. 
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Barrett’s oesophagus 
Definition  
Barrett’s oesophagus, more scientifically known as columnar lined oesophagus, is the 
eponymous description of the metaplastic change from squamous to columnar epithelium 
occurring in the lining of the distal oesophagus.  
Barrett’s oesophagus can extend over distances ranging between a few millimetres to less than 3 
cm in  short or ultra-short segment Barrett’s oesophagus3-6 or to more than 3 cm in long segment 
Barrett’s oesophagus. As is the case with other metaplastic epithelia, Barrett’s oesophagus is a 
pre-malignant condition which precedes practically all adenocarcinomas of the oesophagus 7, 8.  
Originally, three main histological types of Barrett’s oesophagus were described. These were 
atrophic gastric fundic-type epithelium with parietal and chief cells; junctional-type epithelium 
with cardiac mucous glands and intestinal-type epithelium with a villiform surface, mucous 
glands and intestinal-type goblet cells9. A notable finding was that, when present, specialized 
columnar epithelium was almost always the most proximal and gastric fundic epithelium the 
most distal, with junctional epithelium interposed between these two. Such zonation has since  
both been confirmed and denied in series of oesophageal resection specimens containing 
adenocarcinoma of the oesophagus in Barrett’s oesophagus2, 10.  
The finding that only specialised intestinal metaplastic epithelium was associated with 
adenocarcinoma of the oesophagus,7, 10-12 resulted in the definition of Barrett’s oesophagus being 
narrowed down to those cases where specialised intestinal metaplastic epithelium was present13, 
14. Although this refinement had pragmatic advantages in limiting the number of patients 
qualifying for endoscopic surveillance, it obviously raised the question what, if any, was the 
prognostic relevance of columnar lined oesophagus without specialised intestinal metaplastic 
epithelium. 
Surprisingly little, or rather, no attention has been focussed on the further natural history of 
columnar lined oesophagus without specialised intestinal metaplastic epithelium. The present 
definition would appear to imply the existence two separate forms of metaplasia, one pre-
malignant and the other innocent. However, in resected cases of adenocarcinoma of the 
oesophagus, both specialised intestinal metaplastic epithelium and gastric mucosa have been 
shown to exist together in the same specimen2, 7, 10.  
In a large series of long segment Barrett’s oesophagus patients, the prevalence of specialised 
intestinal metaplastic epithelium ranged from 71% in Barrett’s oesophagus segments of 3-6 cm 
to 81% in 6.1-10 cm segments and 100% in segments > 10.1 cm. In addition, cardiac mucosa 
was also found in all cases, again confirming that both types of metaplasia co-exist and may 
represent either parallel or consecutive stages of metaplasia15.  
Clinically, the UK National Barrett's Oesophagus Registry follow up of 232 patients with long 
segment Barrett’s oesophagus over 402 patient years, found a 0.5% adenocarcinoma of the 
oesophagus incidence rate for both patients with and without specialised intestinal  
metaplastic epithelium at their initial biopsy16. Obviously, in a number of cases the absence of 
specialised intestinal metaplastic epithelium may well have been the result of sampling error; 
however, this study calls into question the validity of limiting the diagnosis of Barrett’s 
oesophagus for prognostic purposes to the presence of specialised intestinal metaplastic 
epithelium. It is therefore understandable that the British Society of Gastroenterology has  
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recently abandoned the requirement of specialised intestinal metaplastic epithelium for the 
diagnosis of Barrett’s oesophagus17. 
Anatomical boundaries 
The proximal boundaries of Barrett’s oesophagus are clearly delineated and their recognition 
only requires attention to detail from the endoscopist. Although it is not unusual to find some 
erosive oesophagitis above the proximal limit of Barrett’s oesophagus, this upper  limit would in 
general appear to be stable,18 although in the older literature, before effective treatment was 
available, the upward ascent of the squamo-columnar junction was occasionally observed19-23. 
The distal boundary presents a far more complicated problem. In principle, Barrett’s oesophagus 
comprises all columnar epithelium proximal to the original squamo-columnar junction 24. 
However, in view of the similarity between the columnar epithelium of the cardia and columnar 
lined oesophagus, in Barrett’s oesophagus this landmark is no longer recognisable. Columnar 
epithelium found at a distance greater than 2 cm above the proximal margin of the gastric folds  
currently offers a popular surrogate marker for the original squamo-columnar mucosal junction25.  
However, for careful endoscopists, a remnant of the palisadal capillary pattern above the original 
squamo-columnar junction is frequently still visible26 and can often best be seen in high 
retrovision (personal observation). 
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HISTORICAL OVERVIEW 
Barrett’s Oesophagus 
In 1950 Barrett published his paper “Chronic peptic ulcer of the oesophagus and oesophagitis ”27 
with which he hoped to resolve the existing interdisciplinary confusion between these two 
entities. He argued, citing Allison,28 that reflux oesophagitis caused superficial ulceration, 
fibrosis and shortening of the oesophagus producing  an intrathoracic segment of stomach in 
which peptic gastric ulcers can develop,  a condition previously described by Allison, Johnstone 
and Royce29. Barrett was, in fact, at pains to deny the existence of the condition which 
subsequently bore his name. He did however, subsequently change his mind in 1957 in a paper 
titled:” The lower esophagus lined by columnar epithelium”30. His most novel observation was 
that “a benign stricture at the level of the aortic arch should suggest that the lower esophagus is 
lined by columnar epithelium because sliding hiatal hernias are not usually as large as this”. He 
considered the columnar lined oesophagus was “probably the result of a failure of the embryonic 
lining of the gullet to achieve normal maturity”. 
In 1951 Bosher and Taylor described a case with a peptic stricture in the oesophagus at the level 
of the aortic arch and the distal oesophagus lined by gastric mucosa31. Two years later, Allison 
and Johnstone described 7 similar patients in whom, on the basis of anatomical landmarks i.e. the 
absence of peritoneal covering and the presence of squamous islands, they concluded the 
oesophagus to be lined by a gastric type of mucosa.  These patients also had sliding hiatal 
hernias, a condition which Allison had previously described in combination with gastro-
oesophageal reflux, and superficial peptic ulceration and stricture  of the oesophagus32. They 
mentioned the possibility that the healing of ulcerated squamous epithelium in an acid 
environment might involve the overgrowth by gastric epithelium33.  
In 1961 this hypothesis was expanded by Hayward in a rather iconoclastic publication in which 
he criticised his predecessors. He ridiculed the concept of a congenital cause for gastric 
epithelium in the oesophagus, citing  a series of 25 cases with an average age 62 in whom 
columnar epithelium had been found to extend an unusual distance up the oesophagus 34. He 
summarised the current views as follows: “Medical reasoning about an abnormally long length 
of oesophagus lined by junctional epithelium seems to have proceeded along the following lines: 
1) The oesophagus is lined by squamous epithelium. 2) Oesophagus lined by columnar 
epithelium is not oesophagus.  3) Since columnar epithelium is not oesophageal, it must be 
gastric.4) Therefore columnar epithelium in the oesophagus must be ectopic gastric epithelium. 
5) As it is ectopic, it must be congenital. It would not matter if this reasoning remained on the 
theoretical plane without practical consequence, but this is not the case. There are two more steps 
in the reasoning.6) Congenital anomalies are permanent.7) There is only one thing to do with 
parts which are permanently abnormal, are causing trouble, and can be done without, and that is 
to cut them out.” He defined the oesophago-gastric junction as a segment of junctional mucosa 
within which he projected the cardia as the functioning muscular sphincter. He then argued that, 
reflux from the stomach, resulting from a failure of the cardia and caused by a sliding hiatal 
hernia, digested the squamous epithelium. This allowed metaplastic junctional epithelium to 
creep up to the level of the aortic arch or higher. He believed this process to be reversible35. 
A masterful overview was given by Adler in 196336 in which  he considered the two possible 
causes of columnar lined oesophagus. He rejected the congenital theory, according to which 
columnar lined oesophagus resulted from an incomplete replacement of the columnar epithelium  
 12
by squamous epithelium during foetal development. As this replacement starts in mid-
oesophagus and progresses to each end, there was no reason for columnar lined oesophagus only 
to be found in the distal oesophagus. On the basis of the observed ascent of the squamo-
columnar junction observed by a number of authors19-22, he opted for the acquired theory in 
which columnar lined oesophagus resulted from “an adaptive epithelial change in response to the 
chronic abnormal (acid-pepsin) environment of the oesophagus”. In addition, if the columnar 
lined oesophagus was congenital in origin and produced acid, it would produce symptoms at an 
early age instead of the observed incidence in middle or late life. He summarised three possible 
sources of the columnar lined oesophagus: extension upward from the stomach, metaplasia and 
extension from the cardiac glands, finally opting for the latter as the glands were seen to 
hypertrophy, possibly to protect the deeper layers of the oesophagus. He also advanced the 
possibility that adenocarcinomas originated in columnar lined oesophagus, citing Morson37 who 
had suggested that repeated attacks of inflammatory gastritis led to a pre-malignant intestinal 
metaplasia similar to that encountered in the stomach.  
In 1966 Mossberg reported a young man with “psychogenic vomiting, in whom 3 oesophago-
scopic biopsies taken over a 32 months period, confirmed the appearance of columnar epithelium 
in areas which had previously contained normal squamous epithelium.  He concluded that the 
“ascent” of the columnar lining resulted “from gastro-oesophageal reflux, oesophagitis and 
regeneration of the destroyed oesophageal lining by columnar rather than squamous 
epithelium”23.  
In 1970 Bremner et al. were the first to succeed in inducing columnar lined oesophagus 
experimentally in a canine model. They dissected 6-10 cm of distal oesophageal mucosa away 
from the muscular wall in 3 groups of dogs. In 2 groups, reflux was induced by creating a hiatal 
hernia and performing cardioplasty. In addition, acid production was stimulated by injections of 
histamine in 1 of the 2 reflux groups. The most extensive columnar regeneration was seen in 
dogs with reflux and histamine stimulation, the least in dogs without reflux. This study 
demonstrated that, under conditions of gastro-oesophageal reflux, destroyed squamous 
epithelium was replaced by columnar epithelium and that the degree of acidity of the refluxate 
influenced the extent of this metaplasia. In common with Hayward,35 the source of  the columnar 
lined oesophagus was thought to be upward migration of gastric or junctional epithelium38. 
The latter hypothesis was challenged by Gillen et al. in1988. In their canine model a 2-cm high 
circumferential ring of squamous mucosa was removed from the distal mucosa, leaving a small 
strip intact to identify the squamocolumnar junction. Above this ring a 2-cm high ring was left 
intact and above this, a further 2-cm high ring was resected. Four groups of dogs were, in 
addition, subjected to: 1) cardioplasty, hiatal hernia and pentagastrin injections 38, 2) cardio-
plasty, hiatal hernia and a common bile duct ligation with cholecystogastrostomy (bile+ acid 
group), 3) similar to group 2, with additional cimetidine treatment,  4) only the two 
circumferential resections, the lower oesophageal sphincter left intact. A fifth group, unoperated 
before sacrifice, supplied multiple longitudinal sections from lower oesophagus to upper stomach 
as normal histological controls. Columnar lined oesophagus was only found in both rings in 2/6 
dogs in group1. In group 2, columnar lined oesophagus was only found in the lower ring of 3/6 
dogs while in group 3, under cimetidine, no columnar lined oesophagus was found. Where 
columnar lined oesophagus was absent, regeneration was by squamous epithelium. This study 
showed that it was possible for columnar lined oesophagus to arise in areas not contiguous with 
gastric or junctional epithelium. There was no additive effect of bile while acid inhibition 
prevented regeneration by columnar lined oesophagus. In ulcerating areas, where re- 
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epitheliasation was ongoing, this was seen to be extending from the necks of oesophageal gland 
ducts, suggesting that these were the source of the columnar epithelium39. 
This concept was in turn challenged by a study by Seto and Kobori in a rat model in which total 
gastrectomy and oesophago-jejunal anastomosis induced bile and pancreatic reflux. In addition, 
half of the rats drank syrup with HCl at a ph of 1.8. Reflux oesophagitis was found in all rats, in 
those sacrificed at 12 weeks all 3 had developed columnar lined oesophagus. In some, islands of 
columnar epithelium surrounded by squamous epithelium and distant from the site of the 
anastomosis were found. As rats do not possess oesophageal glands, these islands must have 
resulted from metaplasia of the squamous epithelium40. 
These studies, having lain to rest the congenital origin of Barrett’s oesophagus and having 
confirmed the link to gastro-oesophageal reflux disease, resulted in the search for the aetiology 
of Barrett’s oesophagus shifting to the causes of reflux oesophagitis.  
Barrett’s oesophagus and adenocarcinoma of the oesophagus 
In 1950 Carrie described a case of “adenocarcinoma of the upper end of the oesophagus arising 
from ectopic gastric epithelium.” , currently known as the inlet patch41. He cited Hewlett  who 
suspected that this ectopic gastric mucosa could give rise to adenocarcinoma but found that none 
of the 6 published cases had occurred in the upper oesophagus42.  He consequently remarked: 
“Since then, adenocarcinoma of the upper end of the oesophagus had become somewhat like a 
unicorn, for while the authors of most text-books state that this tumour does occur, they do not 
state that they have seen it themselves, and fail to state who did.” None of the 19 cases of 
adenocarcinoma of the oesophagus seen in his department over the previous 15 years involved 
this area.  
The first clear case of adenocarcinoma of the oesophagus in Barrett’s oesophagus was published 
by Morson and Belcher in 1952. The patient, a male aged 56, underwent a partial oesophageal 
resection for an adenocarcinoma at the level of the tracheal bifurcation. The mucous membrane 
above the tumour was squamous, below glandular, apart from a few islands of squamous 
epithelium. The distal part of the resected specimen “corresponded closely to normal cardiac 
type gastric mucous membrane”. “However, most of it showed chronic inflammatory and 
atrophic change with a tendency towards an intestinal type containing many goblet cells.” The 
authors commented on the rarity of adenocarcinoma of the oesophagus but considered it to be an 
entity which could arise in islands of ectopic gastric mucosa, or, as in this case, from a congenital 
abnormality of the oesophagus lined by a gastric type of mucosa37. Morson’s description, as was 
to be expected from this outstanding pathologist, encompassed all the features of  what is now 
known as adenocarcinoma of the oesophagus in Barrett’s oesophagus, including the finding that 
the histological changes increased in an oral direction. There may, however, have been an earlier 
case in the literature. In a1935 case record 21521 from the Massachusetts General Hospital, a 61-
year old male was presented suffering from coronary artery disease who developed upper 
abdominal discomfort and mild dysphagia. A x-ray examination (by Richard Schatzki who had 
by then emigrated from Germany to the US) revealed an oesophageal diverticulum at the level of 
the aortic arch, where there were also changes suggestive of  varices and a distal stricture over 4 
cm with the fundus of the stomach protruding through the diaphragmatic hiatus. An 
oesophagoscopy was stated to have found haemorrhagic mucosa at 11.5 inches, i.e. 29 cm. from 
the front teeth. The biopsy was reported as epidermoid carcinoma. After a symptomatic 
remission on x-ray therapy the patient died and autopsy was performed. The tumour proved to be  
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an adenocarcinoma extending upwards from the ‘cardiac orifice’. The “varices” were found to 
have been submucosal metastases, extending along the lymphatics and mostly covered by normal 
squamous epithelium. Mallory, the pathologist provided a beautiful description of this now 
classic endoscopic finding which is only seen with adenocarcinomas, but which was then for him 
a novelty43. Was this a true case of adenocarcinoma of the oesophagus in Barrett’s oesophagus? 
It was obviously an adenocarcinoma of the gastro-oesophageal junction, there is no mention of 
tumour in the fundus and there was a hiatal hernia which was, of course, spotted by Schatzki.  
Another early case of adenocarcinoma of the oesophagus in Barrett’s oesophagus was 
mentioned, but not commented on, by Allison and Johnstone in their 1953 paper33. 
A third case was described by Thomas et al in 1954, who apparently were not aware of the 
Morson case. They did cite  6 cases described by Hewlett in 190042 and one by Feldman in 
193944.   
In 1956 Smithers reviewed a number of cases of adenocarcinoma of the oesophagus. His case 
series, which was started in 1936, while illustrating some of the confusion still attending this 
subject, was also one of the first to distinguish the adenocarcinomas of the oesophagus, the 
gastric cardia and the gastro-oesophageal junction.  He cited 6 ways in which adenocarcinoma of 
the oesophagus were thought to arise, 1. from ectopic islets of gastric mucosa, 2. a section of the 
oesophageal mucosa which had failed to undergo squamous transformation before birth, 3. 
mucosa which had undergone some glandular metaplasia following attrition or long standing 
infection, 4.minor extensions or folds of gastric mucosa lining the hiatal canal, 5. a congenital 
short oesophagus and 6. lymphatic spread of gastric tumours. It is interesting to note that this at 
first sight strange collection was actually describing Barrett’s oesophagus in items 2, 3 and 5 and 
short segment Barrett in 4. Smithers noted that if adenocarcinomas did arise in superficial glands 
they should also be seen at the proximal end of the oesophagus surrounded by squamous 
epithelium, the earlier cited unicorn. He also pointed to the difficulty in distinguishing between 
adenocarcinoma of the gastric cardia and the oesophagus. He finally concluded that the finding 
that the oesophageal mucosa was not uncommonly partly lined by gastric mucosa and the interest 
in hiatus hernia had resulted in the more frequent diagnosis of oesophageal adenocarcinoma and 
the acceptance of the existence of this tumour.  In spite of the fact that he considered that 
oesophageal adenocarcinoma mainly arose in mucosa which has failed to undergo squamous 
transformation, he continued to divide his cases of adenocarcinoma of the oesophagus into 26 
without and eight with an hiatal hernia45.  
In 1968 Lortat-Jacob described 16 cases of primary oesophageal adenocarcinoma found in the 
resected specimens of 558 patients undergoing resection for oesophageal cancer. He excluded 85 
cases which he considered to have originated in the cardia and cases originating from gastric 
cancer metastases.  He distinguished three groups, the first in which the tumour developed above 
the cardia and was surrounded by squamous epithelium. In one case the tumour was located at 32 
cm with squamous epithelium distal to it. In the other two cases the anatomical relationship with 
the cardia was not described. The second group comprised 7 cases of “squamous and glandular 
carcinomas and cylindromatous carcinomas” localised in the middle and distal third of the 
oesophagus and finally 6 cases of adenocarcinoma in columnar epithelium. The latter he 
considered to be caused by malignant degeneration of peptic ulcers of the “endo-brachy-
oesophagus as Barrett’s oesophagus was termed in France. He considered that these tumours 
“must be distinguished from adenocarcinomas of the cardia associated with a short oesophagus”, 
a difficult distinction which suggests that some of the tumours classified as adenocarcinomas of 
the cardia were in fact adenocarcinoma of the oesophagus46. 
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The publication which put adenocarcinoma of the oesophagus squarely on the map was by Naef 
et al. who found 12 cases of adenocarcinoma of the oesophagus in 140 patients with extensive 
Barrett’s oesophagus. These had been identified in 3, 981 patients with hiatal hernia and reflux, 
in 1,225 of whom reflux oesophagitis had been found. In a number of patients the upper level of 
Barrett’s oesophagus had been seen to ascend at repeated endoscopies, thus finally proving the 
acquired nature of Barrett’s oesophagus. He considered that the 8.5% incidence of 
adenocarcinoma of the oesophagus in Barrett’s oesophagus to indicate a significant causal 
relationship47. In 1978 a series of 71 oesophageal cancers referred for surgery to Rotterdam over 
a 4-year period and seen in the endoscopy unit of the Rotterdam University Hospital, was 
reported to the British Society of Gastroenterology. Forty-four were squamous cell cancers and 
27 adenocarcinomas. Of the latter, 16 were adenocarcinoma of the oesophagus in Barrett’s 
oesophagus, none of which had previously been recognised as such48. 
Having identified this premalignant condition, the medical profession was confronted with the 
question of: what to do? The obvious answer was prevention, treatment or if both were 
impossible, endoscopic surveillance. In 1983 Spechler voiced a certain enthusiasm for this 
approach49. However, a year later, after observing an incidence of only one adenocarcinoma in 
175 patient-years, Spechler already questioned the value of endoscopic surveillance for patients 
with Barrett’s oesophagus50. However, this view proved unpopular in a dynamic profession and a 
spate of publications appeared over the next 15 years, reporting far higher cancer incidences than 
found by Spechler and emphasising the importance of endoscopic surveillance. A considerable 
number with the highest cancer incidence rates probably owed their appearance in print to 
publication bias51.  
In Rotterdam, where annually scores of patients with adenocarcinomas in Barrett’s oesophagus 
were seen and consequently the clinical importance certainly not underestimated, Dees decided 
to  approach the problem from the viewpoint of the risk run by patient with Barrett’s oesophagus. 
He organised a follow up of 155 patients with Barrett’s oesophagus, diagnosed between 1973 
and 1986. In two consecutive observational studies, separated by 8 years, he found a constant 
adenocarcinoma incidence of 1/180 patient-years. In addition he established that of the 79 
patients who had died, 5 had developed adenocarcinoma of the oesophagus but only 2 had died 
from their tumour52, 53. At a third review in 2002, the incidence rate was still found to be the 
same54,in addition, it revealed that 44 survivors, diagnosed at an average age of 49.6 years, had 
experienced an average ACO free interval of 20 years (range 16.3-26.5 years). 
The debate remains ongoing55. 
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REFLUX OESOPHAGITIS. 
Origins of the concept 
The description of this condition originated from two different disciplines, radiology and 
endoscopy. 
In 1925 Friedenwald and Feldman described the radiological and clinical findings of what would 
now be termed a hiatal hernia56. This concept was developed by von Bergmann in Germany57 
and by Hurst in Britain58. Hurst, citing Knothe59 and Schatzki60, noted that the radiological 
findings could frequently be induced in asymptomatic individuals by increasing intra-abdominal 
pressure, especially in patients over the age of 60. However, there were a number of patients 
with symptoms of: “ pain or a feeling of pressure immediately after swallowing, under the 
xiphisternum or a little to the left, and occasionally in the back; it may radiate to the heart and to 
the left arm and may closely simulate angina. Acid regurgitation is common; occasionally 
vomiting is the only symptom.” “The attacks are in most cases mainly or exclusively nocturnal 
and disappear on sitting up; severe night pain may simulate gall-stones. Intermittent dysphagia 
may occur.”  To prevent nocturnal attacks, raising the head of the bed as far as possible was 
advised, an approach which was still popular until the introduction of effective acid suppression 
in the 1980’s. However, the link between, gastro-oesophageal reflux oesophagitis and the 
radiological diagnosis of hiatal hernia had not yet been laid. 
According to Cross, reflux oesophagitis was first described by Quinke in 1879 and by 
MacKenzie in 188461. However, the present endoscopic concept of peptic oesophagitis was 
formulated by Winkelstein in 1935 on the basis of five cases. He described it as a chronic disease 
of elderly men “characterized by exacerbations and remissions resembling those of peptic ulcer.”  
Three patients had duodenal ulcer, one a peptic ulcer of the oesophagus and one developed a 
lesser curve ulcer. All had “hyperchlorhydria” on the basis of then current tests. In addition, “the 
types of substernal pain, heartburn, sour regurgitations and the hyperchlorhydria in all (patients 
vB.) recall the clinical features of peptic ulcer of the esophagus which have been described in 
this country by Jackson and Friedenwald.”  “However, the esophagoscopy (and radiography, 
which had shown spasm and irregular narrowing (and was the usual indication for endoscopy, 
vB.)  in the cases described here reveals a diffuse inflammation without a definite ulcer”. He 
concluded that this “peptic esophagitis” probably resulted “from the irritant action on the mucosa 
of free hydrochloric acid and pepsin”62. Chevalier Jackson, a prominent oesophagoscopist of that 
era, was in “hearty accord” with Winkelstein and pointed out the relation of this condition with 
the ‘herniated stomach’ and that “the chief reason..... why so little has been heard of peptic 
esophagitis is that so few esophagoscopies are done in patients with gastric symptoms”. 
This lack of (rigid) endoscopic examinations and the fact that peptic ulcer of the distal 
oesophagus could simply be diagnosed by radiology, resulted in it remaining the most commonly 
diagnosed form of peptic oesophageal disease during the nineteen-forties and -fifties. 
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MECHANISMS OF REFLUX OESOPHAGITIS. 
Anatomical studies. 
In his 1946 paper Allison stated that “ulcer (of the oesophagus vB.) occurs where there is such a 
derangement of the mechanism of the cardia that acid gastric juice flows back easily into the 
lower end of the esophagus”. “The disorder which predisposes to ulceration is hernia of the 
stomach through the diaphragmatic hiatus into the posterior mediastinum.” He operated on two 
patients with a radiological diagnosis of short oesophagus and found that “the stomach could be 
replaced easily in its normal position in the abdomen without tension in the esophagus.” This 
may have undermined his belief in the short oesophagus. In his 1948 paper28 he summarised the 
anti-reflux mechanisms of the cardia as the combination of the angle between the oesophagus 
and the fundus and the thick walled tunnel of the diaphragmatic crura, which, by contracting 
during inspiration, prevent both the stomach contents from passing up the oesophagus and the 
cardia from being drawn into the mediastinum by the increased pressure within the abdomen and 
the suction from the chest. This mechanism was obviously lost in sliding hiatal hernias of the 
cardia and by the presence of heterotopic gastric mucosa in the oesophagus. He noted that in 
para-oesophageal hiatal hernias where the cardia remained below the diaphragm, the cardia 
remained competent. In 1951 Allison described 206 cases of hiatal hernia, 170 of which were 
sliding hernias, 34 more or less para-oesophageal and only one a congenital short oesophagus63. 
He also described the application of metal Cushing brain clips to the squamocolumnar junction 
to observe its localisation radiographically, a technique which was recently revived64. He now 
emphasised the role of the right crus of the diaphragm which, after splitting to form the hiatus, 
formed a sling for the oesophagogastric junction, and in analogy with the pubo-rectalis sling, 
compressed it against the spine. In addition, it maintained the angle of His. In 1959 Cross et al  
found hiatal hernias in 103/ 130 patients with oesophagitis61. However, the importance of such 
anatomical aspects, and specifically the relevance of the crural diaphragm and consequentially, 
hiatal hernia, on oesophagitis, was to undergo considerable ups and downs over the following 
decades as the focus of attention shifted to the lower oesophageal sphincter. A study by Cohen 
and Harris published in 1971 and titled “does hiatus hernia affect competence of the 
gastroesophageal sphincter” signalled the nadir of the hiatus hernia. These investigators 
compared patients with severe symptoms of gastroesophageal reflux and asymptomatic patients 
with and without hiatus hernia. ”Symptomatic patients were readily separated from 
asymptomatic ones by their weaker base-line sphincter strength and decreased sphincteric 
response to the stimulus of an increase in intra-abdominal pressure.  However, neither in the 
asymptomatic group nor in the symptomatic groups of patients could any effect of hiatus hernia 
be found”. They concluded that “the rationale for surgical repair of hiatus hernia in patients with 
gastroesphageal reflux must therefore be questioned”65. It took over 15 years before Mittal et al. 
demonstrated the vital effect of the crural diaphragm on the lower oesophageal sphincter 
pressure, specifically in relation to increased intra-abdominal pressure66, 67, and even longer for 
Kahrilas et al. to restore  the  hiatal hernia to its proper place in the pathophysiology of gastro-
oesophageal reflux64. 
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Defective motility. 
In 1883 Kronecker and Meltzer were the first investigators to study the patterns of oesophageal 
pressure changes during swallowing by means of small balloons68. In 1953 Butin et al. published 
the first oesophageal pressure measurements by means of an electric transducer, originally 
intended to record intravascular pressures. The transducer was mounted on the distal tip of 
gastric tube. They described the “normal swallowing complex” consisting of “an initial wave of 
negative pressure and three subsequent waves of positive pressure”. The first positive wave was 
thought to represent the passage of the swallowed material, the others “a distally moving, 
peristaltic wave of contraction in the esophagus”69. In the same year Sanchez et al. published a 
manometric study focussed on the distal oesophagus. The used two open tipped water filled 
catheters attached to each other, with their tips 8 cm apart. While arriving at similar results as 
Butin et al. they could demonstrate the peristaltic nature of the positive wave which they reduced 
to one by registering dry swallows. Their most significant finding was in the distal oesophagus, 
in what they termed the vestibule, where they noted the absence of the positive peristaltic wave 
which led them to suggest “that this distal portion possesses an independent motor function”70. In 
1956 Fyke et al.71 and a year later Atkinson et al.72 were able to demonstrate manometrically the 
presence of the lower oesophageal sphincter and to measure its strength.  
But 10 years later Pope concluded that, “the level of pressure recorded from this area has been 
equated with sphincter competence by most workers. However, other investigators have not 
found a good correlation between sphincter pressure and the presence or absence of reflux”73. 
This problem was not resolved, with important overlaps in lower oesophageal pressures between 
normals and patients with reflux oesophagitis still being found by Kahrilas et al. in 1986. 
However, in addition to the aforementioned overlap, they introduced the factor oesophageal 
peristaltic dysfunction into peptic oesophagitis. This manifested itself in failed primary 
peristalsis, i.e. no peristaltic contraction following deglutition or if the peristaltic contraction did 
not traverse the entire length of the oesophagus. In addition, peristaltic amplitude in the distal 
oesophagus was significantly lower in oesophagitis, with the degree of peristaltic dysfunction 
increasing with more severe degrees of oesophagitis74. The authors pointed to the link between 
their findings and the earlier studies demonstrating prolonged acid clearance in reflux 
oesophagitis75. However, it needed the concept of inappropriate complete lower oesophageal 
sphincter relaxation to advance the problem of correlating sphincter pressures with reflux 
oesophagitis76. 
Experimental reflux oesophagitis. 
(Note, this section is both detailed and contains some gruesome details, general readers and 
anti-vivisectionists are advised to skip it) 
 
The first successful attempt at inducing oesophagitis experimentally would appear to have been 
in 1950 by Ferguson et al. They cited a number of earlier, unsuccessful studies including that by 
Friedenwald who had failed to induce ulcers by plain HCl without previous mechanical ablation 
of the mucosa.77 They employed a wide selection from the animal kingdom including humans 
(cadavers), dogs, cats, rats, guinea pigs, and hamsters. Gastric juice was brought into contact 
with the oesophageal mucosa, either by making the animal vomit or regurgitate, or by perfusion 
with gastric juice from dogs or humans, the former without or after histamine or pilocarpine  
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stimulation, the latter all after histamine stimulation. The pH values were between 1.2 and 1.7 
and 1.4 and 1.9 respectively. In addition, the pylorus was ligated and histamine injected in a 
number of animals while in others the duodenum was ligated distal to the bile and pancreatic 
duct. Vomiting was induced by apomorphine, ether anaesthesia or increased intracranial 
pressure.  
As can be imagined, the enormous diversity of experiments produced a large variety of results. 
However, the final conclusion was that acid gastric juice with peptic activity has a prompt and 
devastating effect, this in contrast to plain HCl. The addition of bile or pancreatic secretions by 
ligation of the distal duodenum, actually inhibited  the effect of gastric juice78. 
A year later, in a rather more focussed study from the same centre, Cross and Wangensteen 
perfused the oesophagi of cats for a maximum of 8 hours, with canine bile, pancreatic juice, a 
combination of these two, sodium taurocholate and glycocholate, jejunal juice and human bile. 
With the exception of jejunal juice, all these fluids caused more or less severe oesophagitis. In 
dogs, duodeno-oesophagostomies, cholecystojejuno-oesophagostomies, jejuno-oesophago-
stomies and total gastrectomies with end to end oesophago-duodenostomies were constructed to 
cause diversion or regurgitation of bile and pancreatic juice, pancreatic juice or bile alone, and 
succus entericus into the oesophagus. They were endoscoped at regular intervals and sacrificed 
after 1-3 months. Bile and pancreatic juice, singly or in combination produced oesophagitis 
which induced anaemia with guiac positive stools. The presence or absence of the acid secreting 
part of the stomach and total gastrectomy made no difference, interpreted as excluding gastric 
juice regurgitation as a factor involved in causing oesophagitis in this model.  Only succus 
entericus and oesophago-antral anastomosis with pyleroplasty (i.e. adequate drainage) failed to 
produce oesophagitis. An important conclusion was that when total gastrectomy is performed in 
man, alkaline oesophagitis, caused by regurgitation from the duodenal loop, should be prevented 
by a Roux-Y-plasty,79 a conclusion which needed to be repeated regularly over the subsequent 
25 years80. 
In 1959 Redo performed perfusion studies in the canine oesophagus for up to 8 hours, comparing 
the effects of gastric juice, pepsin, hydrochloric acid, bile and combinations of these. In addition, 
he examined the effects on various isolated segments of the oesophagus. Both gastric juice and 
HCL with pepsin at a pH < 2, the latter with an optimum at a concentration of 2%, caused severe 
erosions and ulceration. After dialysis the effect of gastric juice was enhanced, suggesting an 
inhibitory factor had been removed. Bile alone had little effect and in combination with 
pancreatic juice occasionally produced slight erosions. The activity of gastric juice was actually 
inhibited by bile.  
The susceptibility of the 3 segments to the ulcerogenic factors tested was found to be similar81. 
These three studies confirmed the effects of gastric juice with pepsin but the two later studies on 
bile and pancreatic juice produced somewhat divergent results. While Cross and Wangensteen in 
both their chronic dog model and in their 8-hour cat perfusion experiments, recorded severe 
effects of these two fluids, the Redo canine perfusion study, which also had a maximal duration 
of 8 hours, found only minor damage from bile and pancreatic juice without HCl79, 81. Both 
species differences and time scales may have been responsible for these divergent results. 
However, in 1972 Henderson et al confirmed the lack of effect of bile alone in dogs by chronic 
perfusion studies, 4 hours daily over a 21 day period. Perfusates consisted of dog bile, 
taurocholate, taurodeoxycholate and glycocholate with and without HCl. The effects were 
monitored by endoscopy and examination after sacrifice at 21 days. In contrast to the Cross and 
Wangensteen chronic dog study, severe oesophagitis was only induced by bile and bile-acids  
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when combined with HCl. The greatest effect was seen from the taurocholate-HCl combination. 
In addition, they registered motor defects, specifically of the high pressure zone similar to those 
found in patients with hiatus hernia. In these dogs the motor disorder was reversible after the 
healing of the oesophagitis82. 
In the same year Gillison et al. employed a chronic monkey model in which the distal 
oesophagus was resected to create reflux. In addition, bile was either excluded from the stomach 
by a Roux-Y procedure or shunted into the stomach by a cholecysto-gastro-stomy, the latter 
group including a subgroup subjected to stimulated acid production by regular histamine 
injections. The effects were examined by endoscopy at one and three months. Reflux with gastric 
juice alone produced only mild oesophagitis; gastric juice contaminated with bile produced more 
substantial oesophagitis ranging from mild to ulceration. Histamine stimulation produced no 
additional effects83. 
 
These 3 chronic studies, demonstrating the effects of bile and/or pancreatic juice, again produced 
divergent results. In the Cross and Wangensteen surgical model no HCl was involved79, in the 
Henderson chronic perfusion model the addition of HCl was essential82 and in the Gillison model 
there was only a minor role for gastric juice. Here, however, in contrast to the Redo findings, the 
activity of gastric juice was enhanced by bile83. Apart from the dangers of alkaline reflux, no 
final, clinically relevant, conclusion could be drawn from all of these experiments. 
 
In 1975 Safaie-Shirazi et al. expanded the field of enquiry by addressing the hypothesis of a 
“mucosal barrier” to H+, which, when broken, allowed the escape of H+ from the lumen. This 
barrier had been shown to exist in gastric mucosa and bile salts were found to have been 
responsible for its breaching. They instilled an HCl solution with and without various 
concentrations of bile salts in isolated oesophageal segments of dogs. The net ion flux was 
determined after 30 minute periods. Bile salts induced a 4-fold higher loss of H+ and Cl- than 
plain HCl. Increasing concentrations of bile salts had no additional effect on the ion flux. In 
addition, severe necrotizing oesophagitis was caused by the combination of HCl and bile salts. A 
similar experiment was performed in humans  
where the distal oesophagus was occluded by a Sengstaken-Blakemore tube, bile salts producing 
a 5-fold increased H+ loss84. The concept of a mucosal barrier to H+ which could be breached by 
bile salts, or possibly, other detergent or enzymatic substances, was established by this study. It 
explained the failure, in previous studies, of plain HCl to cause substantial damage to the 
oesophageal mucosa. 
In 1977 Safaie-Shirazi published another study on the effect of pepsin on ionic permeability. 
Using the same technique as before she now instilled various concentrations of HCl and pepsin. 
She again observed an increased H+ loss after the addition of pepsin which, however, was 
reversed at the highest pepsin concentration. She had demonstrated that pepsin, at certain 
concentrations, was also capable of breaching the H+ mucosal barrier85. 
In 1980 Kivilaakso et al. published the first of two studies on the effects of potential harmful 
agents present in gastric juice and duodenal contents on isolated rabbit oesophageal mucosa in 
vitro. Mucosal integrity was assessed by measurements of transmucosal potential differences, 
tissue electrical resistance and, when acid was present, permeability to H+. Test substances were 
sodium taurocholate, three human deconjugated bile salts, lysolecithin, pepsin, trypsin and 
phospholipase A.  
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Taurocholate at pH 3.5, but not at pH 7.4and both deoxycholate and chenodeoxycholate at pH 
7.4, produced profound effects.  Pepsin in the presence of H+, lysolecithin to a lesser degree and 
trypsin in the absence of H+, produced less profound effects than those caused by bile salts. They 
concluded that in the presence of gastric acid, pepsin and conjugated bile salts contribute to 
oesophagitis, but in the absence of acid,  trypsin and especially unconjugated bile acids were 
responsible86. Their second study, published in 1982, examined the role of luminal H+ on the 
pathogenesis of oesophagitis in an in vivo rabbit model. An isolated segment of oesophagus was 
perfused with taurocholate, pepsin and lysolecithin with and without HCl. The severity of 
mucosal damage was assessed by transmucosal potential difference, net flux of Na+, and two 
neutral molecules of different sizes, 3H2O and 14C-erythrol. Plain HCl again produced minimal 
effects, even in unphysiological high concentrations which, although inducing a markedly 
increased diffusion of H+ into the mucosa, had only a minor influence on mucosal integrity. This 
in contrast to the three tested agents where pepsin caused more extensive mucosal changes than 
taurocholate, the magnitude of the H+ efflux was far greater in the latter, suggesting that the 
damage caused by pepsin was not mediated by accumulation of luminal H+. In fact, the severity 
of the mucosal damage caused by each of the individual test agent was not dependent on the HCl 
concentration used 87.  This study would appear to have displaced HCl from its role as a prime 
mover to that of a facilitator. 
From 1982 Lillemoe et al. published a number of studies into the discordance between 
substances which breached the barrier and those which caused mucosal damage in an in vivo 
rabbit model. They continuously perfused the oesophagus at pH 2 with pepsin, 
taurodeoxycholate or trypsin, the barrier was assessed by net fluxes of  H+, K+ ,glucose, 
haemoglobin and tritiated water, mucosal damage by gross and microscopic examination. Pepsin 
caused both increased permeability of the barrier and mucosal damage, taurodeoxycholate also 
increased permeability but caused no significant pathology while trypsin at pH 2 had no effect 
whatsoever88. A year later they presented a study into the comparative effects of 
taurodeoxycholic acid 89, tauroursodeoxycholic acid (TUDC) and taurochenodeoxycholic acid 
(TCDC) at 3 concentrations on the gastric and oesophageal mucosa, a study prompted by the 
clinical use of the last two bile acids in the dissolution of gallbladder stones. For the oesophagus 
the rabbit model was employed, the barrier function being assessed by measurements of 
transmucosal potential differences, tissue electric resistance and net H+ flux. At each 
concentration TUDC was found to produce far less disruption of the barrier function than either 
TDC or TCDC. There were no differences in gross and microscopic mucosal damage, which was 
actually minimal90.  
Their next study repeated the first, but now at a pH of 7.5 to simulate alkaline oesophagitis. Here 
trypsin caused severe morphologic changes but only minimal disruption of the mucosal barrier, 
taurodeoxycholate caused extensive disruption of the  
mucosal barrier but only minimal oesophagitis. Pepsin, at this pH, had no effect.91 Finally, in 
1985, Lillemoe et al. investigated the effects of taurodeoxycholate 89 on the mucosal damage 
caused by pepsin and trypsin at their optimal pH values of 2 and 7.5 respectively. Surprisingly, 
TDC reduced the mucosal damage and barrier disruption by pepsin in a dose dependent manner. 
The damage caused by trypsin on the other hand, was enhanced by TDC, again dose 
dependently89. This inhibition of pepsin activity by bile acids, had already been demonstrated in 
vitro in several studies by Tompkins et al.92-94. Previously, Mud et al from Rotterdam had 
examined the effects of gastric, biliary and pancreatic reflux in a variety of combinations by 
means of surgical procedures in a chronic rat model. This had only produced oesophagitis in  
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those combinations which included pancreatic juice. Oesophageal washouts before and after 
operation were tested for concentrations of trypsin and bile acids. There were significant 
differences in the concentrations of trypsin, but not of bile acids, between rats with and without 
oesophagitis95. 
These studies appeared to have established a role for bile acids in breaching the H+ barrier with 
conflicting results on the amount of mucosal damage84 and Kivilaakso86, 87 versus Lillemoe88, 90. 
Pancreatic enzymes were found both to breach the H+ barrier and cause extensive mucosal 
damage at their optimum pH. In practice, this optimum pH for pepsin would not often be 
achieved while in contrast to the Gillison findings83, its activity was also inhibited by bile acids.  
The in vivo Mud95 model suggested that, in practice, trypsin, the effect of which was enhanced 
by bile acids, was a prime suspect. The role of HCL now appeared to be reduced to that of 
creating a suitable pH for pepsin activation. 
However, these often contradictory results, which may in part have resulted from species 
differences, have made it impossible to distil hard and fast conclusions applicable to human 
reflux oesophagitis. Obvious shortcomings of all these experiments were that the time scale of 
human reflux oesophagitis could not be measured in hours or weeks, but in months or years. In 
addition, in clinical practice, all sorts of variations which were as yet not examined would occur 
in the already complicated relationships between various potentially harmful substances. 
On the other hand, it should be stressed that these pioneering efforts certainly produced a number 
of basic facts on which clinicians should build in analysing the mechanism of reflux 
oesophagitis. These are, for instance, the fact that the oesophagus is well protected against acid 
and this protection needs to be breached by bile acids and/or enzymes, substances which by 
themselves are also able to cause substantial damage to the oesophageal mucosa. The unexpected 
interaction between bile acids and pepsin add an extra dimension to this already very 
complicated patho-physiological conundrum. Such studies would, in the first place, need to 
accommodate the empirical finding  that reflux oesophagitis heals under strong gastric acid 
inhibition96, 97 which would tend to point towards enzymes and bile acids active at a low pH. 
Clinical studies. 
In 1953 Aylwin was the first to examine the oesophageal juices just above the cardia in 50 
patients with hiatal hernias in whom the degree of oesophagitis had been established, ranging 
between none to stricture. The juices were collected by suction through a thin polythene tube 
while the patients were asleep. There was a clear relationship between the degree of 
oesophagitis, a pH under 4 and the concentration of pepsin in the collected  
juice, although in strictures the results were influenced by collections of saliva. He was surprised 
to find no secretion in 13/19 patients without oesophagitis, concluding that they had no 
incompetence of the cardia at night, possibly through the presence of a sphincter.  
As there were no signs of reflux from the stomach, Aylwin assumed that the refluxate had 
originated from the herniated pouch under vagal influence. He also emphasised the roles of 
saliva and oesophageal gland secretions in protecting the oesophagus and pioneered  the concept 
of nocturnal reflux in oesophagitis98. 
As the results of experimental oesophagitis became available, interest shifted from acid to bile 
and pancreatic juices. These were obviously less easily detected. Gillison et al found a strong 
correlation between symptoms of heartburn and the regurgitation into the stomach of barium 
which had previously been instilled into the duodenum through a tube99. By aspiration of gastric 
juice from the proximal stomach after a liquid meal Kaye and Showalter demonstrated that the  
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post-prandial bile-salt concentrations in juice from patients with symptomatic gastro-
oesophageal reflux were higher than those of normal controls100. At the same time two studies 
were published involving a young surgeon from Rotterdam, Dick Stol and addressing the acid 
output and bile acid concentration in gastric juice from patients with oesophagitis. The first study 
compared patients with hiatal hernias and various degrees of oesophagitis with normal controls. 
Acid output was measured before (basal) and after (peak acid output) pentagastrin stimulation101. 
Basal and peak acid outputs were marginally higher in patients than in controls while the mean 
bile acid levels were significantly higher with, however, a very considerable spread and a 
considerable overlap with controls. There was a tendency towards the combination of more 
severe degrees of oesophagitis with higher acid output and bile acid concentrations although it 
was notable that only 4 of 32 patients had a higher peak acid output above the locally accepted 
normal value102.  
The second was a repeat of the previous experiment with the addition of a test meal. The results 
were disappointing, as the result of 4 outliers the patients had higher mean bile acid 
concentrations after the test meal than controls and the peptic stricture patients again had a 
higher basal acid production103. However, these studies of acid output and gastric bile 
contamination in a static situation were unable to identify the distinguishing factors between 
individuals with and without reflux oesophagitis. Extending the observation time by 24-hour 
ambulatory monitoring of both oesophageal pH104, 105 and bile reflux106, 107 were necessary in 
setting the first steps towards this goal. 
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The Diagnosis of Reflux Oesophagitis. 
Radiology. 
As mentioned previously, radiology was one of the founding disciplines for the concept of the 
hiatal hernia and the main pioneers have been summarised. However, in radiology the link 
between the hiatal hernia, gastro-oesophageal reflux and oesophagitis had not yet been 
established. This changed with a study published in 1953 by Flood et al. who examined the 
relationship between hiatus hernia, insufficiency of the cardia, acid reflux and oesophagitis. They 
had been impressed by a number of English studies emphasising the regurgitation of gastric 
contents into the oesophagus and that this was an important mechanism in the aetiology of 
oesophagitis. Their patients were routinely examined in supine, Trendelenburg and prone 
positions, were asked to strain and pressure was applied to the abdomen. The most successful 
manoeuvre for demonstrating the hernia was found to be the act of turning over from the supine 
to the prone position. Barium reflux into the oesophagus was found in 18 of 34 patients with a 
hiatus hernia. No cases of reflux were found in a control group of patients without hiatus hernia, 
subjected to the same routine.  Only 2 cases of reflux were observed in 100 patients undergoing 
routine gastrointestinal x-ray series. They also tested for reflux in patients in the right recumbent 
position, by passing a 12 French stomach tube after histamine stimulation of the gastric acid 
production and aspirating fluid at 5 cm intervals from 30 cm they attempted establish acid reflux. 
Free acid found at 30 cm below the gum margins (obviously few patients with incisors) probably 
signified oesophageal reflux. Although the correlation between the endoscopically established 
diagnosis of oesophagitis and this early reflux test was understandably tenuous, this study did 
signal the shift from the simple radiological diagnosis of hiatal hernias to the presence of 
reflux108. 
In 1966 radiologists, by employing manometry and cine-radiography managed to distinguish 
between the lower oesophageal sphincter, the A ring, and the B ring representing the hiatus109, 
110. 
In spite the good results of double contrast radiography111 and snide remarks by Meyers about 
the dangers of fibre-optic endoscopy112, the  general availability of endoscopy heralded the 
gradual disappearance of radiology from the diagnostic menu of reflux oesophagitis. 
Endoscopy  
Reflux oesophagitis was first described on the basis of endoscopic observations62 and 
consequently endoscopy has remained the mainstay in diagnosing this condition. However, it 
was only after the introduction of  fibre-optic endoscopy that this technique was able to establish 
its current dominant position113.  Important adjuncts were oesophageal biopsies examined 
according to the Ismail-Beigi criteria114. A classification of different degrees of reflux  
oesophagitis according to Savary Miller was published in 1987115. 
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Manometry 
In 1962 Code et al. developed a manometric test for  hiatal hernia using an array consisting of a 
pressure transducer in a tube over which a tiny balloon filled with water was fitted and three 
water filled polyethylene catheters with lateral orifices. By identifying the hiatus as the point of 
“pressure respiratory reversal” and the lower oesophageal sphincter, which was normally found 
2-3 cm below the hiatus by the balloon-covered transducer, manifested by a zone of elevated 
pressure 3-5 cm in length. A double respiratory reversal as the detecting units traversed the 
junctional region was found to be the most significant indicator of a hiatal hernia116. 
 
Acid perfusion and pH monitoring 
In the absence of easily accessible endoscopy, the acid perfusion test, introduced by Bernstein in 
1958, provided a useful diagnostic tool for oesophagitis117. In this test a tube was introduced 
through the nares over a distance of 30-35 cm in the oesophagus. Subsequently test solutions of 
0.1N HCl or a control solution of 0.9% NaCl were randomly administered over 30 minute 
periods. The test was positive if it elicited persistent and often progressive symptoms while 
control solutions never caused symptoms. The pain was found to be projected to a wide variety 
of locations on the chest and upper abdomen. In his test population Bernstein had established the 
presence of oesophagitis by oesophagoscopy. The test was false negative in one case of 
oesophageal ulcer; however he found apparently false positives in 10/12. He called this condition 
“pseudoesophagitis”, and was the first to describe what is now termed “non-esophagitis reflux 
disease” or “NERD”118. 
 A further refinement was introduced by Tuttle et al. who combined the acid perfusion test with 
simultaneous measurement of intraluminal pressure and pH. After removal of the tube for the 
acid perfusion test a glass pH electrode and a water filled tube for measuring pressure changes, 
with its orifice at the level of the bulb of the pH electrode, were introduced into the oesophagus 
through the nares. This array was passed into the stomach and then withdrawn at 1 cm at a time. 
The pressure inversion point was identified and acid regurgitation diagnosed when a pH of 4 or 
less was encountered at least 4 cm above the pressure inversion point. In 105 of 124 patients 
there was concordance between the two parts of the test and in 15 the acid perfusion moiety was 
negative while acid regurgitation was positive, a discrepancy which was thought to have resulted 
from antacid therapy which might have healed their oesophagitis119.  
Another indirect test was the “Acid clearance test from the distal esophagus” introduced by 
Booth et al. in 196875. Here a pH probe and 3 joined polyvinyl tubes, with their open tips at 5 cm 
intervals, were passed through the nares, with the pH probe placed level with the most distal 
opening, 5cm above the distal oesophageal sphincter. Next 15 ml of 0.1N HCl was injected 
through the most proximal tube and the number of swallows needed to restore the pH to 6.0 
counted and when this pH had been achieved, reflux was tested by the Müller and Valsalva 
manoeuvres and a cough. A fall in pH to below 4.0 was considered positive evidence of reflux. 
In 1964 Miller et al. noted that hiatal hernias can be demonstrated in 10% of asymptomatic 
persons over the age of 40 while a study by Eyring had found 43% of patients with demonstrable 
hiatal hernias to be asymptomatic120. On the other hand, no hiatal hernia was demonstrated in 
21% of patients with endoscopically verified oesophagitis61. The then apparently current policy  
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of operating on hiatal hernias and the high recurrence rates led the authors to conclude: 
“Diagnosis is, of course, of the first order of magnitude, but after having established the presence 
of an anatomical defect, the important question that then arises is, “is surgery indicated?” They 
described a technique for measuring oesophageal pH for up to 24 hours. In controls the pH in the 
terminal oesophagus never fell below 6.5, however, in a patient without a hiatal hernia, pH 
values as low as 2 were found and oesophagitis endoscopically confirmed. The authors 
speculated that “this method may be very useful in establishing the diagnosis of esophagitis, 
especially when the radiological examination is within normal limits”121. 
However, it took another10 years before dissatisfaction with the acid perfusion test led Johnson 
and Demeester to achieve this goal by means of their twenty-four-hour pH monitoring of the 
distal oesophagus. They employed a Beckman gastric pH probe positioned 5 cm above the distal 
oesophageal sphincter as determined by infusion manometry and the measurements were 
recorded on a strip chart recorder. The essential feature was their scoring system of six 
components, comprising the percentage of time with the pH below 4 over the 24-hour period, 
and separately for the periods in supine and upright position, the total number of single reflux 
periods, the number of episodes greater than five minutes and the time of the longest reflux 
episode. Their technique, in combination with their scoring system and later expanded to 24-hour 
ambulatory pH monitoring104, became the standard for the next three decades and made possible 
both the definition and ascertainment of gastro-oesophageal reflux disease or GORD. 
 Interestingly, the pH 4 cut off point was derived from a study by Tuttle who had found the onset 
of pyrosis to occur at this pH122. As this study was performed in a military hospital it is likely 
that both their “normal” volunteers and symptomatic patients were relatively young and the 
applicability of their data to elderly subjects could be challenged. This challenge was presented 
in 1989 by Smout et al. who, employing an ambulatory combined oesophageal pH and motility 
recording device, examined 32 healthy volunteers, 16 under and 16 over the age of 45.  A 
comparison of the results obtained from the two age groups, revealed significantly higher values 
in the over 45 group for both time pH< 4 and for the number of episodes> 5 minutes during the 
upright and total 24 hour periods,. In addition, they found the number of simultaneous 
contractions and the mean duration of the perprandial peristaltic contractions to increase with 
age123. Unfortunately, the volunteers had not undergone endoscopy so the integrity of their 
oesophagus was unknown. 
This challenge was subsequently rejected by Richter et al., including DeMeester, who examined 
the influence of study centre, pH electrodes, age and gender. They pooled the results from three 
study populations, totalling 110 asymptomatic healthy paid volunteers, who had undergone 
ambulatory 24-Hr oesophageal pH studies. Of the four factors examined, the influence of the 
first two was found to be negligible. Males generally tended to have more oesophageal reflux 
than women and men over 50 actually experienced significantly more reflux episodes > 5 
minutes. The gender difference was attributed to the greater acid secretory capacity of males. 
The conclusion was that the existing normal values were still applicable but consideration should 
be given to developing separate standards for men and women124.  
One year later Fass et al. published a study: “Age-and gender-related differences in 24-hour 
esophageal pH monitoring of normal subjects”. They studied 30 asymptomatic volunteers, 15 
<65 years and 15 ≥ 65 years and 15 males and females. They found considerable differences 
between the younger and the older group which were not statistically significant, probably as the 
result of the too small number of subjects. On the other hand there were significant gender  
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differences with all pH variables, except episodes > 5 minutes, lower in females. These results 
suggested a need for redefiningsex-specific normal 24-hr pH monitoring, a suggestion which 
however, does not appear to have been acted upon. Another worrying finding was that 30% of 
their asymptomatic volunteers had abnormal results, raising the question of the frequency of 
“silent refluxers”, an issue which was to resurface in the epidemiology of Barrett’s oesophagus. 
Treatment of reflux oesophagitis. 
Before the introduction of H2 receptor blockers and proton pump inhibitors the medical treatment 
of severe reflux oesophagitis was quite limited and had not changed much from the days of 
Arthur Hurst. In 1973, John Bennett, a foremost British specialist on reflux oesophagitis gave an 
overview of medical treatment. The cornerstone was antacid, hourly doses to begin with, 
possibly in combination with metoclopramide. Patients should stop smoking and if overweight, 
lose weight. The head of the bed should be propped up 8 inches. However, if medical treatment 
failed or there were serious complications such as strictures, not responding to repeated dilations 
or bleeding, surgery was indicated125. A problem remained that many elderly patients requiring 
surgery were considered unfit to undergo an operation.  
An effective treatment for ulcers in Barrett’s oesophagus, developed in Rotterdam, was a 
continuous mid-oesophageal drip with a milk-antacid mixture which cleared up ulcers within a 
few weeks. It was responsible for a large number of referrals, a number of whom were 
subsequently included in the Rotterdam Barrett’s oesophagus follow up cohort. 
It was not until the introduction of H2 receptor blockers in 1978 and more especially proton 
pump inhibitors in 1986 that effective medical treatment of reflux oesophagitis became 
possible126, 127. 
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The Present State of Reflux Oesophagitis, Barrett’s 
Oesophagus and Adenocarcinoma of the Oesophagus 
The continuity, which over the past 40 years, has been established between reflux oesophagitis, 
Barrett’s oesophagus and adenocarcinoma, implies that it represents a classical cascade from 
normal tissue to cancer or, as is technically known, multistage carcinogenesis128, 129.However, 
this field has become so complicated that a detailed review is beyond the scope of a non-
specialist. Therefore this non-specialist has chosen to present a superficial overview of the three 
subjects in the title and eased the burden by mainly relying on expert reviews.  
 In a recently published seminar on reflux oesophagitis the pathophysiology section is mainly 
concerned with the factors influencing the function of the lower oesophageal sphincter130. There 
are, however, only 3 references to chemical factors, a paucity which may well reflect a certain 
lack of interest in this branch of pathophysiology now that effective acid suppression by proton 
pump inhibitors has largely solved the problem of medical therapy without, apparently, creating 
much interest in its mode of action. Chemical factors are obviously essential in understanding the 
process of mucosal damage to the squamous cell lining of the oesophagus resulting in metaplasia 
to Barrett’s oesophagus. Both the supporters of Barrett’s oesophagus originating from 
oesophageal gland ducts131and those who consider these organs to be irrelevant40 could 
presumably agree with this premise. The change from a squamous cell to a cylindrical cell 
mucosa obviously implies changes in gene expression and consequently, the molecular 
phenotype.  
Barrett et al. employing oligonucleotide-based micro arrays, characterised gene expression 
profiles in the three normal upper gastrointestinal mucosae, obtained by endoscopic biopsy and, 
in addition, including Barrett’s oesophagus. They hoped to identify disease specific genes in 
Barrett’s oesophagus and thus gain insight into the molecular basis of early neoplasia. They cited 
earlier studies which had shown that the development of Barrett’s metaplasia and the subsequent 
evolution of neoplasia were associated with the inactivation of the CDKN2A/p16 gene and the 
expansion of clonal populations of epithelial cells. In the event they found clear distinctions 
between the expression profiles of the oesophageal, gastric and duodenal tissues of the upper GI 
tract, and were thus able to identify with clusters of 100-200 genes, specific to each tissue.  
Although Barrett’s oesophagus shared extensive transcriptional similarities with all three, it did 
manifest a separate cluster of 38 specifically up-regulated genes. A lineage-specific 
developmental association with any one of the surrounding tissues was not demonstrated. 
Barrett’s oesophagus did contain trefoil peptides, key mediators of initial restitution of damages 
mucosa in the GI tract but absent in squamous epithelium. In addition, the 38 up-regulated genes 
in the Barrett’s oesophagus cluster also included genes which are associated with a number of 
different pathways including cellular migration, alterations in the cell cycle, apoptosis and stress 
responses, all of which have been associated with neoplasia132. 
 In 2005 Brabender et al. claimed to have developed a technique of gene expression profiling by 
means of a panel of highly selected genes by which they were able to distinguish 
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 between patients with Barrett's oesophagus, patients with Barrett's-associated adenocarcinoma, 
and a healthy control group from endoscopic biopsies taken from the normal squamous 
oesophageal epithelium above the pathological areas. They concluded that they had defined the 
existence of a carcinogenic field effect133. 
Recently Wang et al. performed transcriptional profiling on tissues from patient with a normal 
oesophagus, with Barrett’s oesophagus, subdivided into patients with and without concurrent 
adenocarcinoma of the oesophagus and adenocarcinoma of the oesophagus. 457 genes were 
significantly differentially expressed in adenocarcinoma of the oesophagus versus normal 
oesophagus against 295 between Barrett’s oesophagus and normal oesophagus. However, only 
36 genes were differentially expressed between Barrett’s oesophagus and adenocarcinoma of the 
oesophagus. Finally Barrett’s oesophagus and adenocarcinoma of the oesophagus shared 212 
genes differentially expressed from normal oesophagus. The authors concluded that Barrett’s 
oesophagus is biologically closer to adenocarcinoma of the oesophagus than normal oesophagus. 
They also found 12 genes which were significantly differentially expressed between Barrett’s 
oesophagus with and without concurrent adenocarcinoma of the oesophagus and suggested that 
these 12 genes could be potential biomarkers for diagnosing adenocarcinoma of the oesophagus 
in an early stage134. 
So, given the fact that considerable genetic changes occur in the changes from normal 
oesophageal mucosa to adenocarcinoma of the oesophagus, can any system be discerned? 
The first, self-sufficiency in growth signals or the independence from exogenous mitogenic 
stimulation or inhibition results in the increased rate of proliferation in tumour cells and is 
attributed to inactivation of the retinoblastoma protein (Rb) which normally controls the 
progression through the cell cycle at the restriction or R point. The inactivation of Rb is mediated 
through oncogenes. Normal cellular genes promoting cell growth are, sumwhat pejoratively, 
termed proto-oncogenes, only becoming oncogenes after mutation. Cyclin D1 is such an  
 Hanahan and Weinberg135, in a review titled 
“Hallmarks of cancer”, discussed the rules 
that govern the transformation of normal 
human cells into malignant cancers They 
suggested  “that the vast catalog of cancer cell 
genotypes is a manifestation of six essential 
alterations in cell physiology that collectively 
dictate malignant growth. 
1: self-sufficiency in growth signals, 2: 
insensitivity to growth-inhibitory (antigrowth) 
signals, 3: evasion of programmed cell death 
(apoptosis), 4: limitless replicative potential, 
5: sustained angiogenesis, and 6: tissue 
invasion and metastasis”. (see figure)  
These six items returned in a subsequent 
reviews by Souza and Spechler136 which, 
although focussing on the prevention of 
adenocarcinoma of the distal oesophagus and 
proximal stomach, provided an overview of 
the best known mechanisms involved in each 
of the six steps.  
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oncogene; it interacts with cyclin-dependent kinases which in turn are responsible for 
inactivating Rb through phosphorylation. Cyclin D1 is found over expressed in Barrett’s 
oesophagus. This in contrast to Cyclin B1, which is involved in the G2 to Mitosis transition in 
the cell cycle and is only found in dysplastic Barrett's oesophagus and adenocarcinoma of the 
oesophagus. Another pathway consists of alterations to the growth factors, growth factor 
receptors or the signalling pathways that mediate growth factor-receptor interactions. Ras 
proteins, which have Cyclin D1 as its downstream target, can be activated by growth factor 
receptors of the tyrosine kinase family. Increased expression of epidermal growth factor (EGF) 
and transforming growth factor-α (TGF-α) have been found in adenocarcinoma of the 
oesophagus while increased levels of both the EGF receptor, EGFR and TGF-α have been found 
in Barrett's oesophagus.  
The second step comprises the inactivation of tumour suppressor genes such as p16 and p53, 
which normally block Rb phosphorylation. This inactivation can be caused by mutation, deletion 
of the chromosomal region containing the gene, termed loss of heterogeneity, LOH, and 
promoter methylation. Over expression of MDM2, an inhibitor of p53 is sometimes found in 
those adenocarcinomas of the oesophagus where wild type p53 is still present, thus forming an 
alternative p53 inactivation mechanism to mutation. Inactivation of the adenomatous polyposis 
coli or APC gene by LOH has also been observed in both Barrett's oesophagus and 
adenocarcinoma of the oesophagus.  
The third step, evasion of apoptosis, can be achieved by inactivating p53 but also by the turning 
the tables on lymphocytes on the Fas with Fas-ligand (Fasl) death receptor pathway. Normally, 
Fasl on activated lymphocytes bind to the Fas receptor of the target cell, inducing apoptosis. 
However, adenocarcinoma of the oesophagus cells express Fasl which after binding to the Fas 
receptor on the attacking lymphocytes induce their apoptosis.  Another escape route is the 
synthesis of an apoptosis blocking agents such as cyclooxygenase-2 (COX-2). Over expression 
of COX-2 has been detected in Barrett's oesophagus, with increasing expression during the 
progression to dysplasia and adenocarcinoma of the oesophagus. 
Step 4, involves limitless replicative potential or resistance to cell senescence. Senescence is the 
mechanism by which the capacity of normal cells to proliferate is limited by the shortening of 
telomeres, stretches on non coding DNA situated at the ends of the chromosomes, which occurs 
at every cell replication. Once the telomeres have been reduced to a critical length the cell will 
exit the cell cycle into a G0 state entailing permanent growth arrest. In order to escape this 
mechanism and become immortal, malignant cells need to maintain their telomere length. This 
they achieve by means of telomerase, an enzyme which adds telomeric sequences to the ends of 
chromosomes. Telomerase is not found in normal somatic cells; low levels of expression are 
found in non dysplastic Barrett's oesophagus with increasing levels in the transition from low- to 
high-grade dysplasia and the highest expression in adenocarcinoma of the oesophagus. 
Step 5, continual angiogenesis or the formation of new blood vessels, is obviously essential for 
the sustenance of the rapidly growing mass of tumour cells. The process is stimulated by the 
binding of vascular endothelial growth factors (VEGFs) to their tyrosine kinase receptors or 
VEGFRs which then initiate signalling pathways causing the proliferation and migration of 
endothelial cells. Compared to Barrett's oesophagus, VEGF mRNA and protein expression is 
only significantly increased in adenocarcinoma of the oesophagus, because even dysplastic 
Barrett's mucosa is not yet in need of angiogenesis. 
The final step 6, tissue invasion and metastasis by tumour cells, is thought to involve 
abnormalities in cell to cell connections. Catenins α, β, and γ are cytoplasmic proteins attached to  
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the cytoskeleton to which cell adhesion molecules named cadherins are anchored. The best 
known combination is the E-cadherin-catenin complex. Failure of this interaction impairs cell 
adhesion, resulting in invasion and metastasis. In addition to cell adhesion, β-catenin is also 
involved in cellular signal transduction by stimulating the production of genes promoting cell 
growth. While in squamous oesophageal mucosa  and non dysplastic Barrett's oesophagus both 
E-cadherin and β-catenin are mainly found in the cell membrane, with increasing degrees of  
dysplasia membrane staining for these proteins decreases while an increase is seen in 
cytoplasmatic and nuclear staining. significantly more nuclear accumulation of beta-catenin was 
found in adenocarcinoma of the oesophagus than in that of the gastric cardia137. A second group 
of players in this field are the matrix metalloproteinase’s (MMPs) who thank their name to their 
membership of a family of zinc dependent proteolytic enzymes involved in the destruction of the  
extracellular matrix. MMP-7 or matrilysin has been found to be the principle MMP in both 
Barrett's oesophagus and adenocarcinoma of the oesophagus. 
Very recently Maley published a mini-review on “Multistage carcinogenesis in Barrett’s 
esophagus” in which he approaches the sequence of Barrett's oesophagus to adenocarcinoma of 
the oesophagus from a slightly different angle138. In this he criticises the description of 
multistage carcinogenesis “as a deterministic and linear series of lesions”. Instead he introduces 
an illustrated scheme of neoplastic progression in Barrett’s oesophagus to cancer, see figure 
below. 
Figure. An example of neoplastic 
progression in Barrett's esophagus. 
Frequency in the neoplasm is 
shown on the Y-axis and time is on 
the X-axis. Clonal expansion along 
the Y-axis (frequency) with time 
represents clonal expansion in the 
two-dimensional surface of the BE 
epithelium Clones evolve within a 
neoplasm through processes of 
mutation, natural selection and 
genetic drift that appears to take 
decades 51,139,18,140, 141. 
Evolutionarily neutral mutations 
will randomly increase and 
decrease in  frequency unless they 
occur in a cell that also 
has a selectively advantageous mutation. In this case they are called 'hitchhikers.' Hitchhikers may occur before 
(hitchhiker 1) or after (hitchhiker 2 and 3) the occurrence of the advantageous mutation, as long as they arise before 
the selective sweep is complete. Loss of each allele of CDKN2A (pl6) provides a selective advantage to the mutant 
clone and drives a selective sweep of that clone through the neoplasm 142. Lesions in TP53 appear to only expand in 
the background of a CDKN2A lesion and are thought to be associated with chromosomal instability. Aneuploid 
clones typically arise within TP53- clones143. and oesophageal adenocarcinomas are usually aneuploid144-146. Figure 
copied from 138. 
 
Noting that the “initiation of Barrett’s oesophagus remains a mystery”, Maley advances 3 
hypothetical mechanisms for this initiation. The first is based on the clear association with 
gastro-oesophageal reflux, “so BE may just be the result of altered differentiation of esophageal 
epithelium due to the reflux environment”. After citing the study by Barrett et al.132 mentioned 
above, he highlighted the attention now focused on the homeobox genes CDX1 and CDX2, with 
CDX2 being found in practically all Barrett’s oesophagus samples and even in reflux 
oesophagitis. The role of CDX2 in Barrett’s oesophagus was recently addressed by Moons  
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et al. from Rotterdam, who found it to be strongly associated with the presence of specialised 
intestinal metaplasia, which, in view of its role in the development and differentiation of 
intestinal epithelium, was not unexpected. Predictably, it was not found in gastric metaplastic 
epithelium or reflux oesophagitis. However, low levels of CDX2 mRNA were found in a number 
of squamous epithelial biopsies taken 5 cm above the squamo-columnar junction in patients with 
Barrett’s oesophagus147.  
The second hypothesis, the migration of columnar epithelium from the cardia is  dismissed by 
Maley on the basis of the Gillen study39, while still allowing the possibility of the oesophageal 
gland duct hypothesis. His third and presumably favoured hypothesis is “a mutation which 
confers a competitive advantage on the mutant clone”. He considers the best candidate mutation 
to be the loss of the CDKN2A/p16 tumour suppressor gene, as alterations to this gene are found 
in 85% of Barrett’s oesophagus patients at first endoscopy, possibly because these cells may 
enjoy a selective advantage in the reflux environment. As mentioned earlier, this loss can result 
from loss of heterozygocity, LOH, hypermethylation or sequence mutations.  The 15% without 
this mutation, or the larger group where it is not present in all biopsies, may be the result of 
mutations in other loci of the CDKN2A/p16 pathway.  
The first important genetic alteration in Barrett’s oesophagus is therefore CDKN2A/p16. Its 
inactivation in selective sweeps breaches the tumour suppressive mechanisms of crypt structured 
tissue architecture which eventually leads to the spread of mutant clones across hundreds of 
thousands of crypts. The next to be inactivated is TP53. The loss of TP53, which in Barrett’s 
oesophagus only occurs after the loss of CDKN2A/p16, carries a 16-fold risk of progression to 
adenocarcinoma of the oesophagus. In addition, the larger the clone with TP53 LOH, the greater 
the risk of progression. The loss of TP53 is likely to be responsible for three developments, the 
first two being the suppression of apoptosis and the prevention of cell cycle arrest, which 
potentially provide sources of competitive advantage for a clone. The third involves the 
permitting of genetic instability, which may increase the generation of viable genetic variants. 
Further events in the progression to adenocarcinoma of the oesophagus are tetraploidy and 
aneuploidy, both of which are associated with about 10-fold increased cancer risk and may result 
from the loss of TP53. Senescence via the erosion of telomeres, which constitutes a potential 
cancer suppressive mechanism, may be circumvented by telomerase, the activity of which is high 
in adenocarcinoma of the oesophagus although it is unknown whether there is a specific timing 
during progression or it can be activated at any point. Whether neo-angionesis is already 
activated in Barrett’s oesophagus, as it is in adenocarcinoma of the oesophagus, is unknown, 
Maley apparently having missed the study by Lord et al. who found the angiogenic factors 
vascular endothelial growth factor and basic fibroblast growth factor clearly upregulated in 
adenocarcinoma of the oesophagus but also, to a lesser extent, in some dysplastic Barrett's 
oesophagus specimens and in goblet cells148. Invasion and metastasis may depend on the 
disruption of E-cadherin, the expression of which has been found to decrease during the 
progression from squamous epithelium to Barrett’s oesophagus and adenocarcinoma of the 
oesophagus. 
A similar review by Fitzgerald149devotes attention to genetic aspects. She notes that analyses of 
various pedigrees of families with multiple members suffering from heartburn, Barrett’s 
oesophagus or even adenocarcinoma of the oesophagus, suggest either autosomal-dominant 
patterns of inheritance with variable degrees of penetrance or an autosomal-recessive inheritance. 
While the great majority of cases of Barrett’s oesophagus and adenocarcinoma of the oesophagus 
are sporadic, she cites several lines of evidence for a underlying genetic susceptibility such as  
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familial clustering and the observations that only a subset of patients with reflux symptoms 
develop Barrett’s oesophagus and that neither the degree of reflux exposure nor a previous 
diagnosis of reflux oesophagitis are accurate predictors for the development of Barrett’s 
oesophagus. Fitzgerald also highlights the potential role of genomics, by employing microarray  
technologies, both for uncovering previously unidentified genes predictive of cancer 
development and for gene expression signatures predictive of cancer progression. 
Adenocarcinoma of the oesophagus which arises in Barrett’s oesophagus resulting from reflux 
oesophagitis is a very clear example of an inflammation induced tumour. 
This subject was comprehensively reviewed in a paper named: “Inflammation and Cancer, back 
to Virchow” by Ballkwill and Mantovani, in which they explained that the response of the body 
to a cancer is not a unique mechanism but has many parallels with inflammation and wound 
healing, a fact already  mentioned in the discussion of proto-oncogenes. The inflammatory 
microenvironment of tumours is characterised by the presence of host leucocytes both in the 
supporting stroma and in tumour areas. Such tumour infiltrating lymphocytes may actually 
contribute to cancer growth and spread, and to the immunosuppression associated with malignant 
disease. Three types of leucocytes are discussed. The first, tumour-associated macrophages 
(TAM) are a major component of the infiltrate of most, if not all, tumours. TAM are derived 
from circulating monocytic precursors, and are directed into the tumour by chemoattractant 
cytokines called chemokines. Many tumour cells also produce cytokines called colony-
stimulating factors that prolong survival of TAM. Although, when appropriately activated, TAM 
can kill tumour cells or elicit tissue destructive reactions centred on the vascular endothelium, 
TAM also produce growth and angiogenic factors as well as protease enzymes which degrade the 
extracellular matrix. Hence, TAM can stimulate several of the 6 cancer hallmarks135, tumour-cell 
proliferation, promote angiogenesis, and favour invasion and metastasis. The second cell type, 
dendritic cells, normally has a crucial role in both the activation of antigen-specific immunity 
and the maintenance of tolerance, providing a link between innate and adaptive immunity. 
However, tumour-associated dendritic cells (TADC) usually have an immature phenotype with a 
defective ability to stimulate T cells and consequently TADC are probably poor inducers of 
effective responses to tumour antigens. The third type, lymphocytes, or tumour-infiltrating T 
cells, predominantly consists of the memory phenotype with only few natural killer cells. The 
former produce interleukins associated with a Th-2 response which is ineffective against 
tumours. The inflammatory cytokine network which results from the activities of these cells is 
then shown to be involved in all six stages of carcinogenesis150. 
Fitzgerald was the first to demonstrate the qualitatively and quantitatively differences in the 
immunoregulatory environment  of reflux oesophagitis and Barrett's oesophagus, the latter being 
characterised by a distinct Th-2 predominant cytokine profile compared with the 
proinflammatory nature of reflux oesophagitis151. This finding was recently confirmed by Moons 
et al. from Rotterdam152.  A review from Rotterdam by Bax et al.153 describes the various 
inflammatory mediators, such as cytokines and chemokines, which attract inflammatory cells to 
tissues damaged by gastro-oesophageal reflux. NF-κB a transcription factor, is not only involved 
with the upregulation of pro-inflamatory cytokines and chemokines, but has also been linked to 
oncogenic functions such as proliferation, metastasis and angiogenesis. Activated NF-κB is 
found in about half the specimens of Barrett's oesophagus and in most of adenocarcinoma of the 
oesophagus. In cell culture NF-κB has been found to be activated by deoxycholic acid. NF-κB in 
turn activates the pro-inflamatory chemokine interleukin-8 (IL-8) which attracts neutrophils, the 
most potent producers of reactive oxygen species. Deoxycholic acid again induces the expression  
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of IL-8. IL-8 expression together with that of cytokine IL-1β is increased in Barrett's 
oesophagus, especially near the squamocolumnar junction. On the other hand a paradoxically 
increased expression of the anti-inflammatory cytokines IL-4 and IL-10 has been observed in the 
distal part of Barrett's oesophagus where adenocarcinoma of the oesophagus is most commonly 
found. Besides IL-8 the calprotectin complex is also active in the chemotaxis of neutrophils and 
both subunits, calgranulin A and B have been found associated with the development of high 
grade dysplasia in Barrett's oesophagus, implicating both neutrophils and calprotectin in the 
neoplastic progression. 
Another important player is cyclooxygenase-2 (COX-2), the rate limiting enzyme for the 
conversion of arachidonic acid into prostaglandins such as prostaglandin E2 (PGE2). PGE2 is 
currently a much maligned substance, being associated with the inhibition of apoptosis, 
increasing proliferation and angiogenesis and the induction of metalloproteinase’s. However, it 
should be remembered that prostaglandins (PGs) first entered the literature because of their key 
role in protecting the gastric mucosa against injury caused by a variety of necrotizing agents154-
157. In a recent survey Gudis and Sakamoto highlighted the good work performed by PGE2, 
writing: “We think that PGE2 released by COX-2-expressing gastric fibroblasts plays a pivotal 
role in VEGF production, angiogenesis, and subsequently, the ulcer repair process in gastric 
tissue158. The PGE2 story forms a clear example of how normal physiological mechanisms are 
harnessed to malignant pathways.  
Cyclooxygenase-2 itself can be induced by pro-inflammatory cytokines such as TNFα and TGF-
β and by growth factors. Cyclooxygenase-2 expression is increased ex-vivo by both bile salts and 
acid and its expression is considerably in Barrett's oesophagus and adenocarcinoma of the 
oesophagus and thus becomes a prime suspect in oesophageal carcinogenesis. 
Having established a number of inflammatory mechanisms which are involved in the process of 
carcinogenesis, it is now necessary to return to the factors causing reflux oesophagitis, the 
condition which lies at the base of this inflammation 
. The technique of ambulatory 24-hour oesophageal pH and bile reflux monitoring106 has 
clarified some of the questions raised by the pioneers in the field. The static concept of  
the lower oesophageal sphincter (LOS) pressure determining the degree of reflux has now been 
replaced by the more dynamic concepts. LOS pressure has been found to vary in relation to 
phases of the migrating motor complex159. Transient LOS relaxations (TLOSRs) occur 
spontaneously without a previous swallow and may be the means by which gas can escape from 
the stomach. They are commonly considered a physiological mechanism160 although there have 
been attempts to implicate TLOSRs in the aetiology of reflux oesophagitis161. Currently this 
association is no longer popular162. A study by Allen et al.163 stressed the importance of effective 
oesophageal clearance of refluxate.  
This opinion was underlined by Meneghetti et al. in a study of 827 patients with gastro-
oesophageal reflux disease, confirmed by ambulatory pH monitoring. They were divided into 
three groups on the basis of endoscopic grading of their mucosal injury. Group A had no visible 
oesophagitis, group B oesophagitis grades I through III and group C Barrett's oesophagus. All 
were subjected to oesophageal manometry. As expected, there were significant differences 
between the three groups as far as the mean DeMeester score was concerned, although there 
were also very considerable overlaps between all 3 groups. The motility study confirmed older 
studies indicating that as mucosal damage increased, both oesophageal motility and acid 
clearance worsened, the latter related to progressive oesophageal dysmotility expressed in both 
decreasing distal oesophageal amplitude and LOS pressure. As even in the group A patients,  
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13% had ineffective oesophageal motility and because medical healing of oesophagitis has not 
been found to result in significant improvement peristaltic function, the authors conclude that the 
reflux induced mucosal injury extends into the muscular wall. A fact which the late professor van 
Houten in Rotterdam taught over 30 years ago, stating that in severe oesophagitis the whole 
oesophageal wall had become thickened and completely fibrotic. The authors then raised the 
chicken and egg question concerning the natural history of gastro-oesophageal reflux disease, 
citing the two rival hypotheses. The first, that there are 3 distinct non-communicating categories 
of gastro-oesophageal reflux disease, non-erosive GORD, erosive GORD and Barrett's 
oesophagus, based on separate degrees of abnormality of foregut motility. The second  
hypothesis, which would appear to be more compatible with their own observations, being that 
GORD should be considered a continuum, with a vicious circle of reflux causing mucosal 
damage followed by motility disturbances resulting in more reflux. After side stepping this issue, 
the surgical authors arrived at the, for them, happy conclusion that a laparoscopic fundoplication 
should be performed early in the course of the disease, an operation which  in addition, 
eliminates the hiatal hernia164.  
This resurgence of the relevance of the old surgical bugbear, the hiatal hernia, had already been 
initiated by Kahrilas in 199964 and was recently confirmed in a study from Utrecht where in 16 
patients with a small hiatal hernia (3 cm), prolonged high-resolution manometry was performed 
and both acid and weakly acidic reflux episodes were detected  
by means of pH-impedance monitoring. Even in these patients, with small hiatal hernias, spatial 
separation of the diaphragm and LOS in the nonreduced state resulted in a 2-fold increase in 
acidic and weakly acidic reflux, due to mechanisms other than transient LOS relaxation165. There 
also appears to be a hierarchy of reflux within the group of patients with Barrett's oesophagus. A 
study by Öberg et al. examined 556 patients by stationary motility, ambulatory pH monitoring 
and endoscopy with biopsy. After having found cardiac type mucosa in the oesophagus of 411 
patients, they then assessed the length of intestinal metaplastic mucosa within the cardiac type 
mucosa, which resulted in 3 categories, intestinal metaplasia limited to the gastro-oesophageal 
junction, involving <3cm or >3cm of the oesophagus. An increasing length of intestinal 
metaplasia was found to correlate with worsening sphincter function, acid clearance and  
increased acid exposure166. 
Having found both the motility factors causing gastro-oesophageal reflux disease still relatively 
unchanged and a continuing modest relationship between the DeMeester score and the degree of 
oesophagitis and Barrett’s oesophagus,  the  next question was obviously which components of 
the refluxate were actually doing the damage. 
 The classic studies by Safaie-Shirazi 84, 85 had shown that both bile salts and pepsin at the proper 
pH, breach the mucosal barrier to H+. Subsequent studies, summarised in the section on 
experimental reflux oesophagitis, indicated wide differences in the effects of various bile acids 
and pancreatic enzymes and that the effect of pancreatic enzymes could be inhibited by bile 
acids. At first sight the extensive experimental evidence that on the one hand acid is not the 
prime mover but on the other hand clinical proof that acid suppression does heal reflux 
oesophagitis (but not Barrett’s oesophagus) suggests that we should be looking at substances 
which work at a low pH.  
Early studies of the components of the refluxate looked at aspirated gastric content, with Gillen 
only finding significant differences in post-prandial gastric bile acid concentrations between 
complicated Barrett's oesophagus and 3 other patient groups, including uncomplicated Barrett's 
oesophagus, reflux oesophagitis and normal controls. 167. Examinations of aspirated oesophageal  
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refluxate tended to meet with fairly inconclusive results168-172. However, in 1998 Nehra et al. 
using an automated sampling device, did manage to establish a hierarchy, similar to that found in 
acid reflux, in oesophageal bile acid concentrations between normals, minimal oesophagitis, 
erosive oesophagitis and strictures or Barrett’s oesophagus. Mixed reflux of acid and bile acids 
was mainly seen in more severe oesophagitis but in each of the 3 patient groups there were two 
bile acid refluxers without acid. There was no correlation between total oesophageal bile acid 
exposure and acid or alkaline exposure173. Unfortunately, the authors did not present data on the 
nature, degree of solubility or conjugation state of the bile acids nor were pancreatic enzymes 
determined. The introduction of the Bilitec technique enabled 24-hour oesophageal acid and 
bilirubin monitoring. Vaezi et al, using this technique, found that both acid and duodeno-
gastroesophageal reflux showed a graded increase in severity across the gastro-oesophageal 
reflux spectrum. Acid and duodeno-gastroesophageal reflux were found to have occurred 
simultaneously in the majority of the reflux episodes174. Banki et al. investigating why Barrett’s 
oesophagus was more common in men reviewed the records of 796 patients (462 male, 334 
female) evaluated for symptoms of reflux. Physiologic abnormalities based on results of 
endoscopic, motility, pH, and Bilitec testing were identified, and factors related to the presence 
of Barrett's were determined. Females with reflux symptoms were significantly less likely to 
have a positive 24-h pH test, a defective lower oesophageal sphincter, or a hiatal hernia than 
males with reflux symptoms. Furthermore females with reflux on the basis of an abnormal 24-hr. 
pH test had significantly less oesophageal acid exposure than males with reflux. However, in 
spite of the milder abnormalities in females with gastro-oesophageal reflux disease, oesophageal 
exposure to refluxed acid and bilirubin was similar in females (n = 50) and males (n = 136) with 
Barrett's oesophagus. On multivariable analysis increased oesophageal bilirubin exposure ( i.e. 
duodeno-gastro-oesophageal reflux) was the only significant factor associated with the presence 
of Barrett's oesophagus in both in male and female patients with reflux disease i.e. in severe 
gastro-oesophageal reflux disease females were no longer protected against Barrett's esophagus, 
a conclusion at variance with the far lower percentage of females with Barrett’s oesophagus and 
which failed to analyse the higher mean age of the female patients which would be compatible 
with a postponement of severe reflux disease and Barrett’s oesophagus 175. A study by Stein et al. 
not only confirmed  an exponential increase in the mean oesophageal bile exposure time for 
gastro-oesophageal reflux disease patients without oesophagitis to those with erosive 
oesophagitis and benign Barrett's oesophagus, but also found it to be highest in patients with 
early carcinoma in Barrett's oesophagus (P <0.01). They triumphantly concluded  that 
oesophageal bile reflux was not effectively suppressed by medical treatment, this in contrast to 
Nissen fundoplication176. This issue was presumably raised because two studies had 
demonstrated the, at first sight surprising, finding that acid suppression by means of omeprazole, 
while actually increasing the number of, now non-acid, postprandial reflux episodes177, also 
resulted in a reduction of duodeno-gastro-oesophageal reflux178, 179.  
The simple explanation for this reduction is that decreased gastric acid production requires less 
pancreatic and duodenal secretions for its neutralisation. However, it is also possible that acid 
inhibition increases phase III of the migrating motility complex, resulting in improved gastric 
clearance by increased antro-duodenal motility 180 which may well be a more important 
mechanism for the protection of the duodenum than acid neutralisation181. On the other hand, 
patients manifesting persistent oesophagitis under proton pump inhibitors were found to have 
more duodeno-gastroesophageal reflux than those who remained symptomatic in spite of having 
healed their oesophagitis 182. Although proton pump inhibitors cannot guaranty the control of  
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duodeno-gastroesophageal reflux183, its reduction may well be the key explanation of how acid 
inhibition heals reflux oesophagitis.  
Unfortunately, while demonstrating that duodeno-gastro-oesophageal reflux plays an essential 
aetiological role in both reflux oesophagitis and Barrett's oesophagus, we are not much better 
informed than Aylwin98 in 1953 about which potentially damaging substances, in what 
concentrations and state of solubility  are present in the oesophagus at any particular moment184. 
This in contrast to some sophisticated studies looking at the effects of bile acids at the cellular 
and genetic level185, 186.  
In the mean time there is a new contender for a leading role in the aetiology of reflux 
oesophagitis, Barrett's oesophagus and adenocarcinoma of the oesophagus and cardia, cancers 
which are occurring at the anatomical site where saliva encounters acidic gastric juice and their 
interaction generates reactive nitrogen species which are potentially mutagenic and 
carcinogenic187. These encounter sites have also been shown to lie within Barrett's 
oesophagus188. 
An important question, raised by Maley, is whether gastro-oesophageal reflux continues to play a 
role in the progression from Barrett’s oesophagus to adenocarcinoma of the oesophagus. Daily 
wounding of the Barrett’s oesophagus by acid and bile salts may “trigger wound healing 
responses including mitogens, release from growth inhibition and suppression of apoptosis in the 
base of the crypts”. This process could explain the “over-expression of a variety of oncogenes, 
along with the scarcity of oncogenic mutations”. his mechanism is supported by the fact 
inflammation is commonly observed in Barrett’s oesophagus and could be responsible for 
increases in mutagenesis and proliferation. However, in humans this wounding is in practice only 
seen in reflux oesophagitis138. 
This issue of whether Barrett’s oesophagus requires continued mutagenic stimulation by gastro-
oesophageal reflux or, once set on the path of oncogenesis, will autonomously follow it to the 
end, is of obvious practical importance. Moghissi et al. found no effect of  anti-reflux surgery in 
the prevention of adenocarcinoma of the oesophagus189. In 2004 a review by Sonnenberg, citing, 
amongst others, a meta-analysis by Corey et al.190entitled: “Does a surgical antireflux procedure 
decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus?”, concluded that 
“Fundoplication does not prevent the occurrence of Barrett's oesophagus nor its progression to 
oesophageal adenocarcinoma191. There are currently no published systematic studies into the 
efficacy of proton pump inhibitors in preventing adenocarcinoma of the oesophagus in Barrett’s 
oesophagus. This question (also including an aspirin arm)  is currently the subject of the AspECT 
trial192. In spite of some optimistic data 193, support for the belief in regression of   Barrett’s 
oesophagus under treatment by proton pump inhibitors is not universal194, 195.  
On the other hand, regression of Barrett’s oesophagus by Roux-en-Y gastric bypass  for morbid 
obesity was reported by Cobey in a single patient196. Csendes et al. reported 78 patients with 
Barrett’s oesophagus treated by vagotomy and antrectomy in combination with duodenal bile 
diversion, an operation designed to abolish acid and duodenal reflux into the distal esophagus. 
After 5 years they observed regression of Barrett’s oesophagus from intestinal to cardiac or 
fundic mucosa in about 60% of patients197. The same author reported similar regression of 
intestinal metaplasia to cardiac mucosa in patients 2 years after undergoing gastric by-pass 
surgery for morbid obesity, again without achieving a total reversal of Barrett’s oesophagus198.  
What can be concluded from these studies? The comparison between the disappointing results of 
both conventional surgical antireflux procedures and proton pump inhibitors with the relative 
success  of the heroic surgical interventions by Cobey196 and Csendes198,  suggest that only the  
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complete exclusion of gastro-oesophageal reflux can achieve a certain degree of regression in 
Barrett’s oesophagus and, hopefully, prevent the development of adenocarcinoma of the 
oesophagus. Should the latter assumption prove correct, this would demonstrate that continuing 
gastro-oesophageal reflux is necessary for the progression to malignancy of Barrett’s oesophagus 
and that this progression can be halted surgically. However ,in practice it is questionable whether 
such mutilating surgery would be acceptable for the prevention of adenocarcinoma of the 
oesophagus in Barrett’s oesophagus, the risk of which for an individual patient is probably less 
than 5%53. 
 
  
References 
 
1 Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of 
Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 
2002;122(1):26-33. 
2 Haggitt RC, Tryzelaar J, Ellis FH, Colcher H. Adenocarcinoma complicating columnar 
epithelium-lined (Barrett's) esophagus. Am J Clin Pathol. 1978 Jul;70(1):1-5. 
3 Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of 
metaplasia at the gastro-oesophageal junction. Lancet. 1994;344(8936):1533-6. 
4 Spechler SJ. Short and ultrashort Barrett's esophagus--what does it mean? Semin 
Gastrointest Dis. 1997;8(2):59-67. 
5 Nandurkar S, Talley NJ, Martin CJ, Ng TH, Adams S. Short segment Barrett's 
oesophagus: prevalence, diagnosis and associations. Gut. 1997;40(6):710-5. 
6 Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus--the need for 
standardization of the definition and of endoscopic criteria. Am J Gastroenterol. 
1998;93(7):1033-6. 
7 Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 
1994;25(10):982-93. 
8 Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, Luong QT, et al. Upregulation of 
the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in 
vitro 
Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia 
and adenocarcinoma: a prospective study. Gut. 2003 Feb 
Sep;52(2):174-80. 
9 Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of 
Barrett's esophagus. N Engl J Med. 1976 Aug 26;295(9):476-80. 
10 Thompson JJ, Zinsser KR, Enterline HT. Barrett's metaplasia and adenocarcinoma of the 
esophagus and gastroesophageal junction. Hum Pathol. 1983;14(1):42-61. 
11 Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and 
invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol. 1987;87(3):301-12. 
12 Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-
cytometric and histological progression to malignancy in Barrett's esophagus: prospective 
endoscopic surveillance of a cohort. Gastroenterology. 1992;102(4 Pt 1):1212-9. 
13 van Dekken H. Histopathology of Barrett's esophagus. In: Tilanus HW, Attwood SEA, 
editors. Barrett's esophagus. Dordrecht/Boston/London: Kluwer Academic Publishers; 2001. p. 
159-66. 
 39
14 Mueller J, Werner M, Stolte M. Barrett's Esophagus: Histopathologic Definitions and 
Diagnostic Criteria. World J Surg. 2004 Jan 20. 
15 Csendes A, Smok G, Burdiles P, Korn O, Gradiz M, Rojas J, et al. Prevalence of 
intestinal metaplasia according to the length of the specialized columnar epithelium lining the 
distal esophagus in patients with gastroesophageal reflux. Dis Esophagus. 2003;16(1):24-8. 
16 Gatenby PAC, Ramus JR, Caygill CPJ, Watson A. Incidence of adenocarcinoma in short 
and long segment columnar-lined oesophagus. Gastroenterology. 2004;126(4, suppl.):A.. 
17 Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis 
and management of Barrett's oesophagus. Gut. 2006 Apr;55(4):442. 
18 Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar 
epithelium. Gastroenterology. 1992;103(4):1241-5. 
19 Morris KN. Gastric mucosa within the oesophagus. Aust N Z J Surg. 1955;25:24. 
20 Wolf BS, Marshak RH, Som ML, Winkelstein A. Peptic esophagitis, peptic ulcer of the 
esophagus and marginal esophagogastric ulceration. Gastroenterology. 1955;29:744. 
21 Som ML, Wolf BS. Peptic ulcer of the esophagus and esophagitis in gastric-lined 
esophagus. JAMA. 1956;162:641. 
22 Goldman MC, Beckman RC. Barrett syndrome: case report with discussion about 
concepts of of pathogenesis. Gastroenterology. 1960;39:104. 
23 Mossberg SM. The columnar-lined esophagus (Barrett syndrome)-an acquired condition? 
Gastroenterology. 1966;50(5):671-76. 
24 Clark GWB, Ireland AP, Peters JH, Chandrasoma P, DeMeester TR, Bremner CG, et al. 
Short-Segment Barrett's Esophagus: A Prevalent Complication of Gastroesophageal Reflux 
Disease With Malignant Potential. J Gastrointest Surg. 1997 Mar Dec;1(2):113-22. 
25 McClave SA, Boyce HW, Jr., Gottfried MR. Early diagnosis of columnar-lined 
esophagus: a new endoscopic diagnostic criterion. Gastrointest Endosc. 1987 Dec;33(6):413-6. 
26 Choi do W, Oh SN, Baek SJ, Ahn SH, Chang YJ, Jeong WS, et al. Endoscopically 
observed lower esophageal capillary patterns. Korean J Intern Med. 2002 Dec;17(4):245-8. 
27 Barrett NR. Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br J Surg. 1950 
Oct;38(150):175-82. 
28 Allison PR. Peptic ulcer of the esophagus. Thorax. 1948;3:20-42. 
29 Allison PR, Johnstone AS, Royce GB. Short esophagus with simple peptic ulceration. J 
Thorac Surg. 1942;12:432-57. 
30 Barrett NR. The lower esophagus lined by columnar epithelium. Surgery. 
1957;41(6):881-94. 
31 Bosher LH, Taylor FH. Heterotopic gastric mucosa in the esophagus with ulceration and 
stricture formation. J Thorac  Surg. 1951;21:306-12. 
32 Allison PR. Peptic ulcer of the esophagus. J Thorac  Surg. 1946;15:308-17. 
33 Allison PR, Johnstone AS. The oesophagus lined with gastric mucous membrane. 
Thorax. 1953 Jun;8(2):87-101. 
34 Peters PM. Thorax. 1958;13:1. 
35 Hayward J. The lower end of the esophagus. Thorax. 1961;16:36-55. 
36 Adler RH. The Lower Esophagus Lined by Columnar Epithelium: Its Association With 
Hiatal Hernia, Ulcer, Stricture, and 
Tumor. J THORAC CARDIOVASC SURG. 1963;45:13. 
37 Morson BC, Belcher JR. Adenocarcinoma of the esophagus and ectopic gastric mucosa. 
Brit J Cancer. 1952;6:127. 
 40
38 Bremner CG, Lynch VP, Ellis FH, Jr. Barrett's esophagus: congenital or acquired? An 
experimental study of esophageal mucosal regeneration in the dog. Surgery. 1970 Jul;68(1):209-
16. 
39 Gillen P, Keeling P, Byrne PJ, West AB, Hennessy TP. Experimental columnar 
metaplasia in the canine oesophagus. Br J Surg. 1988 Feb;75(2):113-5. 
40 Seto Y, Kobori O. Role of reflux oesophagitis and acid in the development of columnar 
epithelium in the rat oesophagus. Br J Surg. 1993 Apr;80(4):467-70. 
41 Jabbari M, Goresky CA, Lough J, Yaffe C, Daly D, Cote C. The inlet patch: heterotopic 
gastric mucosa in the upper esophagus. Gastroenterology. 1985 Aug;89(2):352-6. 
42 Hewlett AB. The superficial glands of the esophagus. J Exper Med. 1900-01;5:319. 
43 Anonymous. Case record 21521 from the Massachusetts General Hospital NEJM. 1935 
26 December 1935;213:1311-15. 
44 Feldman M. Adenocarcinomatous pedunculated polyp of the esophagus. Am J Digest 
Dis. 1939;6:453. 
45 Smithers DW. Adenocarcinoma of the esophagus. Thorax. 1956;11:257-67. 
46 Lortat-Jacob J-L, Maillard JN, Richard CA, Fekete F, Huguier M, Conti-Marti J. Primary 
esophageal adenocarcinoma: report of 16 cases. Surgery. 1968;64(3):535-43. 
47 Naef AP, Savary M, Ozzello L. Columnar-lined lower esophagus: an acquired lesion with 
malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J 
Thorac Cardiovasc Surg. 1975 Nov;70(5):826-35. 
48 Dees J, van Blankenstein M, Frenkel M. Adenocarcinoma in Barrett's oesophagus; a 
report of 16 cases. Gut. 1978;19:A976. 
49 Spechler SJ, Sperber H, Doos WG, Schimmel EM. The prevalence of Barrett's esophagus 
in patients with chronic peptic esophageal strictures. Dig Dis Sci. 1983;28(9):769-74. 
50 Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, et al. 
Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology. 1984;87(4):927-
33. 
51 Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the 
reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000;119(2):333-8. 
52 Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in 
Barrett's oesophagus: an overrated risk. Gut. 1989;30(1):14-8. 
53 van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an 
uncommon cause of death in patients with Barrett's oesophagus. Gut. 1996;39(1):5-8. 
54 Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, Kuipers EJ. Oesophageal 
cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean 
follow-up of 12.7 years. Scand J Gastroenterol. 2004 Dec;39(12):1175-9. 
55 Van Blankenstein M. Barrett's esophagus: so what! Dis Esophagus. 2002;15(1):1-4. 
56 Friedenwald J, Feldman M. Amer journ Med Sci. 1925;170:263. 
57 von Bergmann G. Funktionelle Pathologie: eine klinische Sammlung. Berlin: Springer; 
1932. 
58 Hurst AF. Recurrent hernia of the stomach through the hiatus oesophageus of the 
diaphragm. Guy's Hosp Rep. 1934;84:43. 
59 Knothe W. Die "Hiatushernien" von standpunkt des Rontgenologen. Deutsch Med Woch. 
1932;58(16):609-12. 
60 Schatzki R. Die Hernien des Hiatus oesophageus. Deuts Arch fKlin Med. 1932;173:85-
103. 
 41
61 Cross FS, Smith GV, Jr., Kay EB. The surgical treatment of peptic esophagitis. J Thorac 
Cardiovasc Surg. 1959 Dec;38:798-813. 
62 Winkelstein A. Peptic esophagitis. JAMA. 1935;104:906-9-. 
63 Allison PR. Reflux esophagitis, sliding hiatal hernia, and the anatomy of repair. Surg 
Gynecol Obstet. 1951 Apr;92(4):419-31. 
64 Kahrilas PJ, Lin S, Chen J, Manka M. The effect of hiatus hernia on gastro-oesophageal 
junction pressure. Gut. 1999 Apr;44(4):476-82. 
65 Cohen S, Harris LD. Does hiatus hernia affect competence of the gastroesophageal 
sphincter? N Engl J Med. 1971 May 13;284(19):1053-6. 
66 Mittal RK, Rochester DF, McCallum RW. Effect of the diaphragmatic contraction on 
lower oesophageal sphincter pressure in man. Gut. 1987 Dec;28(12):1564-8. 
67 Mittal RK, Fisher M, McCallum RW, Rochester DF, Dent J, Sluss J. Human lower 
esophageal sphincter pressure response to increased intra-abdominal pressure. Am J Physiol. 
1990 Apr;258(4 Pt 1):G624-30. 
68 Kronecker H, Meltzer S. Der Schluckmechanismus, seine Erregnung und seine 
Hemmung. Arch Anat Physiol. 1883:382. 
69 Butin JW, Olsen AM, Moersch HJ, Code CF. A study of esophageal pressures in normal 
persons and patients with cardiospasm. Gastroenterology. 1953 Feb;23(2):278-93. 
70 Sanchez GC, Kramer P, Ingelfinger FJ. Motor mechanisms of the esophagus, particularly 
of its distal portion. Gastroenterology. 1953 Nov;25(3):321-32; discussion, 59-63. 
71 Fyke FE, Jr., Code CF, Schlegel JF. The gastroesophageal sphincter in healthy human 
beings. Gastroenterologia. 1956;86(3):135-50. 
72 Atkinson M, Edwards DA, Honour AJ, Rowlands EN. The oesophago-gastric sphincter 
in hiatus hernia. Lancet. 1957 Dec 7;273(7006):1138-42. 
73 Pope CE, 2nd. A dynamic test of sphincter strength: its application to the lower 
esophageal sphincter. Gastroenterology. 1967 May;52(5):779-86. 
74 Kahrilas PJ, Dodds WJ, Hogan WJ, Kern M, Arndorfer RC, Reece A. Esophageal 
peristaltic dysfunction in peptic esophagitis. Gastroenterology. 1986 Oct;91(4):897-904. 
75 Booth DJ, Kemmerer WT, Skinner DB. Acid clearing from the distal esophagus. Arch 
Surg. 1968 May;96(5):731-4. 
76 Dent J, Dodds WJ, Friedman RH, Sekiguchi T, Hogan WJ, Arndorfer RC, et al. 
Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin 
Invest. 1980 Feb;65(2):256-67. 
77 Friedenwald J, Feldman M, Zinn WF. Ulceration of the esophagus;experimental study. 
Arch Intern Med. 1928;42:521. 
78 Ferguson DJ, Sanchez-Palomera E, Sako Y, Clatworthy HW, Toon RW, Wangensteen 
OH. Studies on experimental esophagitis. Surgery. 1950;28(6):1022-39. 
79 Cross FS, Wangensteen OH. Role of bile and pancreatic juice in production of 
esophageal erosions and anemia. Proc Soc Exp Biol Med. 1951;77:862-6. 
80 Morrow D, Passaro ER, Jr. Alkaline reflux esophagitis after total gastrectomy. Am J 
Surg. 1976 Aug;132(2):287-91. 
81 Redo SF, Barnes WA, Ortez de la Sierra A. Perfusion of the canine esophagus with 
secretions of the upper gastro-intestinal tract. Ann Surg. 1959;149(4):556-64. 
82 Henderson RD, Mugashe F, Jeejeebhoy KN, Cullen J, Szczepanski M, Boszko A, et al. 
The role of bile and acid in the production of esophagitis and the motor defect of esophagitis. 
Ann Thorac Surg. 1972 Nov;14(5):465-73. 
 42
83 Gillison EW, De Castro VA, Nyhus LM, Kusakari K, Bombeck CT. The significance of 
bile in reflux esophagitis. Surg Gynecol Obstet. 1972 Mar;134(3):419-24. 
84 Safaie-Shirazi S, DenBesten L, Zike WL. Effect of bile salts on the ionic permeability of 
the esophageal mucosa and their role in the production of esophagitis. Gastroenterology. 1975 
Apr;68(4):728-33. 
85 Safaie-Shirazi S. Effect of pepsin on ionic permeability of canine esophageal mucosa. J 
Surg Res. 1977 Jan;22(1):5-8. 
86 Kivilaakso E, Fromm D, Silen W. Effect of bile salts and related compounds on isolated 
esophageal mucosa. Surgery. 1980 Mar;87(3):280-5. 
87 Salo J, Kivilaakso E. Role of luminal H+ in the pathogenesis of experimental esophagitis. 
Surgery. 1982 Jul;92(1):61-8. 
88 Lillemoe KD, Johnson LF, Harmon JW. Role of the components of the gastroduodenal 
contents in experimental acid esophagitis. Surgery. 1982 Aug;92(2):276-84. 
89 Lillemoe KD, Johnson LF, Harmon JW. Taurodeoxycholate modulates the effects of 
pepsin and trypsin in experimental esophagitis. Surgery. 1985 Jun;97(6):662-7. 
90 Lillemoe KD, Kidder GW, Harmon JW, Gadacz TR, Johnson LF, Bunte RM, et al. 
Tauroursodeoxycholic acid is less damaging than taurochenodeoxycholic acid to the gastric and 
esophageal mucosa. Dig Dis Sci. 1983 Apr;28(4):359-64. 
91 Lillemoe KD, Johnson LF, Harmon JW. Alkaline esophagitis: a comparison of the ability 
of components of gastroduodenal contents to injure the rabbit esophagus. Gastroenterology. 1983 
Sep;85(3):621-8. 
92 Tompkins RK, Croke JC. Bile acids inhibit pepsin activity against a refined substrate. 
Am J Surg. 1980 Feb;139(2):237-9. 
93 Tompkins GS, Tompkins RK. Inhibition of pepsin activity by unconjugated bile acids. 
Inverse relation to number of hydroxyl groups. Am J Surg. 1982 Sep;144(3):300-1. 
94 Eto T, Tompkins RK. Inhibition of pepsin activity by ursodeoxycholic acids and 
chenodeoxycholic acids. Am J Surg. 1985 Nov;150(5):564-7. 
95 Mud HJ, Kranendonk SE, Obertop H, Van Houten H, Westbroek DL. Active trypsin and 
reflux oesophagitis: an experimental study in rats. Br J Surg. 1982 May;69(5):269-72. 
96 Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, et al. Long-
term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern 
Med. 1994;121(3):161-7. 
97 Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term 
omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence 
on gastric mucosa. Gastroenterology. 2000;118(4):661-9. 
98 Aylwin JA. The physiological basis of reflux oesophagitis in sliding hiatal diaphragmatic 
hernia. Thorax. 1953;8:38-45. 
99 Gillison EW, Capper WM, Airth GR, Gibson MJ, Bradford I. Hiatus hernia and 
heartburn. Gut. 1969 Aug;10(8):609-13. 
100 Kaye MD, Showalter JP. Pyloric incompetence in patients with symptomatic 
gastroesophageal reflux. J Lab Clin Med. 1974 Feb;83(2):198-206. 
101 Baron JH. The clinical use of gastric function tests. Scand J Gastroenterol Suppl. 
1970;6:9-46. 
102 Stol DW, Murphy GM, Collis JL. Duodeno-gastric reflux and acid secretion in patients 
with symptomatic hiatal hermia. Scand J Gastroenterol. 1974;9(1):97-101. 
 43
103 Crumplin MK, Stol DW, Murphy GM, Collis JL. The pattern of bile salt reflux and acid 
secretion in sliding hiatal hernia. Br J Surg. 1974 Aug;61(8):611-6. 
104 Johnsson F, Joelsson B, Isberg PE. Ambulatory 24 hour intraesophageal pH-monitoring 
in the diagnosis of gastroesophageal reflux disease. Gut. 1987 Sep;28(9):1145-50. 
105 Johnsson F, Joelsson B. Reproducibility of ambulatory oesophageal pH monitoring. Gut. 
1988 Jul;29(7):886-9. 
106 Vaezi MF, Lacamera RG, Richter JE. Validation studies of Bilitec 2000: an ambulatory 
duodenogastric reflux monitoring system. Am J Physiol. 1994 Dec;267(6 Pt 1):G1050-7. 
107 Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux 
of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The 
need for surgical therapy re-emphasized. Ann Surg. 1995 Oct;222(4):525-31; discussion 31-3. 
108 Flood CA, Wells J, Baker D. Insufficiency of cardia in hiatus hernia. Gastroenterology. 
1953 Nov;25(3):364-74. 
109 Sokol EM, Heitmann P, Wolf BS, Cohen BR. Simultaneous cineradiographic and 
manometric study of the pharynx, hypopharynx, and cervical esophagus. Gastroenterology. 1966 
Dec;51(6):960-74. 
110 Wolf BS, Heitmann P, Cohen BR. The inferior esophageal sphincter, the manometric 
high pressure zone and hiatal incompetence. Am J Roentgenol Radium Ther Nucl Med. 1968 
Jun;103(2):251-76. 
111 Lahde S, Kaariainen M, Lehtola J, Niemela S, Suramo I. Correlation of double-contrast 
radiography and endoscopy in reflux esophagitis. Diagn Imaging. 1981;50(5):255-8. 
112 Meyers MA, Ghahremani GG. Complications of Fiberoptic Endoscopy. I. 
Esophagoscopy and Gastroscopy. Radiology. 1975 May;115(2):293-300. 
113 Kobayashi S, Kasugai T. Endoscopic and biopsy criteria for the diagnosis of esophagitis 
with a fiberoptic esophagoscope. Am J Dig Dis. 1974 Apr;19(4):345-52. 
114 Ismail-Beigi F, Horton PF, Pope CE, 2nd. Histological consequences of gastroesophageal 
reflux in man. Gastroenterology. 1970 Feb;58(2):163-74. 
115 Siewert JR, Ottenjann R, Heilmann K, Neiss A, Dopfer H. [Therapy and prevention of 
reflux esophagitis. Results of a multicenter study with cimetidine. I: Epidemiology and results of 
acute therapy]. Z Gastroenterol. 1986 Aug;24(8):381-95. 
116 Code CF, Kelley ML, Jr., Schlegel JF, Olsen AM. Detection of hiatal hernia during 
esophageal motility tests. Gastroenterology. 1962 Nov;43:521-31. 
117 Bernstein LM, Baker LA. A clinical test for esophagitis. Gastroenterology. 1958 
May;34(5):760-81. 
118 Quigley EM. Non-erosive reflux disease: part of the spectrum of gastro-oesophageal 
reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol. 2001 
May;13 Suppl 1:S13-8. 
119 Tuttle SG, Bettarello A, Grossman MI. Esophageal acid perfusion test and a 
gastroesophageal reflux test in patients with esophagitis. Gastroenterology. 1960 Jun;38:861-72. 
120 Eyring EJ, Amendola FH. Esophageal hiatus hernia Surgery. 1963;53:222. 
121 Miller FA, Dovale J, Gunther T. Utilization of Inlying Ph Probe for Evaluation of Acid-
Peptic Diathesis. Arch Surg. 1964 Jul;89:199-203. 
122 Tuttle SG, Rufin F, Bettarello A. The physiology of heartburn. Ann Intern Med. 1961 
Aug;55:292-300. 
 44
123 Smout AJ, Breedijk M, van der Zouw C, Akkermans LM. Physiological gastroesophageal 
reflux and esophageal motor activity studied with a new system for 24-hour recording and 
automated analysis. Dig Dis Sci. 1989 Mar;34(3):372-8. 
124 Richter JE, Bradley LA, DeMeester TR, Wu WC. Normal 24-hr ambulatory esophageal 
pH values. Influence of study center, pH electrode, age, and gender. Dig Dis Sci. 1992 
Jun;37(6):849-56. 
125 Bennett JR. Symposium on gastrooesophageal reflux and its complications. 5. The 
physicians's problem. Gut. 1973 Mar;14(3):246-9. 
126 Wesdorp E, Bartelsman J, Pape K, Dekker W, Tytgat GN. Oral cimetidine in reflux 
esophagitis: a double blind controlled trial. Gastroenterology. 1978 May;74(5 Pt 1):821-4. 
127 Walan A. Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase 
inhibitors. Scand J Gastroenterol Suppl. 1986;125:50-4. 
128 Nordling CO. A new theory on the cancer-inducing mechanism. Br J Cancer. 1953;7:68-
72. 
129 Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of 
carcinogenesis. Br J Cancer. 1954 Mar;8(1):1-12. 
130 Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006 Jun 
24;367(9528):2086-100. 
131 Coad RA, Woodman AC, Warner PJ, Barr H, Wright NA, Shepherd NA. On the 
histogenesis of Barrett's oesophagus and its associated squamous islands: a three-dimensional 
study of their morphological relationship with native oesophageal gland ducts. J Pathol. 2005 
Aug;206(4):388-94. 
132 Barrett MT, Yeung KY, Ruzzo WL, Hsu L, Blount PL, Sullivan R, et al. Transcriptional 
analyses of Barrett's metaplasia and normal upper GI mucosae. Neoplasia. 2002 Mar-
Apr;4(2):121-8. 
133 Brabender J, Marjoram P, Lord RV, Metzger R, Salonga D, Vallbohmer D, et al. The 
molecular signature of normal squamous esophageal epithelium identifies the presence of a field 
effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-
associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2113-7. 
134 Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, et al. Transcriptional profiling 
suggests that Barrett's metaplasia is an early intermediate stage in esophageal 
adenocarcinogenesis. Oncogene. 2006 Jan 30. 
135 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70. 
136 Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal 
esophagus and proximal stomach. CA Cancer J Clin. 2005 Nov-Dec;55(6):334-51. 
137 Marsman WA, Birjmohun RS, van Rees BP, Caspers E, Johan G, Offerhaus A, et al. 
Loss of heterozygosity and immunohistochemistry of adenocarcinomas of the esophagus and 
gastric cardia. Clin Cancer Res. 2004 Dec 15;10(24):8479-85. 
138 Maley CC. Multistage carcinogenesis in Barrett's esophagus. Cancer Lett. 2006 May 18. 
139 Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from 
Barrett's metaplasia has regional variations in the west. Gastroenterology. 2002;122(2):588-90. 
140 Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, et al. Non-steroidal 
anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective 
study. Lancet Oncol. 2005 Dec;6(12):945-52. 
 45
141 Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. 
Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003 Sep 
17;95(18):1404-13. 
142 Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. Selectively 
advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's 
esophagus. Cancer Res. 2004 May 15;64(10):3414-27. 
143 Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, et al. Evolution 
of neoplastic cell lineages in Barrett oesophagus. Nat Genet. 1999;22(1):106-9. 
144 Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53-mutant clones and field effects in 
Barrett's esophagus. Cancer Res. 1999 Oct 1;59(19):4784-7. 
145 Hickman ES, Moroni MC, Helin K. The role of p53 and pRB in apoptosis and cancer. 
Curr Opin Genet Dev. 2002 Feb;12(1):60-6. 
146 Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, et al. The 
combination of genetic instability and clonal expansion predicts progression to esophageal 
adenocarcinoma. Cancer Res. 2004 Oct 15;64(20):7629-33. 
147 Moons LM, Bax DA, Kuipers EJ, Van Dekken H, Haringsma J, Van Vliet AH, et al. The 
homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol. 2004 
Oct;57(10):1063-8. 
148 Lord RV, Park JM, Wickramasinghe K, DeMeester SR, Oberg S, Salonga D, et al. 
Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal 
adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg. 2003 Feb;125(2):246-53. 
149 Fitzgerald RC. Complex diseases in gastroenterology and hepatology: GERD, Barrett's, 
and esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2005 Jun;3(6):529-37. 
150 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 Feb 
17;357(9255):539-45. 
151 Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJ. 
Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological 
determinants. Gut. 2002 Apr;50(4):451-9. 
152 Moons LM, Kusters JG, Bultman E, Kuipers EJ, van Dekken H, Tra WM, et al. Barrett's 
oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol. 2005 
Nov;207(3):269-76. 
153 Bax DA, Siersema PD, Van Vliet AH, Kuipers EJ, Kusters JG. Molecular alterations 
during development of esophageal adenocarcinoma. J Surg Oncol. 2005 Nov 1;92(2):89-98; 
discussion 9. 
154 Robert A, Schultz JR, Nezamis JE, Lancaster C. Gastric antisecretory and antiulcer 
properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and 
intrajejunal administration. Gastroenterology. 1976 Mar;70(3):359-70. 
155 Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in 
rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and 
thermal injury. Gastroenterology. 1979 Sep;77(3):433-43. 
156 Konturek SJ, Robert A, Hanchar AJ, Nezamis JE. Comparison of prostacyclin and 
prostaglandin E2 on gastric secretion, gastrin release, and mucosal blood flow in dogs. Dig Dis 
Sci. 1980 Sep;25(9):673-9. 
157 Terano A, Ota S, Mach T, Hiraishi H, Stachura J, Tarnawski A, et al. Prostaglandin 
protects against taurocholate-induced damage to rat gastric mucosal cell culture. 
Gastroenterology. 1987 Mar;92(3):669-77. 
 46
158 Gudis K, Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig Dis 
Sci. 2005 Oct;50 Suppl 1:S16-23. 
159 Gill RC, Kellow JE, Wingate DL. Gastro-oesophageal reflux and the migrating motor 
complex. Gut. 1987 Aug;28(8):929-34. 
160 Dent J. Patterns of lower esophageal sphincter function associated with gastroesophageal 
reflux. Am J Med. 1997 Nov 24;103(5A):29S-32S. 
161 Sifrim D, Tack J, Lerut T, Janssens J. Transient lower esophageal sphincter relaxations 
and esophageal body muscular contractile response in reflux esophagitis. Dig Dis Sci. 2000 
Jul;45(7):1293-300. 
162 Iwakiri K, Hayashi Y, Kotoyori M, Tanaka Y, Kawakami A, Sakamoto C, et al. 
Transient lower esophageal sphincter relaxations (TLESRs) are the major mechanism of 
gastroesophageal reflux but are not the cause of reflux disease. Dig Dis Sci. 2005 
Jun;50(6):1072-7. 
163 Allen ML, Castell JA, DiMarino AJ, Jr. Mechanisms of gastroesophageal acid reflux and 
esophageal acid clearance in heartburn patients. Am J Gastroenterol. 1996 Sep;91(9):1739-44. 
164 Meneghetti AT, Tedesco P, Damani T, Patti MG. Esophageal mucosal damage may 
promote dysmotility and worsen esophageal Acid exposure. J Gastrointest Surg. 2005 
Dec;9(9):1313-7. 
165 Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Intermittent spatial separation of 
diaphragm and lower esophageal sphincter favors acidic and weakly acidic reflux. 
Gastroenterology. 2006 Feb;130(2):334-40. 
166 Oberg S, DeMeester TR, Peters JH, Hagen JA, Nigro JJ, DeMeester SR, et al. The extent 
of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of 
esophageal acid exposure. J Thorac Cardiovasc Surg. 1999;117(3):572-80. 
167 Gillen P, Keeling P, Byrne PJ, Healy M, O'Moore RR, Hennessy TP. Implication of 
duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br J Surg. 1988 
Jun;75(6):540-3. 
168 Mittal RK, Reuben A, Whitney JO, McCallum RW. Do bile acids reflux into the 
esophagus? A study in normal subjects and patients with gastroesophageal reflux disease. 
Gastroenterology. 1987 Feb;92(2):371-5. 
169 Gotley DC, Morgan AP, Cooper MJ. Bile acid concentrations in the refluxate of patients 
with reflux oesophagitis. Br J Surg. 1988 Jun;75(6):587-90. 
170 Johnsson F, Joelsson B, Floren CH, Nilsson A. Bile salts in the esophagus of patients 
with esophagitis. Scand J Gastroenterol. 1988 Aug;23(6):712-6. 
171 Iftikhar SY, Ledingham S, Steele RJ, Evans DF, Lendrum K, Atkinson M, et al. Bile 
reflux in columnar-lined Barrett's oesophagus. Ann R Coll Surg Engl. 1993 Nov;75(6):411-6. 
172 Stein HJ, Feussner H, Kauer W, DeMeester TR, Siewert JR. Alkaline gastroesophageal 
reflux: assessment by ambulatory esophageal aspiration and pH monitoring. Am J Surg. 1994 
Jan;167(1):163-8. 
173 Nehra D, Howell P, Pye JK, Beynon J. Assessment of combined bile acid and pH profiles 
using an automated sampling device in gastro-oesophageal reflux disease. Br J Surg. 1998 
Jan;85(1):134-7. 
174 Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in 
gastroesophageal reflux disease. Gastroenterology. 1996;111(5):1192-9. 
 47
175 Banki F, Demeester SR, Mason RJ, Campos G, Hagen JA, Peters JH, et al. Barrett's 
esophagus in females: a comparative analysis of risk factors in females and males. Am J 
Gastroenterol. 2005 Mar;100(3):560-7. 
176 Stein HJ, Kauer WK, Feussner H, Siewert JR. Bile reflux in benign and malignant 
Barrett's esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest 
Surg. 1998 Jul-Aug;2(4):333-41. 
177 Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. 
Simultaneous intraesophageal impedance and pH measurement of acid and nonacid 
gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001 Jun;120(7):1599-606. 
178 Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Duodenogastroesophageal 
reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology. 1994 
Sep;107(3):747-54. 
179 Marshall RE, Anggiansah A, Manifold DK, Owen WA, Owen WJ. Effect of omeprazole 
20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. 
Gut. 1998 Nov;43(5):603-6. 
180 Verkijk M, Gielkens HA, Lamers CB, Masclee AA. Effect of gastrin on antroduodenal 
motility: role of intraluminal acidity. Am J Physiol. 1998 Nov;275(5 Pt 1):G1209-16. 
181 Savoye G, Oors J, Smout A. Duodenal acid clearance in humans: observations made with 
intraluminal impedance recording. Dig Dis Sci. 2005 Aug;50(8):1553-60. 
182 Tack J, Koek G, Demedts I, Sifrim D, Janssens J. Gastroesophageal reflux disease poorly 
responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid 
reflux, bile reflux, or both? Am J Gastroenterol. 2004 Jun;99(6):981-8. 
183 Todd JA, Basu KK, de Caestecker JS. Normalization of oesophageal pH does not 
guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus. Aliment 
Pharmacol Ther. 2005 Apr 15;21(8):969-75. 
184 Sital RR, Kusters JG, De Rooij FW, Kuipers EJ, Siersema PD. Bile acids and Barrett's 
oesophagus: A sine qua non or coincidence? Scand J Gastroenterol Suppl. 2006 May(243):11-7. 
185 Kaur BS, Ouatu-Lascar R, Omary MB, Triadafilopoulos G. Bile salts induce or blunt cell 
proliferation in Barrett's esophagus in an acid-dependent fashion. Am J Physiol Gastrointest 
Liver Physiol. 2000 Jun;278(6):G1000-9. 
186 Kazumori H, Ishihara S, Rumi MA, Kadowaki Y, Kinoshita Y. Bile acids directly 
augment caudal-related homeobox gene Cdx2 expression in esophageal keratinocytes in Barrett's 
epithelium. Gut. 2006;55(1):16-25. 
187 McColl KE. When saliva meets acid: chemical warfare at the oesophagogastric junction. 
Gut. 2005 Jan;54(1):1-3. 
188 Suzuki H, Iijima K, Scobie G, Fyfe V, McColl KE. Nitrate and nitrosative chemistry 
within Barrett's oesophagus during acid reflux. Gut. 2005 Nov;54(11):1527-35. 
189 Moghissi K, Sharpe DA, Pender D. Adenocarcinoma and Barrett's oesophagus. A clinico-
pathological study. Eur J Cardiothorac Surg. 1993;7(3):126-31. 
190 Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the 
incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. The American 
Journal of Gastroenterology. 2003;98(11):2390-4. 
191 Sonnenberg A. Review article: anti-reflux surgery and endoluminal therapies. Aliment 
Pharmacol Ther. 2004 Oct;20 Suppl 5:81-8; discussion 95-6. 
 48
192 Jankowski J, Sharma P. Review article: approaches to Barrett's oesophagus treatment-the 
role of proton pump inhibitors and other interventions. Aliment Pharmacol Ther. 2004 Feb;19 
Suppl 1:54-9. 
193 Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, et al. 
Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised 
double blind study. Gut. 1999 Oct;45(4):489-94. 
194 Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose 
proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J 
Gastroenterol. 1997 Apr;92(4):582-5. 
195 Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 
mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther. 1998 
Sep;12(9):893-7. 
196 Cobey F, Oelschlager B. Complete regression of Barrett's esophagus after Roux-en-Y 
gastric bypass. Obes Surg. 2005 May;15(5):710-2. 
197 Csendes A, Bragheto I, Burdiles P, Smok G, Henriquez A, Parada F. Regression of 
intestinal metaplasia to cardiac or fundic mucosa in patients with Barrett's esophagus submitted 
to vagotomy, partial gastrectomy and duodenal diversion. A prospective study of 78 patients 
with more than 5 years of follow up. Surgery. 2006 Jan;139(1):46-53. 
198 Csendes A, Burgos AM, Smok G, Burdiles P, Henriquez A. Effect of gastric bypass on 
Barrett's esophagus and intestinal metaplasia of the cardia in patients with morbid obesity. J 
Gastrointest Surg. 2006 Feb;10(2):259-64. 
 
 
 
 
 49
Chapter 2 
 
THE INCIDENCE OF ADENOCARCINOMA IN BARRETT’S 
OESOPHAGUS IN AN INSTITUTIONALISED POPULATION 
 
Mark van Blankenstein1, Clarisse J. M. Böhmer2  ,Wim C.J.Hop3 
1Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center 
Rotterdam, The Netherlands. 
  2Spaarne Hospital Haarlem, Department of Gastroenterology, Haarlem, The Netherlands. 
3Department of Epidemiology and Biostatistics, Erasmus MC, University Medical Center, 
Rotterdam, The Netherlands. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eur J Gastroenterol Hepatol 2004;16:903-909 
 50
ABSTRACT 
 
Objectives. To ascertain the incidence rate of adenocarcinoma in Barrett’s oesophagus 
(ACO) in a stable population of 28 000 institutionalized intellectually disabled individuals 
(IDI) in whom the prevalence rate of Barrett’s oesophagus (BO) was previously estimated  in 
a representative sample by 24-hr pH monitoring and endoscopy and  in which all cases of 
ACO were ascertained over a 6 year period. These IDI do not smoke or drink alcohol and are 
known to have exceptionally high prevalence rates of gastro-oesophageal reflux disease 
(GORD) and consequently of BO. 
Methods. A population comprising 52 038 person years was observed and all cases of ACO 
were ascertained. On the basis of the representative sample, the percentage of this population 
with BO was estimated to be 10.8%. ACO incidence rates could then be estimated and 
compared to those found in a free living population with BO after correction for age and 
gender differences.  
Results. In IDI an incidence rate of ACO of 2.5/1000 person years was found against 
6.3/1000 person years in the free living population. However, the age distributions of the IDI 
and of the free living population were very different, and after correction for this factor there 
was no significantly lower incidence rate of ACO in the IDI (relative risk : 0.79; p= 0.61).  
Conclusions. This is the first reported incidence study of ACO in a stable, well defined 
population. In contrast to squamous cell carcinoma, our findings suggest only a minor role for 
smoking and alcohol in the etiology of ACO.  
. 
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INTRODUCTION 
Barrett’s oesophagus (BO) or columnar lined oesophagus and its most important 
complication, adenocarcinoma in Barrett’s oesophagus (ACO), are the result of longstanding 
severe gastro-oesophageal reflux disease (GORD) 1, 2. In adults this metaplastic lining has 
often undergone specialised intestinal metaplasia entailing a 30-125-fold increased risk of 
malignancy 3, 4. BO has been found in between 0.73% 5and 1% 6of all patients coming to 
endoscopy while a prevalence of 1% was established in an autopsy study7.  Rises in the 
incidence of adenocarcinoma in Barrett’s oesophagus (ACO) ranging between 5- and 8-fold 
over the last 15-20 years have been reported8, 9. The desire to combat this increasingly 
important gastrointestinal cancer by surveillance of patients with BO has stimulated interest 
in the incidence rate of ACO in these patients. However, incidence rates of ACO in patients 
with BO ranging between 1:48 10 and 1:441 11 patient years have been reported. This wide 
range is likely to have been the result of a number of factors including publication bias12 and 
chance. The latter factor is particularly important as these incidence rates were almost all 
calculated on the basis of the follow up of relatively small cohorts of patients with BO over a 
period of a few years 13. Ideally, true incidence rates should be established in large scale 
population-based incidence studies. This would require a stable, geographically defined, 
population, from which it would be necessary to recruit a random, representative, sample to 
undergo endoscopy in order to ascertain the prevalence of BO which, in an asymptomatic 
population, would probably be around 1% 7.  Therefore thousands of volunteers would need 
to be endoscoped in order to obtain meaningful results. In addition, the ascertainment of all 
cases of ACO over a period of years in a free living population moving in and out of the study 
area would present considerable difficulties.  
However, by combining data from two previously published studies, we were able to 
construct a population based study of intellectually disabled individuals (IDI) with an IQ <50 
in residential care in the Netherlands in whom the prevalence of GORD and consequently of 
BO, was known to be high 14, 15. In addition, this population was homogeneous for the non-
consumption of tobacco and alcohol while its diet and social conditions were similar. One 
study ascertained the prevalence rate of BO in a representative sample of IDI drawn from 
various institutions16. The second involved an observational study into the incidence of ACO 
in this stable and well documented population of 28 000 IDI over a period of six years 17. 
The study population was described elsewhere16. Briefly, the prevalence rate of BO in IDI 
was determined during a study in which the prevalence of GORD was established by 24-hour 
pH monitoring in a random sample of IDI drawn from 7 institutions. This sample was chosen 
to reflect both the age and gender composition of the inhabitants of these institutions and that 
of the total population of IDI in the Netherlands in general. 435 IDI were selected, the 
investigation was successful in 386 individuals (166 females, 220 males). All 24-hour pH 
measurements were performed by one experienced investigator (C.B.). GORD was diagnosed 
when the period with a pH < 4 during 24 hrs exceeded 4%, including an upright and a supine 
episode. Subsequently, all IDI in whom GORD was diagnosed underwent endoscopy by 
experienced local gastroenterologists. The diagnosis of reflux-esophagitis was made on the 
basis of the Savary Miller classification. 18. 
 BO was defined as columnar epithelium at least 3cm above the gastro-oesophageal junction 
and confirmed histologically.  
In a parallel study data on the occurrence of ACO in IDI was collected 17. The medical staffs  
of 97 institutions were requested to provide clinical data about the residents in their  
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institutions identified by the Netherlands Cancer Registry between 1989 and 1995 as 
suffering from histologically confirmed cancer of the oesophagus.  All cases of cancer are 
routinely reported to this registry by the histopathology departments of all hospitals in the 
Netherlands.19 19 of 97 institutions, comprising 987 residents, were unwilling to participate. 
Residents from the other 78 institutions, comprising 28 000 persons (mean age: 38.7 yrs; 
57.1% men, 42.9% women) were entered into a six-year long observational study running 
from 1-1-1989 to 1-1-1995.ACO was defined as adenocarcinoma of the oesophagus not 
involving the gastric cardia and preferably, but not necessarily, including BO above the 
tumour 20.  
The incidence rates of ACO were calculated from the age of 45 as no cases of ACO were 
found below this age. This was done as follows, after determining the prevalence rate of BO 
for the over 40-year age-group we estimated the number of person years with BO (i.e. the 
population at risk) during the follow-up period by multiplying the total number of IDI person 
years observed for each gender and  each age band by the observed prevalence rate of BO. 
This estimated number of person years with BO was the denominator in the calculation of   
the age and gender specific incidence rates of ACO. 
The whole procedure is summarized in Figure 1. 
Figure 1 
  28 987 IDI in Dutch institutions 
435 IDI representative  for age and gender composition 
selected for 24 hr pH monitoring 
 
Successful 24-hr pH monitoring in 386  
  
200 GORD negative     186 GORD positive 
 
After endoscopy 22 IDI 
 with BO 
 
 
14 IDI with BO   in the over 40 
age group of 130 →10.8% 
prevalence rate of BO 
 
 
8 673 IDI over the age of 45 observed 
during 6 years= 
 52 038 observed pers.yrs 
 
8 IDI with BO in the under 40 
age group of 125 = 3.1% 
 
52 038 observed pers.yrs      
x 0.108 
= 5 630 observed BO pers.yrs 
 
14 cases of ACE identified during 
52 038 pers.yrs observation of  IDI 
over age 45 
 
5 630 observed BO pers. yrs 
14 ACO 
  
 
 
14 IDI with ACO 
  
ACO incidence rate for IDI = 2.5 / 1000 person years 
 
A flow diagram illustrating the various steps involved in this study. In a representative sample of 
institutionalized intellectually disable individuals (IDI) , gastro-oesophageal reflux disease 
(GORD) was established by 24-hr. pH monitoring, GORD positive  IDI were endoscoped and the 
cases of Barrett’s oesophagus (BO) found served to establish the prevalence of BO in the tested 
sample and subsequently in the entire IDI population. The over-40 years old BO prevalence rate 
was used to estimate the number of observed person years (pers.yrs) of IDI with BO. After 
division by the observed 14 cases of ACO, this produced the ACO incidence rate for all IDI over 
the age of 40 years. Similar calculations were performed for males and females (not shown).  
 
 53
Subsequently, after correction for age and gender distribution, the incidence rates in IDI and a 
free living population studied by v.d. Burgh et al 21were compared by 5-year age cohorts 
starting from the age of 45. This study was chosen for comparison because it was the most 
extensive observational study published and showed consistent results at four and nine years 
follow up. In addition, this population had a similar ethnic background to the IDI 
STATISTICS  
The prevalence rates of BO by gender and age group were compared using Fisher’s exact test. 
The incidence rates of ACO in IDI and the free living population were compared using 
multivariate analysis (Poisson regression) while taking into account the age band and gender 
of the subjects in each group.  
ETHICAL APPROVAL AND INFORMED CONSENT 
The Subcommittee for the Ethics of Human Research of the Academic Hospital Vrije 
Universiteit in Amsterdam gave her consent for this study. All guardians (legal 
representatives of the IDI) were asked for informed consent for the anonymous use of medical 
information for scientific research. 
RESULTS 
The prevalence rate of GORD, determined by 24-hr. pH monitoring in the random sample 
was found to be 48%, comprising 44% (82/166) of the females and 56% (104/220) of the 
males. The prevalence rates of GORD remained constant for both genders over all age 
groups. Endoscopy in all subjects with GORD revealed reflux-esophagitis in 69%, 68% 
(56/82) in females and 70% (73/104) in males. BO was found in 22 (11.8%), comprising 
36.% (8/22)  in females and 64% (14/22) in males.16. The prevalence rate of BO was then 
calculated for all 386 tested subjects, both GORD positive and negative, assuming that no BO 
would be found in GORD negative IDI. 
The prevalence rate of BO was found to be significantly higher in the population over 40 
years, 10.8% (14/130), versus 3.1% (8/256) in the under-40 age group, p =0.004. In the 
GORD positive over-40 age-group 25.8% (8/31) of the males and 19.4% (6/31) of the females 
had BO (p=0.76 n.s.). In the whole tested sample (GORD + and ─) 11.3% (8/71) of the males 
and 10.2% (6/59) of the females had BO (p=1.0 n.s). Table 1. 
 
Table 1.The prevalence rates of Barrett’s oesophagus (BO) found in the random sample of IDI tested by 24-hr 
pH monitoring by age group, gender and gastro-oesophageal reflux disease (GORD) status (positive or negative) 
GORD Positive  (n=186) GORD  Negative (n=200) ALL TESTED (n=386) Age 
group  
males females total males females total males females total 
under 
40  
8.2%  
(6/73) 
3.8%  
(52/2) 
6.4% 
(125/80) 
─ 
 (0/76) 
─ 
(0/55) 
─ 
(0/131) 
4% 
(6/149) 
1.9% 
(2/107) 
3.1%# 
(8/256) 
over 
40 
25.8%§ 
(8/31) 
19.4%§ 
(6/31)  
21.9%  
(14/61) 
 ─ 
(0/40) 
  ─  
  (0/29) 
─ 
(0/69) 
11.3%* 
(8/71) 
10.2%* 
(6/59) 
10.8# 
(14/130) 
The prevalence rates of BO are expressed as percentages. The figures between parentheses are: the 
number of IDI with BO/ number tested in each category. In GORD negative IDI  no endoscopies were 
performed as it was assumed that none had BO. The observed prevalence rate of BO was 10.8%.  
§ difference not significant, p=0.76, * difference not significant, p= 1.0,  # difference significant, p = 0.004 
 
The over-40 prevalence rate of 10.8% was subsequently used in estimating the number of BO 
person years (i.e. the population at risk), which in turn was the denominator in calculating 
ACO incidence rates. 
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The number of all cancers of the oesophagus and gastric cardia in IDI over the age of 45,  
observed during 52 038 person years, was 20. Of these two were squamous cell carcinomas, 
four adenocarcinomas of the gastric cardia and 14 were ACO. After correction for age and 
gender distribution, the incidence of these first two tumours was in accordance with, but that 
of ACO considerably in excess of, the expected incidence in the general Dutch population19. 
The number of person-years observed, the estimated number of BO person-years, the 
number of cases of ACO and the resulting incidence rates are presented in Table 2.  
..  
The overall ACO incidence rate for IDI was 2.5/1000 person years. For males this was 
3.5/1000 person years and for females 1.2/1000 person years.  
The ACO incidence in our free-living population was 6.3/1000person years. For males this 
was 9/1000 person years and for females 3.4/1000 person years. (Table 3). 
However, after correction for differences regarding the age and gender distributions, there 
was no significant difference in the incidence rate of ACO between the IDI group and the free 
living population. The relative risk of ACO in IDI versus our free living population was 0.79 
(p = 0.61). 
 The gender specific ACO incidence rates for both populations showed a male predominance 
which in IDI just failed to reach significance. 
  
Table 2. The number of observed person years for all institutionalized intellectually disabled 
individuals (IDI) and the estimated number of person years with Barrett’s oesophagus (BO) 
Cases of Adenocarcinoma of the Oesophagus Observed 1989-1995 
Column 
1 
Column 
 2 
Column 
3 
Column 
 4 
Column 
 5 
Column 
 6 
Column 
 7 
Column 
8 
Column 
 9 
Column 
    10 
Age bands All 
Males 
BO pos. 
x 0.108 
All 
Females 
BO pos.
x 0.108 
All 
M+F 
BO pos. 
x 0.108 
Males Females Total 
45-49 years 8 156 881 6 178 667 14 334 1 548 1 0 1 
50-54 years 5 432 587 4 426 487  9 858 1 074 1 0 1 
55-59 years 5247 567 3 927 424  9 174    991 1 0 1 
60-64 years 4 075 440 2 975 321  7 050    761 1 0 1 
65-69 years 2 967 320 2 265 245  5 232    565 1 1 2 
70-74 years 1 641 177 1 467 158  3 108    335 3 0 3 
75-79 years 1 118 121    850 92  1 968    213 1 2 3 
>79    years    748 82    566 61  1 314     143 2 0 2 
Totals 29 384 3 175 22 654 2 455  52 038 5 630 11 3 14 
Incidence rates: males: 11/ 3175= 3.5 /1000 person years (column 8/3); females: 3/2455= 1.2 /1000 person 
years (column  9/5; males + females: 14/ 5630= 2.5 / 1000 person years (column 10/7). 
Columns 2 and 4 present the number of person-years by age and gender observed during the six year follow up. 
Column 6 presents the numbers for both genders combined. Columns 3, 5 and 7 represent the estimated number 
of observed person years of IDI with BO obtained by multiplying the numbers in columns 2,4 and 6 by 0.108 
(10.8% prevalence rate of BO ). Columns 8, 9 and 10 represent the incidence of ACO by age, gender and both 
genders combined. Incidence rates of ACO were calculated by dividing the totals in columns 8, 9 and 10 by 
those in columns 3, 5 and 7. 
 
 55
 
 
DISCUSSION 
 
This study was designed to estimate the incidence rate of adenocarcinoma of the oesophagus 
for individuals with Barrett’s oesophagus (BO) belonging to a unique institutionalized 
population of Intellectually Disabled Individuals (IDI). The prevalence rate of BO in this 
population was estimated from a BO prevalence rate previously established in a 
representative sample of IDI from a number of these institutions. As this prevalence rate was 
probably at least tenfold higher than in the general population, the incidence of 
adenocarcinoma of the oesophagus (ACO) found in this population was far higher than would 
have been found in a general population of the same size and age distribution. In addition, the 
ascertainment of individuals with BO was unique in not being based on the presence of 
symptoms leading to endoscopy but on the random selection of individuals to be tested for 
GORD. 
The overall incidence rate of ACO found of 2.5/1000 person years was far lower than both the 
incidence of 5/1000 person years recently estimated on the basis of 25 BO follow-up studies 
12 and the overall ACO incidence rate in our free living population, used for comparison, of 
6.3/1000 person years.  
This lower incidence rate was, however, both a reflection of the difference in gender 
distribution and, most importantly, of the life expectancy of IDI, which is far lower than that 
of the general population. Consequently, their age and gender distribution differed greatly 
from both that of the population at large and from that of our free living population in having 
relatively younger individuals. Therefore, adjustment for age and gender distribution was 
essential for an unbiased comparison. After this correction no significant difference was 
found between the incidence rate of ACO in our free living population versus the IDI (relative 
risk 0.79, p=0.61). Therefore, this study, failed to demonstrate different risks of developing 
ACO for individuals with BO of the same age from both populations. However, in view of its 
limited size, it  was also unable to disprove the existence of  some differences in ACO risk in 
Table 3. A comparison of the estimated observed person-years for intellectually disabled individuals 
(IDI) and the observed person years for free living patients, by age band and gender, and the 
incidence of ACO for both populations. 
 IDI Free living BO cohort 
 Males Females Males Females 
Age bands Person- 
years 
ACO Person- 
years 
ACO Person- 
years 
ACO Person- 
years 
ACO 
45-49 years 881 1 667 0 55 0 8 0 
50-54 years 587 1 487 0 73 1 6 0 
55-59 years 567 1 424 0 88 0 26 1 
60-64 years 440 1 321 0 101 0 39 0 
65-69 years 320 1 245 1 127 2 62 0 
70-74 years 177 3 158 0 120 3 110 0 
75-79 years 121 1 92 2 52 0 146 0 
>79   years 82 2 61 0 57 0 192 1 
Totals 3 175 11 2 455 3 673 6 589 2 
Incidence 
rates 
3.5 /1000 person-
years 
1.2 / 1000 person- 
years 
8.9 / 1000 person-   
years 
3.4 / 1000 person- 
years 
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either directions, i.e. the risk in IDI to be higher or lower than in the free living population. 
In addition, our findings are a clear example of the fact that a comparison of incidence rates 
of ACO between various cohorts of patients with BO can only be valid after correction for 
age and gender differences. 
An additional unique feature of this institutionalized population was its homogeneity for the 
factors non-consumption of tobacco and alcohol, ethnic background, diet and social 
conditions. The fact that their incidence rate of ACO did not differ significantly from that of 
our free living population, in which a considerable mortality from smoking related diseases 
was found 21 supports the modest role of smoking and alcohol consumption in the aetiology of 
ACO which was recently summarized in a review of case-control studies by Cameron 22. For 
smoking he found odds ratios between smokers and controls varying between 1.5 and 3.4, far 
lower than in squamous cell carcinoma where odds ratios of 10.4 and 16.9 were recorded.23-28. 
as can be seen in Tables 4 and 5 
 
 
On the influence of alcohol, Cameron found only a modest correlation with heavy alcohol  
intake in 3 of 6 case-control studies, but no correlation in the other 3 which included the two 
largest. Although not reaching statistical significance, we found a higher incidence rate of 
ACO in male IDI compared to that of females of about 3 to 1, which was actually lower than 
published sex ratios in the incidence rates of ACO in the general population ranging between 
6 and 8 to1 8, 9.  
In theory this sex ratio could merely reflect the lower prevalence rate of BO in females but no 
gender specific differences in the prevalence rates of BO of this magnitude have as yet been 
published and the cause of this excess male incidence is as yet unexplained. 5, 6, 29, 30 
 
 
Table 5.           Smoking and squamous cell carcinoma: case control studies 
Author Location Cases 
n. 
Smoking: Odds Ratio versus  controls 
(95% confidence interval) 
Vaughan 199525 Oesophagus 106 16.9 (4.1-69) (>80 pack  years) 
Lagergren 200028 Oesophagus 167 10.4 (5.6-19.4) (> 20 cigarettes >35 yrs) 
    
Table 4         Smoking and adenocarcinoma: a summary of case-control studies 
Author Adenocarcinoma  
Location 
Cases  
 
Smoking: Odds Ratio versus 
controls (95% confidence interval) 
Kabbat  199323 Oesophagus. and cardia 122                 2.3 (1.4-3.9) 
Brown  199424 Oesophagus. and cardia 174 2.1 (1.2-3.8) 
Vaughan  199525 Oesophagus. and cardia 298  3.4 (1.4-8.0)  
Zhang  199626 Oesophagus. and cardia 95 1.5 (0.7-3.0) 
Gammon  199727 Oesophagus 293 2.2 (1.4-3.3) 
 Cardia 261 2.6 (1.7-4.0) 
Lagergren 2000 28 Oesophagus 189 1.6 (0.9-2.7) 
 Cardia 262 4.5 (2.9-7.1) 
Tables 4 and 5 data adapted from Cameron22  with permission of the author.  
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 However, in IDI the excess male ACO incidence ratio cannot have been caused by differing 
lifestyles, including smoking and would appear to reflect some inherent protection against 
ACO by female gender. 
Obviously, the reliability of the incidence of ACO calculated for the IDI population hinged on 
the accuracy with which the prevalence of BO was ascertained in the sample population. This 
prevalence rate was determined by means of a random sample of IDI drawn from 7 
institutions, which was subsequently shown to be representative for the total population of 
IDI in the Netherlands. The diagnosis of GORD by 24-hour pH measurement is a well 
established technique 31, 32. The separation between normal and pathological reflux in the 
sample of IDI was extremely clear-cut with only 4 cases in the intermediate zone with a pH< 
4 between 4.5-6% of the measured time. Also the prevalence rate of GORD remained 
constant over the various age-groups 16.There was a significant rise in the prevalence of BO 
around age 40, similar to that found in other studies 5, 6, 30. In addition smaller studies found 
similar prevalence rates of BO in IDI 14, 15, 33. Finally, the diagnosis of BO was established by 
5 experienced endoscopists and confirmed by histology. 
IDI without GORD did not undergo endoscopy because it was assumed that BO would not 
occur in the absence of GORD. However, two studies suggested that this combination could 
occur and the authors kindly communicated their detailed data. They found 6 of 51 and 3 of 
16 cases of BO respectively (a total of 9/66) with 24-hour pH measurements within the 
normal range 32, 34. As there is no published data on the prevalence of BO in an unselected 
population without GORD, it was impossible to calculate a statistically reliable figure for the 
prevalence of BO in IDI without GORD. However, on the basis of these 9/66 cases of BO 
without GORD, it was estimated that 3 such cases could have been missed in the prevalence 
study through false negative 24-hour pH measurements. The addition of these 3 cases to the 
original 14 would have increased the BO prevalence rate to 13% instead of 10.8%. However, 
recalculations with this higher prevalence rate resulted in ACO incidence rates for IDI which 
again did not significantly differ from that found in our free living population, with a relative 
risk of 0.65, (p=0.37).  
It could be argued that IDI, by the nature of their condition, cannot be considered a suitable 
model for the effects of GORD in the intellectually normal population. However, besides their 
I.Q., their only fundamental difference from the general population, lies in their abnormally 
high prevalence of GORD for which no clear explanation has yet been  found but is already 
present from childhood, the most important factor appearing to be an IQ < 35. 16. 
In addition, the prevalence of BO in IDI with GORD was not higher than that found in studies 
of patients with GORD of normal intelligence 35, 36. 
The ascertainment of ACO in the population of IDI is likely to have been accurate.  
Oesophageal cancer invariably becomes symptomatic. The fact that some IDI with ACO 
would have been asymptomatic at the end of the observation period is offset by the fact that a 
similar number would have been asymptomatic at the start of observation period. In addition, 
the incidence of squamous cell carcinomas and carcinomas of the gastric cardia was in 
accordance with the age related incidence in the general population.  
In conclusion, this is the first observational study into the incidence rate of ACO in a stable, 
well observed and defined population in which the prevalence rate of BO was first established 
by a randomly selected representative sample. As this population does not consume alcohol or 
tobacco this incidence rate, corrected for age and gender, should be considered as the 
minimum for observational studies. That this incidence rate did not differ significantly from 
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that found in a free living population supports the case control studies indicating that the role 
of alcohol and tobacco in the aetiology of ACO is far smaller than in squamous cell 
carcinoma of the oesophagus. In addition, our data do not support the theory that the lower 
incidence rate of ACO in females mainly results from differences in lifestyles such as 
smoking or alcohol consumption. 
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ABSTRACT 
Background: Both the demographics underlying the sex ratio in the prevalence of Barrett’s 
oesophagus (BO) and the status of BO without intestinal metaplasia (IM) is unclear. 
Aims:  To establish the demographics of histologically proven BO, IM positive and IM negative, 
over a 15 year period from a primary referral, endoscopy unit.  
Patients and methods: For all BO patients aged 20-89 identified between 1982-96, IM positive 
or IM negative, prevalence rates were calculated per 100 first endoscopies.   
Results. 492 cases of BO, 320 (248 IM positive) in males, 172 (127 IM positive) in females were 
identified in 21,899 first endoscopies (10,939 males, 10,960 females).  Between ages 20-59 in 
males and 20-79 in females, IM positive, IM negative and all BO prevalence rates rose by 
±7.36% for each additional year of age (p=0.92) with however, a 20 year age shift between the 
sexes, resulting in an male: female O.R. 4.15 95%CI 2.99-5.77. A declining rate of increase in 
over 59 males resulted in an overall male: female O.R. 2.14, 95%C.I. 1.77-2.58. Over the age of 
79, BO prevalence rates/100 first endoscopies fell from a maximum of 5.1 in males and 3.65 in 
females to 3.38 and 2.53 respectively. 
Conclusion: The 4:1 sex ratio and 20 year age shift between males and females in the prevalence 
of BO, both IM positive and IM negative, found in younger age groups, was the main cause of 
the overall BO 2:1 sex ratio. The very similar demographics of IM negative and IM positive BO 
suggest they may be 2 consecutive stages in the same metaplastic process.  
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INTRODUCTION 
Over the last 50 years Barrett’s oesophagus (BO) has evolved from  a medical oddity1to a pre-
malignant condition thought to lie at the root of most2,if not all3cases of adenocarcinoma of the 
oesophagus (ACO) which constitutes the gastrointestinal malignancy with the fastest growing 
incidence in the industrialised world4. Considerable effort is currently directed towards secondary 
prevention by means of endoscopic surveillance5 of the about 5% of the individuals identified 
with BO6.  
Designing effective preventive strategies for patients with BO requires a greater knowledge of the 
epidemiology of BO. The usual methods of ascertaining BO, endoscopy with biopsy and the less 
usual, autopsy7, are neither acceptable nor feasible for  large scale population surveys. In 
addition, a large proportion of the 95% unidentified BO population6 is asymptomatic6, 8, 9, 
probably because of their relatively insensitivity to reflux symptoms10-14. Consequently, only 
random surveys would be able to ascertain the true prevalence of BO in the general population. 
Attempts in patients undergoing colonoscopy have produced conflicting results. A 7% prevalence 
of long segment BO was found in a group of 110 asymptomatic, predominantly male, veterans 
with a mean age of 61 years15. In contrast, only 1.2% long segment BO was reported from a 
group of 961 patients, mean age 59 years, including symptomatic patients,  40% women and 20% 
blacks16.  Therefore, large scale epidemiological data can, as yet, only be derived from findings in 
patients who have undergone endoscopy but who, for reason of selection bias17 cannot be 
representative for the whole BO population. Consequently no conclusions about the BO 
prevalence within the general population can be drawn from such studies. However, the 95% 
‘silent majority’ with BO who ultimately present with ACO6 was found to  display a male 
predominance and an age specific incidence  rise18  similar to that found in BO prevalence17, 19.     
Therefore, in the absence of better data, the age and sex specific BO prevalence rates found in 
large series of endoscoped patients from primary referral centres may serve to provide an 
impression of the relative BO prevalence rates within the population of their catchment areas and 
help in understanding BO sex ratios.  
A previously published study on the occurrence of BO provided the data base for the present  
study20. It came from a single endoscopy unit in a community hospital serving an area of over 
400 000 inhabitants over the age of 2021 and to which patients were directly referred by general 
practitioners, thus avoiding the accumulation of selected cases often found in referral centres.  
These existing data were reanalyzed by calculating the prevalence of BO, including cases with 
(IM positive) and without (IM negative) intestinal metaplasia (IM), per 100 first endoscopies for 
both sexes by 10-year age bands over the 3 consecutive 5-year periods. These results were then 
analyzed statistically in order to establish the constancy in pattern of prevalence rates for all three 
categories over each of the three 5-year periods, to search for the origins of the sex ratios in BO 
prevalence rates and investigate demographic differences between IM positive  and IM negative 
BO. 
 
METHODS  
Endoscopies at the Wexham Park Hospital endoscopy unit were performed by a team of 
endoscopists under supervision of a senior endoscopist with a special interest in BO. 
All original upper gastrointestinal endoscopy paper report forms from this unit for the period 
January 1977 to December 1996 were searched manually (From 1990 information was kept on an  
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electronic database) looking for description of features attributable to BO or mentioning BO in 
the diagnosis. Histology reports were attached to the original endoscopy reports.  
A diagnosis of BO was made when the squamo-columnar junction was seen to be proximal to the 
upper limit of the gastric folds, whatever the length of lesion. Only the 80% of cases where there 
was histological confirmation from biopsies taken from the correct site were included in this 
series. BO was diagnosed when the biopsies showed columnar type mucosa with either gastric-
type mucosa or intestinal metaplasia (IM). No specialist staining was performed for IM but this 
was recognized by the presence of goblet cells on H&E stained sections. If seen, IM was 
automatically mentioned in the histopathology report. Gastric-type mucosa was included in our 
analysis as it was thought to be a possible precursor of IM22.  
Results from the period 1977-1981 period were discarded as the number of cases of BO 
identified was far smaller than in the subsequent 5-year periods. In addition, results from the age 
bands 0-19 and 90+ were also discarded as both the number of cases of BO and the number of 
endoscopies were too small to provide meaningful data. In order to avoid overestimation of the 
number of endoscopies in calculating prevalence rates, it was essential that the numerator should 
only consist of first endoscopies. This was established by entering all patient identifiers on a 
computer database and removal of multiple records for the same patient.  The prevalence rates of 
BO (IM positive or IM negative) per 100 first endoscopies could then be calculated from the 
number of cases of BO (IM positive or IM negative) by sex, 10-year age bands and 5-year 
periods.  
 
STATISTICS. 
Logistic regression analysis of the prevalence results was applied in three steps. The first was to 
identify possible differences by sex for the age specific BO (IM positive or IM negative) 
prevalence rates between the three 5-year periods by the interaction of age and sex plus the three 
5-year periods (age and period as categorical variables). The second looked for differences by sex 
in the patterns of the age specific BO (IM positive or IM negative) prevalence rates by the 
addition of the interaction of age and 5-year period.  
 In the third step the exponential segments (for males from ages 20-59, for females from ages 20-
79) of the age specific rise in the prevalence rates of BO (IM positive or IM negative)  for both 
sexes, which appeared to display specific patterns, were further analyzed by estimating their rates 
of increase for each additional year of age by logistic regression.  
This resulted in sigmoid curves. To fit these curves age was now used as a continuous predictor, 
with the mean ages per age band as values. This allowed the estimation of  
BO (IM positive or IM negative) prevalence rates per 100 first endoscopies for every possible age 
within the age ranges over which logistic regression of the rates of increase was consistent with a 
simple sigmoid curve.  
 
RESULTS 
The percentage distribution of the population over the age of 20 of the catchment area for the 
endoscopy unit and a similar percentage breakdown of the endoscoped population by 10-year age 
bands and sex are displayed in figure 1. There were considerable differences between these two 
age distributions. In addition, it can be seen that there were relatively more males endoscoped 
between the ages of 20-40 and relatively more females over the age of 70. However, as the BO 
prevalence rates were calculated per 100 first endoscopies, these were not influenced by these 
discrepancies.  
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Figure 1. A comparison between the age and sex distribution of the population of the catchment area in 1991 and 
that of the patients undergoing a first endoscopy at Wexham Park Hospital between 1982 and 1996.  
 
The number of cases of BO (IM positive or IM negative) identified, tabulated by age and sex, 
together with the number of first endoscopies and the resulting BO (IM positive or IM negative) 
prevalence rates/100 first endoscopies for both the three 5-year periods and the overall 15-year 
periods, are shown in Tables 1 and 2 and are graphically presented in Figures 2, 3 and 4. In males 
the number of first endoscopies was 11 195, identifying 320 cases of BO, 248 IM positive and 72 
IM negative, in females these figures were 11 211 and 172, 127 IM positive and 45 IM negative 
respectively. The mean age at diagnosis of BO was about 62 for males and 72 for females. In 
both sexes, the levels of the BO prevalence rates for the periods 1982-1986 and 1987-1991 were 
similar. However, those for 1992-96 were 50% higher (p<0.001) than found in the two previous 
5-yr periods. In both sexes the patterns of the age specific IM positive, IM negative, and all BO 
prevalence rates, as shown in Figures 1 and 2, did not differ significantly for the three 5-yr 
periods and the total 15-yr period (p = 0.34 for all males, p = 0.55 for IM positive mal es and  p = 
0.13 for all females, p = 0.07 for IM positive females.) 
In males, the age specific BO prevalence rates for 1982-96 rose rapidly between the ages of 20 
and 59 to 3.83/100 first endoscopies ( 3.1 IM positive. 0.73 IM negative.),  after which the rate of 
increase fell sharply.  The male BO prevalence rates eventually reached a maximum of 5.1/100 
first endoscopies (3.96 IM positive, 1.14 IM negative) in the 70-79 age band. In females, the age 
specific BO prevalence rates for 1982-96 were initially far lower, only reaching the 1.0/100 first 
endoscopies level in the 55-59 age band. They eventually attained a maximum BO prevalence of 
3.65/100 first endoscopies (2.7 IM positive, 0.95 IM negative) in the 70-79 age band. The 
maximum BO prevalence for both sexes combined in the 70-79 age band was 4.29/100 first 
endoscopies (3.26 IM positive, 1.03 IM negative).  Above the age of 59 for males and the age of 
79 for females, the rates of increase in the BO prevalence rates were no longer consistent with a 
simple sigmoid curve. 
 
 
  66
 
 
Table 1.The Numbers and Prevalence rates/ 100 First Endoscopies of IM Positive, IM Negative 
and all Cases of Barrett’s Oesophagus, by 10-year Age Bands for the Three 5-year Periods and 
for the Total 15-year Period. 
    Males      
                                 Age bands 20-29 30-39 40-49 50-59 60-69 70-79 80-89 Totals 
5-year periods   Endoscopies      n. 416 484 508 580 562 409 113 3 153 
1982-86 BO IM positive.       0 1 8 9 11 15 3 47 
 Prevalence  0 0.2 1.57 1.55 1.96 3.67 2.65 1.49 
 BO IM negative        0 2 1 4 10 3 1 21 
 Prevalence  0 0.42 0.20 0.69 1.24 0.98 0.88 0.67 
 All BO               n. 0 3 9 13 21 18 4 68 
 Prevalence  0 0.62 1.77 2.24 3.2 4.65 3.53 2.16 
1987-91 Endoscopies      n. 405 480 555 595 675 511 182 3 487 
 BO IM positive.       0 4 5 13 23 12 3 60 
 Prevalence   0 0.83 0.9 2.18 3.4 2.35 1.65 1.72 
 BO IM negative        2 2 1 4 5 10 1 25 
 Prevalence  0.49 0.42 0.18 0.68 0.75 1.95 0.55 0.72 
 BO total            n. 2 6 6 17 28 22 4 85 
 Prevalence  0.49 1.25 1.08 2.86 4.15 4.3 2.2 2.44 
1992-96 Endoscopies      n. 441 691 744 758 838 695 297 4 555 
 BO IM positive.       0 7 16 38 33 37 10 141 
 Prevalence  0 1 2.15 5 3.94 5.32 3.37 3.1 
 BO IM negative        0 2 5 6 6 5 2 26 
 Prevalence  0 0.3 0.67 0.8 0.71 0.68 0.67 0.56 
 All BO               n.    0 9 21 44 39 42 12 167 
 Prevalence  0 1.3 2.82 5.8 4.65 6 4.04 3.66 
      15-yr period Endoscopies      n. 1 262 1 655 1 807 1 933 2 075 1 615 592 11 195 
1982-1996 BO IM positive.       0 12 29 60 67 64 16 248 
 Prevalence  0 0.73 1.6 3.1 3.23 3.96 2.7 2.21 
 BO IM negative        2 6 7 14 21 18 4 72 
 Prevalence  0.16 0.36 0.4 0.73 1.01 1.14 0.68 0.65 
 All BO               n. 2 18 36 74 88 82 20 320 
 Prevalence  0.16 1.09 2 3.83 4.24 5.1 3.38 2.86 
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Subsequently, in the 80-89 age band the BO prevalence rates declined steeply in both sexes to 
3.38/100 first endoscopies (2.7 IM positive, 0.68 IM negative) in males and 2.53/100 first 
endoscopies (1.81 IM positive, 0.72 IM negative) in females. No significant differences between 
the age specific rates of increase in the prevalence rates of IM positive, IM negative and all BO 
were found, males p=0.23, females p=0.86.  (Tables 1 and 2, Figure 4).  
Logistic regression applied to the BO prevalence rates for males between the ages of 20-59 and 
for females between the ages of 20-79, demonstrated that for each additional year of age, the BO 
prevalence rates in both sexes increased by similar percentages: 7.59% for IM positive, 6.51% for 
IM negative and 7.36% for all BO, p=0.92. (Figure5) For these two limited age ranges a male: 
female O.R. of 4.15, 95% C.I. 2.99- 5.77 was found. 
Table 2. The Numbers and Prevalence rates / 100 First Endoscopies of IM Positive, IM 
Negative and all Cases of Barrett’s Oesophagus, by 10-year Age Bands for the Three 5-year 
Periods and for the Total 15-year Period. 
 Females 
                                   Age bands              20-29 30-
39
40-49 50-59 60-69 70-79 80-89 Totals 
5-year periods   Endoscopies      n. 224 338 448 478 489 496 235 2 781 
1982-86 BO IM positive.       0 1 0 0 7 16 1 25 
 Prevalence    0 0.3 0 0 1.43 3.23 0.43 0.9 
 BO IM negative        0 0 1 0 2 4 4 11 
 Prevalence  0 0 0.22 0 0.40 0.77 1.7 0.39 
 All BO                n. 0 1 1 0 9 20 5 36 
 Prevalence  0 0.3 0.22 0 1.84 4 2.13 1.29 
1987-91 Endoscopies       n. 280 381 509 510 620 585 321 3 290 
 BO IM positive.        0 0 4 5 6 10 4 29 
 Prevalence  0 0 0.79 0.98 0.97 1.71 1.25 0.88 
 BO IM negative        0 0 1 3 6 9 1 20 
 Prevalence  0 0 0.18 0.59 0.97 1.54 0.31 0.60 
 All BO                n. 0 0 5 8 12 19 5 49 
 Prevalence  0 0 0.98 1.57 1.94 3.25 1.56 1.48 
1992-96 Endoscopies       n. 422 623 786 870 877 919 549 5 140 
 BO IM positive.        0 2 5 8 15 28 15 73 
 Prevalence  0 0.32 0.64 0.92 1.71 3.05 2.73 1.42 
 BO IM negative        0 0 0 3 2 6 3 14 
 Prevalence  0 0 0 0.34 0.23 0.65 0.55 0.27 
 All BO                n. 0 2 5 11 17 34 18 87 
 Prevalence  0 0.32 0.64 1.26 1.94 3.7 3.28 1.69 
15 year period         
1982-96 Endoscopies       n. 926 1 342 1 743 1 858 1 986 2 000 1 105 11 211 
 BO IM positive.        0 3 9 13 28 54 20 127 
 Prevalence  0 0.22 0.52 0.7 1.41 2.7 1.81 1.13 
 BO IM negative        0 0 2 6 10 19 8 45 
 Prevalence  0 0 0.11 0.32 0.50 0.95 0.72 0.40 
 All BO                n. 0 3 11 19 38 73 28 172 
 Prevalence  0 0.22 0.63 1.02 1.91 3.65 2.53 1.53 
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Because the overall age specific BO prevalence curves were non-linear, the overall age shift 
between males and females could not be calculated. However, as shown above, for males 
between the ages of 20 and 59 and females between the ages of 20 and 79, this age shift was 20 
years. For the whole age range between 20 and 89, after correction for age and period, logistic 
regression demonstrated the BO prevalence in males to be double that  
in females, O.R.2.14, 95%C.I.1.77-2.85. However, because of the age shift mentioned above, this 
O.R. was strongly influenced by the age distribution of patients examined i.e. a different age 
distribution would have resulted in a different outcome. 
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Figure 2. The 
male BO 
prevalence 
rates/100 first 
endoscopies for 
the three 5-year 
periods and all 
BO and IM 
positives for the 
whole 15-year 
period. There 
were no 
significant 
differences 
between the 
patterns found 
for each of the 
three 5-year 
periods and 
both 15-year 
periods, p=0.34 
for all BO, 
p=0.55 for IM 
positives.  
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Figure 3. The 
female BO 
prevalence 
rates/100 first 
endoscopies for 
the three 5-year 
periods and all 
BO and the IM 
positives for the 
whole 15-year 
period. There 
were no 
significant 
differences 
between the 
patterns found 
for each of the 
three 5-year 
periods and 
both 15-year 
periods, p=0.13 
for all BO, 
p=0.07 for IM 
positives. 
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Figure 4. The male and female prevalence rates/100 first endoscopies for IM positive and all BO over the whole 15-
year period. The area between the all BO and IM positive lines encompasses the IM negative patients. The overall 
male: female, O.R. was 2.14, 95%C.I. 1.77-2.58.  
 
DISCUSSION 
This study analyzed the demographics of a population of almost 500 subjects with Barrett’s 
oesophagus (BO) and by the inclusion of all cases of columnar lined oesophagus, made possible a 
demographic comparison of subjects with and without intestinal metaplasia (IM). In addition, it 
demonstrated the origin of the overall male: female ratio of 2:1 in the prevalence rates of BO. 
We did not attempt to extrapolate BO prevalence rates from our patients undergoing endoscopy 
to BO prevalence rates for the catchment population. A valid extrapolation would require two 
conditions. The first was a similar age and sex distribution between the catchment population and 
the patients undergoing endoscopy. Figure 1 shows that this was not the case. More importantly, 
the patients should be selected at random, a condition obviously never met in clinical medicine. 
In patients with symptoms of reflux, the prevalence of BO is known to be far in excess of that 
found in those with other symptoms17, 23, 24. On the other hand, between 35% and 48% of the 
patients presenting with adenocarcinoma of the oesophagus (ACO) and therefore with BO, had 
no history of reflux symptoms2, 8, 9, 25, 26.   Therefore, in clinical endoscopy there are factors 
leading to both over- and to under diagnosis of BO and their relative proportions are unknown. 
However, a large proportion of the BO population is likely to be missed by clinical endoscopy27.  
Both the size of our sample of 22 400 (5.5%) of the 404 000 inhabitants over the age of 20 in our 
catchment area undergoing a first endoscopy and the consistent BO prevalence patterns over the 
three 5-year periods (Figures 2 and 3), encouraged us to suppose that the patterns of the age and 
sex specific prevalence rates and the sex-ratios found in this study provided the best available 
estimate of these parameters within the BO population of this particular district. 
For both sexes the age specific BO prevalence rates/ 100 endoscopies increased without any 
significant differences between IM positive, IM negative, and all BO individuals (Figure 4). 
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In addition, for males between the ages of 20 to 59 and for females between the ages of 20-79, 
the prevalence rates for IM positive, IM negative and all BO individuals increased by practically  
identical  percentages (7.59%, 6.51% and 7.36% respectively, p=0.92) for each additional year of 
age. (Figure5) Over this limited age range, the male: female O.R. was in excess of 4:1 and an age 
shift was found between the parallel incidence rate curves of 20 years. Conceptually, the female 
curve could be considered to have started from the same value but 20 years later than the male 
curve.  
In males over the age of 59 the rate of increase in the BO prevalence rates for each additional 
year of age suddenly declined, causing the logistic regression model for males to be terminated at 
age 59. 
 Had the 7.36% rate of increase in males been maintained after the age of 59, this would have 
resulted in over 400 cases of BO between the ages of 59 and 79, instead of the 170 actually 
observed. The sudden onset of a competing cause of death, specifically affecting over 50% of the 
males with BO in this age group is unlikely2, 28, 29.  The absence of a similar decline in females 
below the age of 79 would also appear to contradict, although not rule out, a birth cohort effect. 
This effect describes a continuous rise in the BO prevalence rates in consecutive birth cohorts, 
resulting in relatively lower BO prevalence rates in the elderly. 
Whatever the cause, the ‘loss’ of over 50% of the potential males with BO over age 59, resulted 
in the final overall (ages 20-89 for both sexes) male: female O.R. of 2.14. This O.R. was mainly 
the result of the 20-year age shift between male and female age specific prevalence rates. 
Male: female ratios in the prevalence of BO ranging between 2:1 and 4.1:1 were found in 3 
previous studies17, 19, 30. Both the GOSPE and our study (Figure 4) found a slower age specific 
rise in the female BO prevalence rates under the age of 60. In contrast, a Mayo Clinic study 
found a parallel rise in the age specific BO prevalence rates for both sexes and here an age shift 
was obviously absent19. The reason for this difference between European and US female age 
specific BO prevalence patterns is not apparent.  
The maximum prevalence rates for both sexes combined in  both the GOSPE and the Mayo 
Clinic study were about 1%17, 19. This figure recurred in a later update of the Mayo Clinic data for 
the total of 12 097 residents of Olmsted County undergoing endoscopy in the 33 years between 
1965-9730. Our study, derived from 22 400 first endoscopies in 15 years, found a maximum BO 
prevalence for both sexes combined of 4.29%. This difference may indicate both true regional 
differences in prevalence rates31 or in  referral  patterns. 
As in the two earlier studies17, 19, 31 we did observe a steep fall in the BO prevalence rates after the 
age of 79 in both sexes. 
A recent study from the UK National Barrett’s Oesophagus Registry, comprising 5717 patients 
with BO, found a mean age at diagnosis of BO of 61.4±14.5 for males and 67.5±13.9 for 
females32. Although these were not prevalence rates and may have been skewed by a higher 
endoscopy rate in older people, the clear difference between the mean ages for both sexes do 
support the existence of an age shift. In addition, the mean age at diagnosis of ACO in this study 
was 64.7±8.2 for males and 74.0±8.5 for females, again suggesting a later onset of BO in 
females. 
The 4.15:1 sex ratio found in the young and middle-aged groups could help to explain the   6-8 
fold higher incidence rates of ACO in males33, 34. As the period between developing BO and 
symptomatic ACO probably spans decades27,  most victims of ACO are likely to have acquired 
BO before the age of 60. In addition, with females developing BO at a higher age than males, 
many would not survive long enough to progress to symptomatic ACO. 
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Figure 5. The rate of increase in the all BO prevalence rates/100 first endoscopies for each additional year of age as 
estimated by logistic regression, between the ages of 20 and 59 in males and 20 and 79 in females, was 7.36%, 
p=0.45. The points represent the mean values for each age band. In both sexes, the rates of increase for each 
additional year of age for IM positive and IM negative, were 7.59% and 6.51%, p=0.92.(Not shown separately in the 
figure.) The male: female O.R over this limited age range was 4.15, 95%C.I. 2.99-5.77,  the age shift between the 
male and female prevalence curves was 20 years.  
 
The age shift of 20 years in the onset of BO in females found in our study resulted in a low BO 
prevalence in females during their reproductive years, possibly by female hormones affording a 
certain degree of protection against the development of BO. A recent study of over 1800 patients 
with severe reflux esophagitis (grades C and D) and an earlier population based study both found  
a 2:1 male: female ratio in the prevalence of oesophagitis35, 36, again suggesting a certain degree 
of protection against reflux esophagitis enjoyed by females.  
There is evidence that the age specific increase in the severity of reflux esophagitis is caused by a 
diminished protective saliva response to reflux with increasing age, however, there are no data on 
female hormonal effects on saliva or oesophageal mucosal secretions37-42.   
The, statistically significant, increased BO prevalence rates found during the last 5-year period 
cannot be interpreted as certain evidence of a rising prevalence of BO.  They could have resulted 
from of a greater awareness of the endoscopists to the presence of BO, the inclusion of more 
patients with short segment BO30or a change in referral patterns. However, the cohort effect 
mentioned earlier could well have been partly responsible. 
Our inclusion of gastric-type metaplasia in the diagnosis of BO was contrary to current fashion 
which demands the presence of specialized intestinal metaplasia (IM), including goblet cells, as 
ACO was found to develop exclusively in this type of metaplasia30, 43, 44and the finding gastric 
type metaplasia was thought to be  the result of too distal biopsies45.  
However, it is inconceivable that a series of biopsies accidentally located outside the oesophagus 
could have resulted in IM negative demographics which were statistically indistinguishable from 
those of the IM positive category found in this study. It is, however, quite possible that biopsies  
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were taken from IM negative areas adjacent to IM positive areas. In a study describing the 
relationship between the length of columnar epithelium and the presence of IM, all cases of long 
segment columnar epithelium the oesophagus were also found to contain cardiac type mucosa, 
while, in spite of extensive biopsies, no IM was found in 15/7146. Consequently, there were 
probably a number of false IM negative biopsies but, in view of the demographic similarity 
between IM positive and IM negative, these did not influence the all BO results.   We propose 
that IM negative gastric-type metaplasia in the oesophagus may be the first stage after squamous 
to columnar cell metaplasia. This metaplasia was recently demonstrated in vitro47 and can occur 
rapidly in vivo48. Subsequent stages, comprising IM positive metaplasia, low-grade and high 
grade dysplasia, finally result in ACO. This concept was confirmed by recent data documenting 
the occurrence of 5 cases of ACO during the follow-up of 137 IM negative subjects49.  
There would then seem to be no reason for withholding the diagnosis of BO from patients with 
IM negative gastric-type metaplasia found in the oesophagus and, consequently, depriving them 
of the possible benefits of endoscopic surveillance. 
In conclusion, this study of the prevalence of histologically confirmed BO in over 22 000 patients 
undergoing endoscopy in a primary referral centre, demonstrated that the observed overall 2:1 
sex ratio in the BO prevalence rates, predominantly resulted from a 20 year age shift between the 
parallel age specific BO prevalence curves, for males  between the ages of 20-59 and for females 
between the ages of 20-79. During this period the BO sex ratio was in excess of 4:1.This age shift 
resulted in relatively low age specific BO prevalence rates in females during their reproductive 
years. The practically indistinguishable demographics of IM positive and IM negative subjects 
suggest that they represent consecutive stages in the same metaplastic continuum. 
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ABSTRACT. 
 
Background: Adenocarcinoma limited to the oesophagus (ACO) arises in Barrett’s 
oesophagus (BO).The incidence of ACO is therefore restricted to this BO sub-population, 
whose size is unknown and which is for 95% unidentified. 
Aims: To determine the age and gender specific incidence rates of ACO, limited to the BO 
sub-population, within a defined geographical area and to compare them with those of 
squamous cell carcinoma of the oesophagus (SCC), which can affect the entire population.    
Methods: The age and gender specific incidence rates for ACO and adenocarcinoma of the 
cardia (AGC) were calculated after an expert panel classified 87% of all cases of 
adenocarcinoma of the oesophagus reported to the Danish Cancer Registry over a six year 
period as ACO or AGC.  
Results: The age specific incidence rates of ACO for males rose from 0.09/105 (30-34 yr) to 
14.14/105 (80-84 yr), falling to 7.2/105 (85+ yr), for females from 0.19/105 (45-49 yr) to 
2.79/105 (80-84 yr) , falling to 2.43/105 (85+ yr) and yielding a gender ratio of 5.9:1; AGC 
demonstrated a similar pattern and a gender ratio of 4.26:1.  However, the incidence rates of 
SCC continued rising after age-80, with a gender ratio of 2.5:1.  
Conclusions: The continuing rise in the SCC incidence rates in the elderly demonstrated that 
the unexpected decline and fall in the incidence rates of ACO over age-80 did not result from 
under diagnosis but were most probably caused by a declining prevalence rate of BO, 
restricting the elderly BO sub-population at risk of developing ACO.  
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INTRODUCTION 
The rate of increase in the incidence of adenocarcinoma of the oesophagus and the gastric 
cardia is currently thought to exceed that of all other cancers in many western industrialized 
countries1-4.  
Gastro-oesophageal reflux5 and specifically its  pre-malignant complication, Barrett’s 
oesophagus (BO), are the conditions which are associated with both  adenocarcinoma limited 
to the oesophagus (ACO) 6, 7 and, to a lesser extent, with adenocarcinoma of the gastric cardia 
(AGC)8, 9. 
The incidence rates of cancers in the general population are influenced by a large number of 
environmental and genetic factors. The population at risk can generally be defined by criteria 
such as age, gender, lifestyle or occupation. However, both the size of the BO sub-population 
and the individuals involved  are largely unknown10.  In common with other tumours, the size 
and the age and gender composition of the BO sub-population at risk must influence the 
incidence of ACO. However, individuals with BO can only be identified by clinical 
endoscopy for symptoms, which inevitably introduces selection bias. While BO  is over 
represented in patients with reflux symptoms, 11 these are known to be  absent in between 
35%  and 48%  of  BO patients presenting with ACO12-17.    In addition, 15-20% of the 
general population regularly report reflux symptoms 18-20. Consequently, the ‘silent majority’ 
of BO patients without clinically significant reflux symptoms leading to endoscopy is even 
higher. This was reflected in a  systematic review of patients coming to surgery for ACO in 
which only about 5% had a previous diagnosis of BO10.  
This suggests that the extent and composition of the majority of this unidentified BO 
population can currently only be gauged indirectly through the incidence rates of ACO in the 
population at large.  
In contrast to ACO, which only affects the small segment of the population with BO, the 
entire population is at risk of developing squamous cell carcinoma of the oesophagus (SCC). 
A comparison between the age and gender specific patterns of incidence rates of these two 
tumours within the same organ, with similar symptoms and methods of diagnosis, might be 
able to provide some hints about the composition of the BO sub-population. 
Such a comparison required population based incidence data for both ACO and SCC. The 
latter were readily available. However, population based studies of the age and gender 
specific incidence rates of ACO were limited to a single publication21.  
This may well be because performance of such studies is handicapped by the lack of reliable 
data on the true number of cases of ACO, as it is hard to distinguish between ACO and AGC 
and cancer registries have to rely on the diagnostic accuracy of the reporting clinicians22. 
AGC is a complicated tumour 23 and in the absence of clear  genetic or genomic criteria24, 25,  
differentiation between ACO and AGC will continue to  depend on complex anatomical 
criteria8. Another potential weakness of population based studies is under reporting in the 
elderly as a result of medical under diagnosis26.  
The present study set out to establish basic epidemiological data for the three cancers of the 
oesophagus and gastro-oesophageal junction, i.e. age and gender specific incidence rates for 
ACO, AGC and SCC, within a large, geographically defined population. It utilized data from 
a previous Danish study ‘Adenocarcinoma of the oesophagus and Barrett’s oesophagus’, 
which originally focused on both the eight-fold increase in the incidence of adenocarcinoma 
of the oesophagus between 1970-91 and the clinical aspects of the ACO patients. An 
additional feature provided essential data for the current study. It consisted of the results of a 
single panel of experts analyzing the clinical data on all adenocarcinomas of the oesophagus 
reported to the Danish Cancer Registry over a six-year period2. 
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Their differentiation between ACO and ACG should ensure more incidence study we added 
both the age and gender of all patients to the original data base and the SCC incidence data 
from the Danish Cancer Registry in order to enable age and gender specific incidence rates for 
ACO, AGC and SCC to be calculated. 
We were then able to compare the incidence rates of ACO and SCC within the same 
population and over the same 6-year period. 
  
 METHODS 
These have in part been reported in detail in a previous publication2. 
Briefly, the study population comprised all cases of cancer of the oesophagus reported to the 
Danish Cancer Registry over the 6-year period between 1987-92. Tumours were classified 
according to a modified version of the International Classification of Diseases (ICD-7), 
expanded to include information about histology and tumour behaviour.  The Danish Cancer 
Registry is population based, nation-wide and regarded as almost complete 27, 28. The 
incidence data for squamous cell carcinomas of the oesophagus (SCC) (ICD-7 code 150.0) 
were taken directly from this register. For the cases of adenocarcinoma of the oesophagus 
(ICD-7 code 150.1) the original medical records were retrieved for review and, after the 
exclusion of 15 misclassified cases, there remained 580 cases of histologically confirmed 
adenocarcinoma of the oesophagus and gastric cardia. 
Subsequently endoscopic, radiological, surgical and autopsy reports were used to determine 
the location of the tumour in relation to the gastro-oesophageal junction. Tumours located 
entirely within the oesophagus were classified as ACO, tumours within the oesophagus but 
extending across the gastro-oesophageal junction as AGC. 
All classifications were performed by a panel of 4 medical gastroenterologists. 
After adding the age and gender of all cases of ACO, AGC and SCC to the original data base  
mean one-year incidence rates were calculated from the number of cases of ACO, AGC and 
SCC, reported during the six year period, by age band and gender. Population data were 
derived from Danish population statistics for 1990.29 The following formula was used:  
100 000 х  n.ACO   (or AGC or SCC). 
n.population   6   
= incidence rate/100 000 
The relations between the age and gender specific incidence rates for ACO and SCC were  
investigated by log linear regression which fitted curve 
s for males and females. The standard errors resulting from the regression output allowed 
95% confidence intervals to be constructed around these gender specific incidence ratios. 
Quadratic curves were fitted to the observed incidence rates for ACO and SCC by 5-year age 
band and tested for age-specific differences in shape by the likelihood ratio test.  This last 
analysis was repeated in a data subset limited to the over 60-year ACO and SCC age groups. 
 
RESULTS 
During the 6-year period 1660 cases of cancer of the oesophagus were reported to the Danish 
Cancer Registry. 580 of these 1660 were adenocarcinomas and 1080 squamous cell cancers of 
the oesophagus (Table 1). 
It was possible to retrieve relevant medical data for 526 (90.7%) of these 580 cases of 
adenocarcinoma of the oesophagus from the Danish Cancer Registry, including the results of 
endoscopy with biopsy in 487. Subsequently 507 of the 580 (87.2%) adenocarcinomas could 
be classified, 349 as ACO and 158 as AGC. However, 73 cases (12.8%) were unclassifiable 
(Figure 1). The quantitative relationships between classified and unclassified cases by age for 
the two genders were illustrated in Figures 2 and 3.    
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Figure 1. An organization chart showing the differentiation of the 580 patients with adenocarcinoma 
of the oesophagus into adenocarcinomas limited to the oesophagus (ACO), the gastric cardia (AGC) 
and patients  unclassified because of absent or insufficiently detailed medical data. 
Table 1 .The Histological Findings in 1660 Cases of Carcinoma of the Oesophagus Reported to 
the Danish Cancer Registry between 1987-92.  
Squamous Cell Carcinoma Adenocarcinoma Oesophagus and Cardia 
       
Sex 
Number 
of 
Patients 
Average 
age 
yr. 
S.D. 
± yr. 
Age 
range 
yr. 
 
Sex 
Number 
of 
Patients 
Average 
age 
yr. 
S.D 
± yr. 
Age 
range 
yr. 
Males 710 66.3 11.1 38-92 Males 465 68.4 10.2 30-95 
Females 370 71.9 11.6 44-99 Females 115 73.4 11.4 46-96 
Total 1 080    Total 580*    
*Note, a total of 578 was given in the original paper. 
580 patients with adenocarcinoma of the esophagus reported to the Danish Cancer 
Registry 1987-92 
Medical Data retrieved 
526 patients 
422 Males, 104 Females 
No medical data,  
Males 43, Females11, Total 54 
 
Oesophagus only (ACO) 
Males 285, Females 64, Total 349 
Oesophagus and cardia (AGC) 
Males 121, Females 37, Total 158 
Insufficient data 
Males 16, Females 3, Total 19 
Unclassifiable patients 
Males 59, Females 14, Total 73
  82
 
Males
0
5
10
15
20
25
40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Age bands
In
ci
de
nc
e 
ra
te
s/
 1
00
 0
00
All Adeno Ca ACO AGC Unclassified
Figure 2. The incidence 
rates of: all 
adenocarcimas of the 
oesophagus (All Adeno 
Ca), adenocarcinomas in 
BO and limited to the 
oesophagus (ACO), 
adenocarcinoma of the 
gastric cardia (AGC) and 
unclassified cases in 
males. The majority of 
unclassified cases 
occurred after the age of 
75, all three categories 
showed the same steep 
decline in the 85+ age 
band. These unclassified 
cases (Unclassified) 
implied that the 
incidence rates of ACO 
and AGC in the over 75 
age groups were, in fact, 
higher than reported. 
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Figure 3.. The incidence 
rates of: all 
adenocarcimas of the 
oesophagus (All Adeno 
Ca), adenocarcinomas in 
BO and limited to the 
esophagus (ACO), 
adenocarcinoma of the 
gastric cardia (AGC) and 
unclassified cases 
(Unclassified)  in 
females, note that the 
scale of the y-axis is 
1/5th of that in males.  
 
 
  83
 
 
 
Table 2 The Incidence Rates of Adenocarcinoma, Limited to the Oesophagus (ACO) by Age and 
Gender, Denmark 1987-92  
 Males  Females 
Age 
Bands 
Population 
1990 n. 
ACO 87-92 
n. 
Incidence 
rates/100 000 
 Population 
1990 n. 
ACO 87-92 
n. 
Incidence rates 
/100 000 
30-34 190 126 1 0.09  180 894 0 0 
35-39 188 443 1 0.09  182 047 0 0 
40-44 210 290 7 0.55  201 915 0 0 
45-49 178 635 11 1.03  173 493 2 0.19 
50-54 141 558 21 2.47  141 613 1 0.12 
55-59 124 390 24 3.22  129 484 4 0.51 
60-64 118 163 32 4.51  128 697 3 0.39 
65-69 112 767 46 6.8  132 065 8 1.01 
70-74 87 960 45 8.53  111 463 15 2.24 
75-79 68 013 54 13.23  99 711 11 1.84 
80-84 38 892 33 14.14  71 656 12 2.79 
85+ 23 026 10 7.2  54 832 8 2.43 
Totals  285    64  
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Figure 4. The 
incidence rates of 
adenocarcinomas 
limited to the 
oesophagus (ACO) by 
age and gender. In 
males the steep rise in 
incidence rates 
levelled off from the 
age band 75-79 and 
showed a steep 
decline in the 85+ age 
band. In females the 
rise in incidence rates 
was much less 
pronounced, as was 
the fall in the 85+ age 
band. The gender ratio 
was 5.9:1, 95% C.I. 
4.4-7.9. 
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 The incidence rates for ACO were displayed in Table 2 and graphically represented in Figure 
3. In both genders they increased with age, for males from 0.09/105 in the 30-34 age-band to 
14.14/105  (95% CI 10.0 - 19.9) in the 80-84 age-band, then falling to 7.2/105 (95%C.I. 3.9-
13.4/105) in the 85+ age-band and for females from 0.19/105 in the 45-49 age-band to 
2.79/105 (95% CI  1.6-4.9) in the 80-84 age-band, then falling to 2.43/105 (95% CI 1.3-5.1)in 
the 85+ age-band. The log linear regression curves ran parallel, indicating a similar pattern for 
both genders. The resulting age-adjusted male: female OR was 5.9:1, 95% CI 4.4-7.9. 
 The incidence rates of ACO and AGC were graphically represented in Figure 5. Those of 
AGC also increased with age in both genders, for males from 0.32/105 in the 35-39 age band 
to7.65/105 in the 75-79 age band and then falling to 1.74/105 in the 85+ age band and for 
females from 0.12/105 in the 40-44 age band to 2.01/105 and then falling to 1.09/105 in the 85+ 
age band. The age adjusted male: female OR was 4.26:1, 95% CI 2.94-6.17.        
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Figure 5. The 
age and gender 
specific 
incidence rates 
for 
adenocarcinomas 
limited to the 
oesophagus 
(ACO) and 
adenocarcinomas 
of the gastric 
cardia (AGC). 
The gender ratio 
for AGC was 
4.26:1, 95% C.I. 
2.94-6.17, the 
ratio between the 
incidence rates 
of ACO and 
AGC was 2.2: 1. 
  
         
The incidence rates of SCC by age and gender were graphically represented in Figure 6.The 
incidence rates of SCC rose for males from 0.35/105 in the 35-39 age band to 25.3/105 (95% 
CI 19.6-32.6) in the 80-84 age band, then falling to 23.9/105 (95% CI 17-33.6) in the 85+ age 
band and for females from 0.17/105 in the 40-44 age band, rising uninterruptedly to 18.6/105 
(95% CI 14.4-24.9) in the 85+ age-band. The log linear regression curves ran parallel, 
indicating a similar pattern for both genders. The age-adjusted male: female OR was 2.46, 
95% CI 2.17-2.78.  
The age and gender specific log-transformed parabolas for ACO and SCC incidence rates just 
achieved significant differences (p=0.034). However, comparison of these parabolas for the 
over 60-year age groups ( comprising 277 cases of ACO and 824 of SCC)  revealed far 
clearer differences (p<0.001), with a continuing rise for SCC but a levelling off, followed by a 
decline for ACO from around the age of 80 years. (Figure 7)  
  85
 
0
5
10
15
20
25
30
35
30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Age bands
SC
C
 in
ci
de
nc
e 
ra
te
s/
 1
00
 0
00
Males CI
max
Males
Males CI
min
Females
CI max
Females 
Females
CI min
 
Figure 6. The incidence rates of squamous cell carcinomas of the oesophagus (SCC) by age and 
gender. In males there was a slight decline in the 85+ age band, which was compensated by a steep 
rise in females in the 85+ age band resulting in a continuing rise for all age groups combined.  
The gender ratio was 2.46, 95% C.I. 2.17-2.78. 
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Figure 7. The 
age and 
gender 
specific 
logarithmic 
transformation 
parabolas for 
ACO and 
SCC for the 
over-60 age 
group 
comprising 
277 cases of 
ACO and 824 
of SCC, 
showing the 
significant 
differences in 
the incidence 
patterns (p < 
0.001), 
specifically in 
the over-80 
age group. 
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DISCUSSION  
This study set out to establish the age and gender specific incidence rates of adenocarcinoma 
limited to the oesophagus (ACO) over a 6-year period within a defined geographical area 
(Denmark) comprising about 5 million inhabitants. Its strength lay in that  87% of all cases of 
adenocarcinoma of the oesophagus were defined as either ACO or adenocarcinoma of the 
gastric cardia (AGC) on the basis of adequate clinical data by a panel of experts.2 The great 
majority of the unclassified cases were found in the over-75 age groups (Figures 1 and 2). In 
addition, it looked for differences between the patterns of the incidence rates of ACO and of 
squamous cell carcinoma of the oesophagus (SCC). 
Within the group of 580 cases of adenocarcinoma of the oesophagus registered over the six 
year period, 349 cases were identified as ACO. 
The age and gender specific incidence rates of ACO (Figure 3) showed an initial exponential 
rise, particularly marked in males, gradually levelling off around the age of 80 and finally 
declining steeply in the over-85 age band. The age-adjusted male: female incidence ratio was 
5.9:1. This gender ratio was slightly lower than the age-adjusted 6 to 8:1 ratio found in a 
recent update of the National Cancer Institute’s Surveillance, Epidemiology, and End Results 
(SEER) data between 1977-96. 30 Both gender ratios were, however, unusually high for a non-
genital tumour.  
The declining ACO incidence rates in the oldest age groups were not in accordance with 
accepted multistage models indicating that the age-specific incidence of many human cancers 
increases roughly with a power of age.31-33  
An earlier analysis of SEER data from 1972-82 by Yang et al.21 also reported age specific 
rises in  ACO incidence rates without  the  declining incidence rates in the over-80 age group, 
which was however, shown graphically in a subsequent analysis of SEER data, 
undifferentiated for gender, for the years between 1987-96.30  
The pattern of the AGC incidence rates mirrored that of ACO to a certain degree (Figure 4) 
although in males the age specific rise in incidence rates was far lower than in ACO. The 
AGC male: female ratio of 4.26: 1 was, as expected 8, 9, lower than in ACO. 
The ACO: AGC incidence rate ratio was 2.2: 1, contrary to that found in the SEER study 
where AGC rates exceeded those of ACO, although here a secular trend towards parity was 
observed30, 34. The difference between the Danish and the US findings may have been due to a 
better differentiation by the expert panel or to geographical variations34.  
The 1080 cases of SCC presented a markedly different incidence pattern from that of ACO, 
with the age specific rise in incidence continuing into the oldest age bands (Figure 5) and a 
male: female incidence ratio of 2.46:1, less than half of that found in ACO.  
In the over 60-year age group this difference between the rise in the age specific incidence 
rates of SCC, continuing into the 85+ age band and the declining pattern from age-80 in ACO, 
was found to be highly significant (p< 0.001) (Figure 6). The latter analysis included 63 cases 
of ACO and 196 cases of SCC over the age of 80.  
 In theory this declining ACO incidence rate could have resulted from less exposure to 
carcinogens, i.e. tobacco and alcohol, in the 80+ cohort. The absence of a similar effect on the 
80+ SCC incidence rate clearly contradicts this hypothesis. 
 We propose that these clear differences in the patterns of the 80+ incidence rates of ACO and 
SCC were the result of the limited size of the 80+ BO sub-population at risk, thus restricting 
the number of cases of ACO and thereby reversing the expected age specific exponential rise 
in the incidence rate of ACO in the general population.  
 How could the size of the 80+ BO sub-population have been limited? Within the 80+ BO 
sub-population itself, the age specific ACO incidence rate was likely to have continued to rise 
exponentially. Therefore, in theory, the ACO incidence rate within the BO sub-population 
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could have approached a level of 100% between the ages of 80 to 84, thus preventing further 
increases.   
 This hypothesis must be rejected as three studies of the prevalence of BO in clinical 
endoscopy found substantial numbers of patients with BO, but free of ACO, in their eighth 
and even their ninth decades. However, all three studies did find falling prevalence rates of 
BO in the over-80 year age-group11, 35, 36.  
The falling incidence of ACO in the elderly could also have been caused by decreasing 
diagnostic effort or competing causes of death in this age group. However, the absence of a 
similar decline in the over-80 incidence rate of SCC led us to reject under diagnosis or under-
reporting as its cause.  In view of the strong relationship between SCC and smoking and 
drinking habits, 37, 38  the incidence rates of  symptomatic SCC, especially in males, were 
almost certainly curtailed by competing causes of death such as cardiovascular diseases and 
other cancers. As  these lifestyle factors are of relatively smaller importance in the aetiology 
of ACO, 37-41  such competing causes of death were likely to have had the greatest negative 
impact on SCC incidence rates. 
Our ACO and AGC incidence rates can be criticized on the grounds that 12% of the cases 
remained unclassified. However, as shown in Figures 1 and 2, the great majority of these 
unclassified cases occurred in the over-75 age groups, possibly because only limited 
diagnostic efforts were applied as these patients were only considered suitable for palliation. 
The incidence rates of ACO and ACG in these older age groups were therefore higher than 
given in Figures 3 and 4 but, at least for males, the sharp decrease in the 85+ age band 
remained unchanged (Figure 1). 
Our conclusions were based on the assumption that, in practice, all cases of adenocarcinoma 
of the oesophagus, not originating from the true gastric cardia, arise in BO42-46. It implied a 
strict ‘entry criterion’, BO, which could only be met by a small, but ill defined fraction of the 
population. This in contrast to SCC, which had no such ‘entry criterion’.  
We cite a number of additional arguments for this assumption. With the exception of the 
unexplained findings in a  single population based study,47 ACO has exclusively been seen to 
arise prospectively  in BO48, 49. Identifying BO in ACO requires both experience and devotion 
to detail. In our group of 349 patients with ACO, derived from a Cancer Registry, BO was 
only diagnosed in 19%. 2 In a study by Lagergren et al., where all patients were examined 
according to standardized protocols, BO was detected in 62%5. That a 100% result was not 
achieved was explained by Sabel et al. who found that the  only difference between 
adenocarcinomas of the oesophagus with and without visible BO tissue was that  the latter 
were larger and more advanced, suggesting that these aggressive tumours had overgrown all  
the original BO.50 This is especially true for tumours arising in short segment BO45, 46. In 
addition, if adenocarcinomas could arise in any part of the oesophagus, cases should be found 
with a circumferential area of squamous epithelium between the tumour and the 
squamocolumnar junction. However, in classifying thousands of oesophageal cancers for the 
Rotterdam Oesophageal Cancer Group over a 25 year period, only one such case was seen. (J. 
Dees, 2003, personal communication).  Although in theory cases of ACO could arise without 
an intervening stage of BO, these rare events would not affect our conclusions. 
We suggest that the greater than twofold difference in gender ratios for two tumours arising in 
the same organ again reflected the effect of BO prevalence. This is known to  have a male: 
female ratio of  between 2 and 4: 111, 35, 36, 51. Obviously, the gender ratio in SCC may also 
have been influenced by gender related differences in lifestyles. In fact, in females the 
incidence of SCC continued to rise to 24.73/105 in the 90+ age group (n. SCC: 21). 
Our hypothesis explaining the declining incidence rates of ACO in the elderly obviously 
raised the question as to the cause of the age specific decline in the prevalence of BO. 
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We submit three hypothetical mechanisms, the excess mortality from ACO, obviously limited 
to the BO population, an increased susceptibility to other, non-related causes of death caused 
by an unhealthy life-style52 and a birth-cohort effect 53. This last mechanism would imply that 
over the twentieth century birth-cohorts, consisting of all Danes born in consecutive 5-year 
periods, would have demonstrated a secular increase in the prevalence rate of BO, with the 
lowest rates in the oldest birth-cohorts.  
 However, in the absence of further data, we were unable to choose between these three 
mechanism, although the finding of a birth cohort effect on the incidence rates of ACO in a 
recent review of the SEER results from the United States would tend to support the third 
mechanism30. 
The most important practical aspect of our study is that the currently often quoted  estimate of 
the annual ACO incidence rate of 0.5% in patients with BO 54 cannot be applied to individual 
BO patients as we have shown  their cancer risk to be linked to both age and gender. There is 
urgent need for new risk estimates taking these factors into account. There are also 
consequences for the economic modelling of  BO surveillance, which already has to revise 
age limits as oesophagectomy is no longer the sole available treatment for HGD and early 
ACO55, 56.  Consequently, it would be logical to introduce both age and gender into the 
calculations of the optimal frequency of surveillance endoscopies, especially with advanced 
age no longer being a ground for exclusion.  
In conclusion, this Danish population based demographic study described the age and gender 
specific incidence rates of ACO. It demonstrated that their age specific exponential rise 
gradually levelled off around the age of 80 and actually fell in the over-85 age group. AGC 
demonstrated a similar pattern, this in contrast to the continuing rise in incidence rates of SCC 
in the elderly. Therefore, the falling incidence rate in ACO was not caused by under diagnosis 
in the elderly but most likely demonstrated the effect of an age specific decline in the 
prevalence rate of BO in the elderly. In ACO a 6:1 gender ratio was found, more than twice 
the 2.5:1 gender ratio found in SCC.  
This difference again reflected the influence of BO prevalence rates on the incidence rates of 
ACO, in this case the 2:1 or greater gender ratio in the prevalence of BO. 
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ABSTRACT 
Background: A recent study of the adenocarcinoma of the oesophagus (ACO) incidence 
rates in Denmark revealed a steep fall in the over-80 population, interpreted as the result of a 
declining prevalence of Barrett’s oesophagus (BO) in this age group for which three 
hypotheses were advanced: the specific mortality from ACO and, superimposed, either excess 
mortality from causes of death unrelated to ACO or a birth cohort effect.  
Aims: To create models estimating the BO population fitting each of these 3 hypotheses, to 
select the most plausible hypothesis and gain insight into the Danish BO population. 
Methods: Models were designed for three hypotheses, conforming to the generally accepted 
0.4-0.5% annual ACO incidence in BO patients. These models employed expectation-
maximization algorithms, Danish life tables and the observed ACO incidence rates. The 
models enabled the estimation of a BO population for each hypothesis. 
Results: After testing against set criteria, the most plausible model was found to be that 
describing a birth cohort effect which predicted a ± 5% annual rise in the prevalence of BO 
and consequently, in the incidence rate of ACO in Denmark. This prediction was borne out 
over the subsequent decade. 
Conclusions: This rising ACO incidence rate is likely to continue into the foreseeable future. 
The use of EM algorithms enabled a first estimate of the BO population at risk of ACO  
although, owing to the limitations imposed by  the models, the age and gender specific ACO 
risk for the entire Danish BO population could not as yet be ascertained.  
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INTRODUCTION 
Barrett’s oesophagus (BO), or columnar metaplasia of the distal oesophageal mucosa, is a 
well recognized pre-malignant condition1, 2 and presumably the precursor of practically all 
cases of adenocarcinoma limited to the oesophagus (ACO) 2-5. The incidence of ACO is rising 
rapidly in the Western World6-11.  
In a recent study, we described the age and gender specific ACO incidence rates for the 
population of Denmark around 1990 in which an unexpected steep fall of the ACO incidence 
in elderly over 80 years of age was observed. We ascribed this to a declining BO prevalence 
in this age group. Three hypotheses were advanced to explain this declining BO prevalence. 
These hypotheses were:1) the increased mortality rate for the BO population, as compared to 
the general Danish population, caused by the mortality from ACO, uniquely inherent to the 
BO population and, in addition to this specific ACO mortality, 2) excess mortality from other 
causes of death due to  a hypothetical inferior state of health of the BO population, or 3) a 
birth cohort effect, i.e. a secular increase in the prevalence rate of BO in consecutive birth 
cohorts during the twentieth century, resulting in relatively smaller BO populations in the 
elderly12.However, as there were no data on the size and composition of the Danish BO 
population, it was impossible to decide which of these 3 hypotheses was the most plausible.   
We hypothesized that the age-specific prevalence of BO in Denmark could be deduced from a 
combination of our observed incidence rates of ACO and the published age and gender 
specific incidence rates of ACO for BO derived from large BO populations with an adequate 
follow up period. We set out to estimate the size of its BO populations for each of the above 
mentioned three hypotheses, by means of models based on expectation-maximization (EM) 
algorithms. In each model the age and gender specific incidence rates of ACO for its 
estimated BO population had to approach the observed ACO incidence rates as closely as 
possible.  
Finally, the outcomes of the three models were tested against set criteria to select the most 
plausible hypothesis. 
 
METHODS 
Unfortunately in the absence of adequate data on the age and gender specific prevalence of 
BO, we had to make do with the generally accepted annual incidence of ACO in patients with 
BO ranging around 0.513, 14.  This relatively low ±0.5% annual incidence rate of ACO implied 
that, within any given group of BO patients, the incidence of ACO must be spread over a 
considerable period of time. This presumed  time spread resulted from the combination of a 
wide variety in the ages of onset of BO15, 16and, in analogy with chronic inflammatory 
diseases such as ulcerative colitis17, an incubation period of up to several decades between the 
onset of BO and symptomatic ACO. The length of the incubation period introduced a second 
unknown variable into the models, a third being the age at onset of BO. These problems were 
overcome by defining our BO population as having acquired BO before the age of 46 and by 
setting the incubation period at over 30 years. Consequently, very few individuals acquiring 
BO after the age of 45 would survive to develop symptomatic ACO. Although not 
conforming to reality, these restrictions enabled us to construct the three models. 
Models. 
Input data for all models were the observed ACO incidence rates and Danish life tables. 
Models were designed for the 3 hypotheses, model 1, the specific mortality from ACO, model 
2, the excess mortality from causes of death unrelated to ACO and model 3, the birth cohort 
effect.  Each estimated the size of the age and gender specific of the BO population  
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for each age band over the age of 45, further referred to as the modelled BO population. All 
BO patients were defined as having acquired BO before the age of 46. The 45-year age  
limit was chosen because only very few cases of ACO occurred before this age. In all 3 
models the age specific decline in the BO population was assumed to have been more rapid 
than that of the general Danish population because of the inherent extra mortality from ACO, 
unique to the BO population. In model 1, the basic model, this formed the only source of the 
more rapid decline. In addition, model 2 included excess mortality from causes of death 
unrelated to ACO and model 3 the birth cohort effect.  
 In all models the variables to be calculated were the size of the modelled BO population by 
age and gender for each age band and the resulting ACO incidence rates which had to 
approach the observed ACO incidence rates as closely as possible. The additional variables to 
be calculated were in model 1 the size of the modelled BO population as a percentage of the 
general population at the age of 45 (the modelled BO population between 45 and 75), in 
model 2 the size of the excess mortality and in model 3 the annual percentage growth of the 
BO population over the previous decades, the birth cohort phenomenon. For models 2 and 3, 
the unknown size of the  modelled BO population between 45 and 75 first had to be estimated 
by introducing a variety of percentages within a range derived from the literature of about 
0.5% per year18, 19until a result emerged within the target range (see under External criteria for 
judging the plausibility of the three models  below). To compensate for the incomplete 
ascertainment of cases of ACO in our previous incidence study20, amounting to at least 13%, 
the number of cases of ACO entered in each 5-year age band in the present study was the 
number actually observed during a six year period of the previous study.  
 
 The EM algorithm 
The estimates of the age and gender specific prevalence rates of the modelled BO population 
for each model were calculated through a so called expectation-maximization  
(EM) algorithm which here attempted to fit an internally consistent description of the BO 
population as closely as possible to the observed population ACO incidence 21. Data entered 
into the EM algorithm were derived from the incidence rates of ACO for the population of 
Denmark between 1987-92 19 and the Danish life tables for the years 1989-90.22 
An exact description of the EM algorithm and the resulting models can be found in the 
Appendix.  
The EM algorithm started with a rough estimate of the fraction of the general population with 
BO, for instance 1%, for each age band. This percentage provided the number of people at 
risk for ACO, i.e.  the modelled BO population, by age band which was then used to estimate 
an exponential curve describing the increasing ACO incidence rate by age. The actually 
observed numbers of ACO by age were used as outcomes for this log linear regression. This 
first estimate of the incidence of ACO by age in the modelled BO population, 1% in this 
example, enabled the estimation of the differences in survival between the modelled BO 
population and the general population. The comparison of these two survival curves then 
resulted in an improved estimate of the modelled BO population in each age band and this 
was used to estimate a new exponential curve describing the increasing ACO incidence rate 
by age. All these steps were repeated until they eventually led to a stable, optimal solution. 
 
Assumptions. 
In order to keep the models manageable five assumptions had to be made. These were:  
1. For models 2, and 3;  a 2:1 male: female gender ratio for the modelled BO prevalence at 
age-4523-25. 
2. That all cases of ACO originated in BO2-5. 
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3. That the age specific incidence rates of ACO within the BO population would increase 
exponentially26-28. 
4. That the ‘incubation’ period between developing BO and symptomatic ACO was so long 
that in practice an insignificant number of individuals acquiring BO after age 45 survived to 
manifest symptomatic ACO.  
5. That all cases of ACO were removed from the modelled BO population as the risk had 
materialised.  
 
Set criteria for judging the plausibility of the three models  
The main criterion for all models was a target range of ACO incidence rates in BO patients 
based on the available literature13, 14, 29.  We assumed that most of the patients with BO, 
included in the surveys on which these estimates were based, were between the ages of 45-75. 
As the available estimates did not differentiate for age or gender, we were obliged to combine 
the results of the ACO incidence rates estimated by each model for both genders. We 
therefore chose the average of the combined male and female ACO incidence rates for the BO 
population between ages 45-75, as estimated by each model, to represent its outcome for 
comparison with the target range. This average figure, further referred to as the modelled 
ACO incidence rate45-75, was calculated from the sum of the person- years observed for the 
male and female modelled BO population between the ages of 45 and 75 and the sum of the 
number of cases of ACO estimated by each model for these same age groups. The target 
range for the modelled ACO45-75 incidence rate was set at between 0.4/10014 and 0.5/100 
person-years13.  
  Additional criteria were, for the basic model 1, the plausibility of the prevalence rates of the 
modelled BO population between 45 and 7518, 19 resulting from this model and for model 2 
the height of the excess mortality. 
For model 3, an additional criterion was the annual rate of increase in the ACO incidence 
compared with the available data on rise in incidence of adenocarcinoma of the  
oesophagus, undifferentiated for ACO and adenocarcinoma of the gastric cardia (AGC), 
observed over the 13-year period, 1987-99. 
 
RESULTS. 
The results of the three EM algorithms are shown in Table 1. 
 All three models generated estimated ACO incidence rates (column 9 in tables 2a and 2b) 
which fitted well with the observed ACO incidence rates (column 3),(Scaled deviance of 
3.407 to 3.955 for 10-3 = 7 degrees of freedom). This meant that choosing the most plausible 
model had to be based on the results of the modelled ACO incidence rate45-75 and the set 
criteria listed previously.  
In the basic model 1, the extra attrition of the modelled BO population, as compared to the 
general population, was caused by mortality from ACO. The modelled ACO incidence rate45-
75 was 1.36/100 person-years. This fell well outside the target range of between 0.4 and 
0.5/100 person years and in addition, the modelled BO populations between 45 and 75 of 
0.387% for males and 0.079% for females were considered highly implausible18, 19Model 1 
was therefore rejected. 
Model 2, with an optimal modelled BO population between 45 and 75 of 1% in males and 
0.5% in females and which, in addition to ACO, included excess mortality unrelated to ACO, 
produced a modelled ACO incidence rate45-75 of 0.41/100 person-years, within the target 
range. However, the calculated excess mortality for males of 51% (95% C.I. 26-76%) and for 
females of 76% (95% C.I. 3-155%) was, after weighing up the available literature30-34, 
considered too high. Although conforming to the set target modelled ACO incidence rate45-75, 
we therefore considered model 2 to be only moderately plausible. 
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Table 1.                               The Results of the Three EM Algorithms 
The modelled BO 
population at 45  
Model Modelled ACO 
incidence rate45-75 
Males Females 
Model 1 1.36 0.387% 0.079% 
 
The  optimal modelled 
BO population at 45 
Extra mortality from 
unrelated causes 
Birth cohort effect, 
annual  increase % Model Modelled ACO incidence rate45-75 
Males Females Males Females Males Females 
Model 2 0.41 1% NA NA 
Model 3 0.42 1.5% 
0.5% 
0.75% 
51% 1) 
NA 
76% 2) 
NA 4.4% 6.3% 
Abbreviatons: EM = expectation maximation; NA = not applicable; ACO = adenocarcinoma of the 
oesophagus; BO = Barrett’s oesophagus. 
1)  95% CI  26-76% ;  2) 95% CI  3-155%. 
 
 
Table 2a. The Modelled BO Population and its Estimated ACO Incidences calculated for a  BO 
Prevalence of 1.5% of the General Population at Age 45 
Model 3, Males
1 2 3 4 5 6 7 8 9 
Age 
Bands 
Male 
population 
1990 
number
s 
Observed  
ACO 
incidence
n/5 yrs. 
Non-BO 
population 
percentage 
survival 
Modelled 
BO pop 
percentage 
survival 
Modelled 
BO 
population
percentage 
Modelled 
BO 
population  
numbers 
Modelled 
ACO 
incidence/ 
100 pers.yrs. 
Estimated 
ACO 
incidence    
n/5 yrs. 
Age 45 178 635  100% 100% 1.5% 2 679.0    
45-49 178 635 11 98.7 98.4 1.377 2 459 0.11 13.4 
50-54 141 558 21 95.7 94.7 1.104 1 563 0.21 16.6 
55-59 124 390 24 90.7 88.4 0.879 1 094 0.42 22.7 
60-64 118 163 32 83.4 78.8 0.689 815 0.81 33.1 
65-69 112 767 46 72.9 65.0 0.525 593 1.59 47.0 
70-74 87 960 45 59.0 47.1 0.379 333 3.1 51.6 
75-79 68 013 54 42.5 27.4 0.246 167 6.05 50.6 
80-84 38 892 33 25.6 11.0 0.130 51 11.8 29.9 
85+ 22 026 9 15.7 2.6 0.038 8 24.0 10.1 
Totals 982 404 275    7 083  275.03 
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Abbreviations; ACO = adenocarcinoma of the oesophagus; Barrett’s oesophagus =  BO 
 
Tables 2a and 2b, explanation of headings. 
The modelled BO population: The BO population estimated by the model for each age band.  
All data are presented by 5 year age bands. The numbers refer to columns. 
2. Male/Female population 1990 numbers: Population figures for Denmark in 1990. 
3. Observed ACO incidence n/ 5 yrs: The observed number of cases of ACO between 1987-92.  
4. Non-BO population percentage survival: The percentage of the general population surviving 
according to Danish life tables for 1990, data used to estimate the survival of the population without 
BO. 
5. The modelled BO population percentage survival: The estimated percentage of the BO population 
surviving as estimated by the model in comparison with the general population (column 4).  
6. The modelled BO population percentage: At age 45, the optimal percentage of the general 
population with BO employed by the model. Subsequently, the percentage of this BO population  that 
was still alive at age 45 according to column 5 for each age band. 
7. The modelled BO population numbers: The estimated size of the BO population, column 6 x 
column 2 divided by 100. 
8. Individual ACO incidence: The incidence rate of ACO estimated by the model for the modelled BO 
population per 100 person-years. 
9. Estimated ACO incidence/ 5 yrs: The number of cases of ACO between 1987-92  
estimated by the model, (col7 x 5)col.8 , calculated to approach the observed number as 
                                           100 
 closely as possible. Compare with column 3.   
 
Model 3, the birth cohort effect, with an optimal modelled BO population between 45 and 75 
of 1.5% in males and 0.75% in females, produced a modelled ACO incidence rate45-75 of 
0.42/100 person-years, within the target range.  The birth cohort effect, i.e. the annual rise  
Table 2b. The Modelled BO Population and its  Estimated ACO Incidences calculated for a BO 
Prevalence of  0.75% of the General Population at Age 45 
Model 3, Females
1 2 3 4 5 6 7 8 9 
Age 
Bands 
 
Female 
Population 
1990 
numbers 
Observed 
ACO 
incidence 
n/ 5 yrs. 
Non-BO 
population 
percentage
survival  
Modelled 
BO pop. 
percentage 
survival 
Modelled 
BO 
population 
percentage 
Modelled 
BO 
population
numbers 
Modelled 
ACO 
incidence/ 
100 pers.yrs. 
Estimated 
ACO 
incidence 
n/ 5 yrs. 
Age 
45
173 493  100% 100% 0.75% 1300   
45-49 173 493 2 99.1 99.1 0.666 1156 0.03 1.6 
50-54 141 613 1 97.1 96.7 0.491 695 0.06 2.2 
55-59 129 484 4 93.7 93.0 0.360 467 0.13 3.1 
60-64 128 697 3 89.0 87.4 0.263 339 0.29 4.9 
65-69 132 065 8 82.4 79.2 0.190 251 0.63 7.9 
70-74 111 463 15 73.4 67.1 0.133 149 1.37 10.2 
75-79 99 711 11 61.1 50.5 0.089 88 3.0 13.1 
80-84 71 656 12 44.9 29.8 0.052 38 6.45 12.1 
85+ 51 914 7 36.8 12.8 0.019 10 15.4 7.8 
Totals 1 040 096 63    3 191  63 
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in the prevalence of BO in the population at large, was estimated at 4.4% for males, 6.3% for 
females and 5.1% for both genders combined. Assuming that this annual rise in BO  
prevalence was paralleled by a similar annual rise in the incidence of ACO, this should have 
resulted in the ACO incidence increasing by 4.6-5.1% per annum for both genders combined 
in the over-45 population of Denmark. This prediction was tested for our study period and the 
last 3 years for which incidence data were available. 
The incidence of all adenocarcinomas of the oesophagus, not differentiated for ACO and 
AGC, over the 6-year period 1987-1992, was 580 (465 males, 115 females) and over the 3-
year period 1997-1999, 428 (354 males, 74 females).  On the basis of Poisson regression, the 
observed annual increase in the incidence of ACO and AGC combined for the over-45 
population of both genders between 1987 and 1999 actually amounted to 4.74%, 95% C.I. 
3.28-6.22. Model 3 was therefore judged to be the most plausible. The detailed results of 
model 3 are shown in Tables 2a and 2b and illustrated in Figures 1 and 2. 
 
 Discussion 
The incidence of both Barrett’s esophagus (BO)35 and adenocarcinoma of the oesophagus 
(ACO)7-9, 11 is rapidly increasing in Western populations. Cost-utility studies have suggested 
confining endoscopic surveillance to patients with BO experiencing an expected risk of ACO 
of at least 0.5/100 person-years36-38. However, this advice is gratuitous as there are currently 
no clinical criteria for  estimating  the ACO risk for  individual patients other than the 
presence of dysplastic histological changes, which already herald the latter stages of the BO 
cascade to ACO39.  
In contrast to other malignancies affecting the whole population (or just one gender) this risk 
cannot be estimated from the available population based incidence rates of ACO. This is 
because the essential denominator, the size and composition of the BO population, is 
currently unknown as there is currently only one BO prevalence studies in a large randomly 
selected population19. However, the 16 cases of BO identified were too few to provide 
meaningful age and gender specific data. Our study represents a first step in an attempt to 
estimate this size and composition of the BO population from ACO incidence rates as these 
two factors are obviously interrelated. For our ACO data we chose our earlier study on the 
incidence rates of ACO in Denmark, which described an unexpected fall in the ACO  
 
0
5
10
15
20
25
45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Age bands
A
C
O
 in
ci
de
nc
e 
ra
te
s/
 1
00
 B
O
 p
er
so
n 
ye
ar
s.
Males
Females
 
Figure 1. 
The 
incidence 
curves 
calculated on 
the basis of 
model 3 for 
BO 
prevalence 
rates of 1.5% 
for males 
and 0.75% 
for females 
resulting in a 
modelled 
ACO 
incidence 
rate45-75 of 
0.42%. 
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Figure 2. The 
same curves as 
in figure 1 
detailed for the 
age bands 
between 45-75 
years. 
The 0.5/100 
person-years 
incidence limit 
is achieved at 
about 55-60 
years in males 
and about 65 
years in 
females, but is 
only valid for 
patients 
acquiring BO 
before the age 
of 46.  
 
incidence rate of the over-80 population around 1990. This was attributed to a declining 
prevalence rate of BO in this age group and for which 3 hypotheses were advanced 20. Three 
models, based on EM algorithms for these 3 hypotheses, were tested against external criteria, 
the most important of which was a modelled ACO incidence rate45-75 of between 0.4 and 0.5/ 
100 person years.   Model 1 was rejected as it did not conform to this and the other set criteria. 
 Model 2, although conforming to the modelled ACO incidence rate45-75 was considered less 
plausible because of the height of the excess mortality involved. Whether such excess  
mortality exists is a matter of dispute.  A fundamental problem is the symptom overlap with 
ischaemic heart disease 40, as was demonstrated in a recent UK population based  
study in which the calculated excess mortality lost its significance after correction for the 
presence of ischaemic heart disease41. The BO cohort follow up study from Rotterdam, 
reporting an excess mortality of 50%31, included a large proportion of patients already 
suffering from severe unrelated diseases. Conflicting results were reported for the survival in 
a cohort of 117 BO patients from Olmsted County32  and an earlier study from the same 
centre30. Two recent studies, from Germany and from Northern Ireland, failed to find an 
increased overall mortality in substantial cohorts of BO patients33, 34. 
By conforming to all criteria, model 3, describing the birth cohort effect, was finally judged 
the most plausible. This conclusion was in accordance with the finding of a significant birth 
cohort effect in the incidence rates of ACO reported in a recent analysis of SEER data.11.  
The implications of the birth cohort effect may be far reaching. If the calculated age specific 
expansion of the Danish BO birth cohorts of around 4%-5% per annum continues, it will 
cause a similar rise in the incidence of ACO. This process is then likely to continue until the 
BO population achieves its maximum. The existence of a secular rise in the prevalence of BO 
was recently confirmed in a study from The Netherlands 35. 
Currently, the most important underlying causes for this mounting BO prevalence are thought 
to be the combination of the secular fall in the prevalence of Helicobacter pylori infection42-45 
and the increasing prevalence of obesity in industrialized countries46-51.  
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An intriguing alternative hypothesis was recently launched, focusing on the increasing nitrate 
consumption from nitrogenous fertilizers in the 20th century, specifically after  
World War II, resulting in high nitrite concentrations in the saliva.  This nitrite, when 
encountering gastric acid, causes high concentrations of NO at the gastro-oesophageal  
junction which can act as a carcinogen52-55.  
As the observed increased cancer rate manifests itself as adenocarcinoma and not as 
squamous cell carcinoma, this hypothesis requires an initial BO induction by NO, which is 
quite conceivable55-57. Although this pathogenesis bears some of the hallmarks of a period  
effect, the birth cohort effect may have resulted from the fact that, in comparison with the 
younger birth cohort, the older birth cohorts experienced a smaller cumulative exposition. 
Our method required several assumptions. To overcome the problem of the unknown date of 
onset of BO, we defined the modelled BO population as having developed BO before the age 
of 46. It should therefore be emphasized that the ACO incidence rates found in model 3 were 
only valid for a population which had acquired BO before the age of 46.As a result, with the 
exception of patients diagnosed with BO before this age, our incidence rate data as illustrated 
in figures 1 and 2 can only be employed as a worst case estimate for BO patients diagnosed at 
a later age. Two recent studies have shown a constant age specific rise in the BO prevalence15, 
16, confirming that the majority of patients do indeed acquire BO at an advanced age. 
Therefore, the majority of the BO population would have acquired BO after the age of 46 and 
consequently, the entire Danish BO population was obviously far larger than our modelled 
BO population. As this majority was not included in our model 3, this model could not predict 
their prognosis. 
We also assumed a long incubation time between the onset of BO and symptomatic ACO 
based on the following considerations. First, although in theory the generally accepted  
0.5% annual incidence of ACO in BO patients could result from random occurrences, the 
cascade: intestinal metaplasia without dysplasia to low-grade and finally to high-grade  
dysplasia and ACO58 implies a time frame which, even in the case of high-grade dysplasia, 
can still amount to over 7 years59. Second, an analysis of data from the last of 3 consecutive  
reports from the Rotterdam study of 155 BO patients followed up for between 17 and 27 years 
and in which a constant ACO incidence rate of around 0.5 per 100 person years was 
observed31, 60, 61,  revealed that 44 survivors, diagnosed at an average age of 49.6 years, had  
experienced an average ACO free interval of 20 years (range 16.3-26.5 years). An incubation 
period of at least 20 years for individuals acquiring BO before age 46 is therefore plausible.  
A basic assumption in our study was that practically all ACO arise in BO2-5. This concept was 
recently challenged by Chang, citing studies by Bytzer 7and Lagergren62  who found BO in 
only 19% and 62% respectively of patients with ACO63. However, the first study consisted of 
data from a cancer registry, while in the second all patients were examined according to 
standardized protocols, resulting in a far higher BO score. Sabel et al. found that the only 
difference between ACO with and without visible BO tissue was that the latter tumours were 
larger and more advanced, suggesting that these aggressive tumours had overgrown  the 
whole original metaplastic  surface64. The final test for the existence of ACO without BO 
would be the finding of oesophageal adenocarcinomas originating from non-metaplastic 
columnar epithelium, i.e. sub-mucosal oesophageal mucous glands. A number of such cases 
were published in case series from the nineteen-sixties, each of which included only one case 
of ACO, suggesting that, at that time, this was the most common type of adenocarcinoma of 
the oesophagus65, 66. However, only two such cases have been published in the recent 
literature67, indicating the impact of these tumours on current ACO epidemiology to be 
negligible. We therefore maintain BO to be an essential condition for the development of 
ACO and a valid basis for our estimates.  
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In conclusion, this study described a first attempt at estimating the hitherto invisible BO 
population of Denmark from ACO incidence data. It succeeded in estimating the size of   
a limited segment of the BO population by age and gender, by means of EM algorithms and 
established a cohort effect as the most plausible cause for an observed decrease in the elderly 
BO population. However, owing to the limitations imposed by the models employed, it was 
unable to ascertain the age and gender specific ACO incidence for the entire Danish BO 
population. This goal will require the development of entirely new models which admit the 
inclusion of a BO population whose age at onset of BO is based on realistic data. Our study 
also underlines the importance of developing techniques able to estimate the duration of the 
presence of BO in individual patients.  
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APPENDIX. 
 
The mathematical models. 
An expectation maximation model (EM) algorithm was constructed for the ACO incidence 
rates. EM algorithms are an iterative extension of regression models designed to handle a 
latent variable: a variable that cannot be observed explicitly; here the fraction of the 
population with BO. The Model-step (M-step) estimated the incidence curve, given a fraction 
at risk. This was used to calculate life tables for both the exposed (BO) and non-exposed 
(general) population. The Estimate- step (E-step) then combined these life tables to estimate 
the fraction at-risk which could be used again in the next M-step. Steps were iterated until an 
optimum was reached. 
Model 1, the basic model  
The first step (the M-step) estimated the exponential curve as 
Ŷa =Φa.Pa e α+β.Xa   ;Y ≈ Poisson  
with: 
Ŷa estimated incidence at age a 
Φa fraction with BO at age a 
Pa total number of person-years at age a  
e α+β.Xa  incidence rate within the group at risk 
 (Φa was fixed in this step and α and β were estimated) 
In the second step the life tables for the BO and non-BO population were calculated: 
La = ∏ (1−Ia).(1−Ma) 
λ=45,a 
with: 
La fraction surviving at age a  
 Ia incidence rate of ACO at age a  
Ma background mortality at age a 
The mortality from ACO was assumed to be both equal and simultaneous with the incidence 
and was obviously zero in the non-BO population. The background mortality was derived 
from the Danish life tables and not corrected for ACO mortality because of the very small 
contribution of ACO to total mortality.  
Subsequently the fraction with BO at age 45 could be calculated from the combination of the 
life tables and the observed ACO incidence (the E-step): 
 Φ45.L′a 
 Ŷa = —————————PaI  ; Y ≈ Poisson  
 Φ45.L′a+ (1−Φ45).La 
with, 
Ŷa  estimated incidence rate at age a  
Φ45  fraction with BO at age 45 
L′a survival within the BO population  
La survival within the non-BO population 
Pa total number of person-years at age a 
Ia incidence rate of ACO in the BO population at age a 
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(in this step the incidence rate of ACO was fixed and the single parameter Φ45 was estimated) 
After estimating the fraction of the population with BO at age 45 the fraction at other ages 
could be calculated on the basis of the survival curves and the first step, estimating the 
exponential incidence curve within the BO population, could be repeated. 
 
Model 2, the effect of excess mortality from unrelated causes 
In the basic model ACO was the only extra cause of death in the BO population as compared 
to the general population. If, in addition, the BO population should suffer a higher death rate 
from unrelated causes this would add to the speed of depletion of the group at risk of ACO. 
The basic model was adapted to include the effect of such extra mortality on the BO 
population: 
                                    La = ∏ (1−Ia). (1−R.Ma) 
                                            λ=45,a  
with: 
 
R the relative risk of mortality in the BO population from unrelated causes of death. 
To maintain a balance between the amount of available data and the number of parameters to 
be estimated, the prevalence rate of BO at age 45, Φ45 was set at 1% for males and 0.5% for 
females. 
Models 3, the cohort effect 
Another adaptation of the basic model 1 investigated the effect of an increase in the 
prevalence rate of BO over the decades before 1990. This would imply that the falling 
incidence rate of ACO in the elderly was not so much the result of depletion, but of a lower 
initial prevalence rate of BO in these age cohorts. This was achieved by extending another 
part of the basic model: 
Φ45.ρ−[a-45].L′a 
Ŷa =  ——————————— .Pa.Ia ; Y ≈ Poisson 
Φ45.ρ−[a−45].L′a+ (1−Φ45).La 
with, 
ρ  the relative annual increase of the fraction BO at age 45 before 1990. 
Here the prevalence rates of BO at age 45 were set at 1.5% for males and 0.75% for females 
and ρ, α and β were estimated. 
Confidence intervals were calculated by the method for likelihood based confidence 
intervals68.  
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Background: In common with other industrialized countries, The Netherlands has experienced a 
rising incidence of oesophagus-cardia adenocarcinoma, raising the question of the respective 
roles of the two constituent tumours, i.e., adenocarcinoma of the oesophagus (ACO) and 
adenocarcinoma of the gastric cardia (AGC) in this rise. 
Aims: To compare and contrast time trends for the incidence of ACO and AGC.  
Methods: The trends in the 1989 to 2003 annual incidence rates by 3-year age classes and gender 
for ACO and AGC, as provided by the Netherlands Cancer Registry, were compared. In addition, 
these data were analyzed for age-period-cohort patterns. 
Results: Over the 15-year period, the annual rise in the incidence rate of oesophagus-cardia 
adenocarcinoma was 2.6% for males and 1.2% for females. This was the net outcome of annual 
increases in ACO incidence (7.2% for males and 3.5% for females) and annual declines in AGC 
incidence of over 1% for both genders. For ACO and AGC, both genders exhibited a non-linear 
cohort pattern, whereas a non-linear period pattern was only observed for males with AGC.    
Conclusions: The divergent time trends and age, period and cohort patterns between ACO and 
AGC clearly establish their epidemiological heterogeneity. The declining AGC incidence 
probably resulted from a secular decline in the number of male smokers and the two main 
etiological factors considered to be driving the rising ACO incidence not affecting the incidence 
of AGC. 
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INTRODUCTION 
Before 1950, carcinoma of the oesophagus was practically always thought to be synonymous 
with epidermoid (squamous cell) carcinoma1. The only rarely occurring adenocarcinomas were 
considered to have arisen from an upward extension of gastric cancers2, oesophageal glands3, or 
ectopic gastric mucosa in the proximal oesophagus ( the “inlet patch”)4. However, from the early 
1970’s adenocarcinomas of the oesophagus rapidly became more common5. 
The recognition that such adenocarcinomas can6, 7, and mainly do8 develop in a columnar lined 
oesophagus (Barrett’s oesophagus9) has created a great deal of interest in the factors causing 
Barrett’s oesophagus and its subsequent progression to adenocarcinoma10, 11.  In addition, it 
enabled the current division of oesophagus-cardia adenocarcinoma into adenocarcinoma of the 
oesophagus, arising in Barrett’s oesophagus (ACO) and adenocarcinoma of the gastric cardia 
(AGC). 
Over the past decades a steady rise in the incidence rates of oesophagus-cardia adenocarcinoma 
has been reported by cancer registries from the United States and  Europe12-16. However, whether 
this rise involved both ACO and AGC to the same extent has remained unclear, as most of these 
cancer registries were unable to distinguish between the two cancers. This is not surprising 
because, even for pathologists examining resected specimens, this fine distinction remains 
problematic17-19. In Denmark, where Eurocim data20 had registered a 1.8:1 incidence ratio 
between AGC and ACO in males, a panel of experts, after reviewing the original clinical data 
over the same period, reversed this ratio to 1:2.421. 
 The Netherlands is one of the countries with the highest incidence rates of both ACO and 
AGC22.  This finding obviously invited further investigation into the epidemiology of the 
constituent tumours of the oesophagus-cardia adenocarcinoma. Specifically, this study examined 
the epidemiological homogeneity of ACO and AGC in The Netherlands and their respective roles 
in the rising incidence of oesophagus-cardia adenocarcinoma by analyzing the differential time 
trends in the incidence of these two cancers and the presence of non-linear cohort-period patterns. 
 
MATERIALS AND METHODS 
The Netherlands, a country of 16 million inhabitants, is well served by a system of 9 regional 
Comprehensive Cancer Registries to which both hospital medical record departments and 
histology departments report all malignancies. This double case ascertainment ensures a high 
degree of accuracy. The Netherlands Cancer Registry in turn collates the data from all 9 
Comprehensive Cancer Registries. The ascertainment of symptomatic oesophageal cancer in The 
Netherlands is likely to be high, as it practically always results in endoscopic and histological 
diagnosis for curative or palliative interventions23. This Registry provided the annual age and 
gender specific incidence rates of ACO (ICD.10 C.15,3,4 and 5) and AGC (ICD10. C.116.0) for 
the 15-year period from 1989 to 2003, subdivided in 3-year age classes.   
The time trends for each cancer were analyzed by log-linear Poisson regression models. For the 
estimation of the cohort models a mean year of birth was calculated for each 3-year age class. 
The estimated drift parameters constituted the annual percentage change in the incidence rates, 
corrected for age and population size. We used splines to test for non-linear period and cohort 
patterns. An observed annual percentage change may represent a period or a cohort effect but a 
choice between the two is only possible when one or the other is nonlinear. Therefore, instead of 
one exponential curve from the beginning to the end of the period, we extended the model to 
three exponential lines connected by knots at 1993 and 1998 for period estimates and 1926 and 
1944 for those of birth cohort. 
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In both cases, the knots were placed at (approximately) one and two thirds of the time axis, 
without attempting to optimize their choice. Likelihood ratio tests (comparison of scaled 
deviances) showed whether significant non-linear period or cohort effects were present24, 25. 
Male-female ratios were estimated from a model including incidence year, age class and gender. 
 
RESULTS 
Time trends by log-linear regression models for oesophagus-cardia adenocarcinoma, ACO and 
AGC 
The incidence rates of oesophagus-cardia adenocarcinoma (ACO and AGC) rose from 7.4/105 to 
10.0/105 (34%) in males, from 1.7/105 to 2.1/105 (25%) in females and from 9.1/105 to 12.1 /105 
(33%) in both genders combined over the period 1989-2003. The time trends for ACO and AGC 
for these years by gender are shown in Figure 1. The overall incidence rates of the two tumours 
over the total 15-year period were practically identical, for ACO 4.3/105 males and 0.96/105 
females and for AGC 4.3/105 males and 0.92/105 females. However, while initially the male AGC 
incidence rate was far in excess of that of ACO, over the 15-year period the combination of a 
strongly rising ACO incidence rate with a downward trend in that of AGC, finally reversed this 
relationship starting from 1998 on. A similar, but less pronounced pattern was seen in females.  
The annual changes in the incidence rates, after correction for age, for both genders over the 15-
year period 1989-2003 are shown in Table 1. The annual AGC incidence rates declined by -1.2% 
in females (p=0.05) and -1.7% in males (p= 0.0002). This in contrast to the annual ACO 
incidence rates, which increased by 7.2% (p<0.001) for males but only 3.5% (p= 0.006) for 
females. It can be concluded that ACO and AGC had contrary effects on the incidence of 
oesophagus-cardia adenocarcinomas. 
The explanation for the 2-fold difference in the annual percentage increases in the ACO 
incidence rates between men and women is shown in Table 2. The annual percentage increases 
for both genders were highest in the 40-60 year age band, subsequently decreasing significantly 
for both genders in the 61-84 age bands (p=0.03). However, in males this decrease only 
amounted to 25% against 62% in females. Consequently the 1.2:1 male: female ratio in the 40-60 
age band rose to 2.3:1 in the 61-84 age bands and this increased ratio was eventually to a large 
extent responsible for the differences between the genders in the annual rate of increase of 7.2% 
and 3.5% respectively. 
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Figure 1: the annual age corrected incidence rates for ACO and AGC for1989-2003 by gender. In 
males ACO incidence rates rise rapidly, while in AGC they gradually decline.  
 
 
Table 1.  Annual Percentage Changes in the Incidence Rates of Adenocarcinoma 
of the Oesophagus and the Cardia by Gender 1989-2003 
Oesophageal 
Tumour 
Gender Numbers 
Observed 
Incidence 
Rates/105 
Annual % 
Change 
95% CI  
Annual Change 
p 
values 
ACO Males Females 
4 949 
1 589 
4.43 
0.96 
+7.2% 
+3.5% 
   +6.5 ;  
   +2.3 ; 
+7.9 
+4.7. 
<0.001 
<0.001 
AGC Males 
Females 
4 863 
1 441 
4.34 
0.92 
–1.7% 
–1.2% 
   –2.4 ; 
   –2.4 ; 
–1.1 
–0.0 
  0.0002 
  0.05 
                                                                   Source basic data: The Netherlands Cancer Registry 
Table 1: the annual changes each represent the average value over the 15-year period. The 
incidence rates are corrected for age.  
 
Table 2. The Annual Percentage Changes in the Incidence Rates 
of Adenocarcinoma of the Oesophagus by Age and Gender. 
Age bands 40-60 61-66 67-72 73-78 79-84 85+ 
Males 9.0% 5.9% 6.0% 7.0% 7.8% 5.5% 
Females 7.5% 4.8% 3.6% 0.6% 2.5% 4.3% 
Table 2: the annual percentage increases corrected for age. The gender ratio for the age band  
40-60 was 9% to 7.5%. Note the major differences between males and females after age 61. The 
male “dip” was short-lived, in females recovery only started around age 80. Over the 61-84 age 
bands the average male percentage increase was 6.7% against 2.9% for females, resulting in the 
overall 7.2% to 3.5% gender ratio.  
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Table 3.          Cohort or Period Effects for Adenocarcinoma of the Oesophagus (ACO) 
and the Gastric Cardia (AGC) by Gender 1989-2003 
Tumour Gender Cohort Effect <1926 1926-44 >1944 
p 
value 
Period Effect 
1989-93 1994-99 1999-03 
p 
value 
Annual 
% change
ACO Males +7.2 +7.1 +9.1 0.08 +6.8 +6.5 +8.4 0.5 +7.2 
ACO Females +2.1 +7.1 +4.0 0.006 +2.9 +2.9 + 5.4 0.6 +3.5 
AGC Males +0.1 -3.0 -3.1 <0.0002 +1.4 1.2, -5.9 0.0001 -1.7 
AGC Females -2.6 +0.1 +4.1 =0.01 +1.4 -1.4, -3.4 0.3 -1.2 
Table 3: the age-cohort effects and age-period effects for ACE and AGC by gender. Cohort effects are 
tabulated separately for patients born before 1926, between 1926 to 1944 and after 1944. Period effects 
are tabulated separately for the years 1989 to 1993, 1994 to 1998 and 1999 to 2003. Statistical 
significance was calculated by comparing the values of these intervals.  
 
 
Age-period-cohort models 
The results of the cohort and period estimates are shown in Table 3.  For each tumour, the mean 
changes in the annual incidence rates for each of three periods (before 1926, from 1926 to 1944 
and after 1944) were differentiated by year of birth for cohort effects and by incidence year for 
period effects. A significant difference between the values for the three periods indicated the 
presence of a non-linear cohort or period effect. For example, the ACO incidence rates for males 
born before 1926, showed an annual change of 7.2% against 7.1% for patients born between 1926 
and 1944, and increasing to 9.1% for patients born after 1944. However, the differences between 
these three percentages were not significant (p=0.08) (Figure 2). For the ACO period effect in 
males, the annual changes were +6.8 between 1989 and 1993, +6.5 between 1994 and 1998 and 
+8.4 between 1999 and 2003 (p =0.50) (Figure 3), i.e. there were no significant non-linear cohort 
or period effects in males with ACO.  This in contrast to females with ACO where a significant 
non-linear cohort effect was seen (p=0.006), with the greatest increase in the 1926-44 cohorts 
(Figure 4), but here again there was no significant period effect (p=0.64). 
For AGC, a non-linear cohort effect was found in males, p<0.0002, demonstrating a steady 
declining trend in cohorts born after 1926. This in contrast to the non-linear cohort effect in 
females, p=0.01, which demonstrated a rising trend in cohorts born after World  
War II (Figure5). Finally, for AGC a non-linear period effect in males, p=0.0001 (Figure 3), 
partly mirrored in females, p=0.3 suggested a decline caused by a period effect setting in around 
1995.  
  
 117
 
0
10
20
30
40
50
60
70
80
19
00
19
03
19
08
19
11
19
14
19
17
19
20
19
23
19
26
19
29
19
32
19
35
19
38
19
41
19
44
19
47
19
50
19
53
19
56
19
59
19
62
19
65
Year of birth
A
ge
 c
or
re
ct
e 
in
ci
de
nc
e 
ra
te
s/
 1
00
 0
00
Age
Corrected
Incidence
Rates
Males ACO
Spline
 
Figure 2: the age-cohort model diagram for ACE in males. The seeming decline in the youngest 
birth cohorts is an artefact caused by a wide scatter in incidence rates. In spite of the large annual 
increases, especially in the birth  cohorts born after 1944, the differences between the 3 sets of 
birth cohorts were not significant, p=0.08. 
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Figure 3: the age-period model in males for both ACO, without a significant age-period effect, 
p=0.5 and AGC with a very significant age-period effect. AGC incidences are seen to declining 
from around 1994 and this trend increases after 1999, p=0.0001. 
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Figure 4: the age-cohort model diagram for ACO in females. Here there is a significant age-
cohort effect, p=0.006. 
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Figure 5: the age-cohort model diagram for AGC in males and females. In males there is a very 
significant birth-cohort effect, demonstrating a steadily declining trend in AGC incidences in 
consecutive birth cohorts born after 1926, p<0.0002 and in females a significant age-cohort  
effect which, in contrast to males, consists of  rising AGC incidences in birth cohorts born after 
1944,  p=0.01. 
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DISCUSSION 
These results from The Netherlands confirm the world-wide trend towards rising incidence rates 
of oesophagus-cardia adenocarcinoma13-15. While this rising trend was very pronounced for ACO, 
the AGC incidence rates actually declined for both genders.  This epidemiological inhomogeneity 
represents the major finding of this study, indicating that, at least in The Netherlands, the rising 
incidence of oesophagus-cardia adenocarcinoma over the past 15 years was entirely due to ACO.  
Obviously, our results can be called into question on the basis of our previous criticism of the 
reliability of cancer registries in distinguishing between ACO and AGC1. However, as Dutch 
cancer registries registered adenocarcinomas of the gastro-oesophageal junction as AGC unless 
Barrett’s oesophagus was mentioned, it is likely that a substantial number of cases of distal ACO 
were misclassified as AGC. On the other hand, it is unlikely that AGC would have been 
misclassified as ACO12. Therefore, in our opinion, our ACO incidence rates actually represent a 
minimum. When analyzed for cohort and period effects, the annual percentage changes in ACO 
incidence in males were found to be linear, i.e. not significant (Table 3) However, there were 
obviously very considerable annual increases, amounting to over 9% in the youngest age-cohorts 
(Figure 2). Therefore, in the absence of factors causing a period effect, such as a sudden change 
in tumour classification or the appearance of a new carcinogen and because of the significant 
cohort effect in females (Figure 4), we are convinced that there was in fact, a cohort effect for 
ACO in both genders. This outcome confirms an analysis of US SEER-data by El-Serag et al. 
who found a cohort effect for ACO but not for AGC19. 
We were surprised by the 2-fold gender differences in the annual percentage increases in the 
ACO incidence rates (Table 1). In The Netherlands, the annual percentage increase in the 
incidence of Barrett’s oesophagus was recently demonstrated to be equal for both genders26. This 
had led us to expect equal annual percentage increases in the ACO incidence rates for both 
genders. However, a further analysis including the factor age, revealed the source of this large 
gender difference. It proved to be a precipitous “dip” in the annual percentage increases in the 
ACO incidence rates for females in the 61-84 age bands, i.e. born between 1905-40. As the 
percentage increases for the 40-85+ age group were calculated separately for each of the 15 
years, this “dip” did not represent a temporary phenomenon. We suggest two mechanisms which 
may have been responsible for this dip, secular changes in female smoking habits and NSAID use 
by the elderly. Four case-control studies on the effect of smoking on the incidence of ACO and 
AGC combined and two of ACO and AGC separately, reported odds ratios ranging between 1.5 
to 3.427. In The Netherlands, a study of the relative risk of lung cancer as an indicator of smoking 
intensity, found a steady decline in male smokers born since 1914. This in contrast to females, 
where smokers have steadily been increasing in successive birth cohorts since the second half of 
the 19th century and, after a relative plateau between 1928-37, continued to increase, with their 
numbers doubling in the1945 to ≥1958 birth cohorts28. Therefore, although the effect of smoking 
on the incidence of ACO may not have been very great, the relatively low number of female 
smokers in the 1905-40 birth cohorts may well have contributed to the observed dip.  
For NSAIDs, although there are currently no randomized trials29, there are some basic studies30-32 
and epidemiological reports33-36 suggesting a protective effect of NSAIDs against ACO in 
patients with Barrett’s oesophagus. In addition, there is evidence of considerable gender 
differences in the use of NSAIDs in the elderly37, 38. In the Netherlands, the Integrated Primary 
Care Information data base which harbours the complete longitudinal electronic medical records 
of over 500 000 patients, revealed both a NSAID user rate, rising from 10% below age 45 to 23% 
over age45 and a 1.5-fold higher user rate in females (Dr. M.C.J.M. Sturkenboom, personal  
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communication). We therefore suggest that chronic NSAID use, by postponing or preventing the 
onset of ACO in individuals with Barrett’s oesophagus over the age of 61 and more specifically 
in females, because of their higher NSAID consumption, contributed to the significant reduction 
the annual rise in the ACO incidence rates in both genders.  
The declining incidence rate of AGC was less surprising. AGC mortality trends between 1968-
1994 from Netherlands already showed a decline39. However, the downward trend could also 
have resulted from a diagnostic shift from AGC to ACO by clinicians reporting to the cancer 
registries. While the presence of visible Barrett’s oesophagus was for a long time considered a 
condition sine qua non for the diagnosis ACO, the current trend is to look at the location of the 
major bulk of the tumour12, 18. Such a diagnostic shift would be a perfect explanation for the 
observed period effect for AGC in both genders. However, a diagnostic shift of this size should 
have resulted in a complementary period effect for ACO which was completely absent (Figure 3). 
Therefore, we believe the falling incidence rates of AGC over the past decades to represent a true 
phenomenon.   
This raises two questions, what is AGC and which are the factors involved in its aetiology? The 
diagnosis AGC encompasses a complex tumour. The most commonly used Siewert classification 
defines AGC as an adenocarcinoma with its centre 5 cm proximal or distal from the anatomical 
cardia. It distinguishes 3 types, type I arising from Barrett’s oesophagus and therefore ACO, type 
II, true AGC, arising from the cardiac epithelium or a short segment of intestinal metaplasia at 
the osophagogastric junction and type III, subcardial gastric cancer, infiltrating the cardia from 
below17. It should be pointed out that this is but one of a variety of hypotheses about the anatomy 
of the cardia40. However, several studies have suggested an intermediate epidemiological position 
for AGC between ACO and distal gastric cancer17, 18. It would, for instance, be conceivable that 
in type II AGC, gastro-oesophageal reflux plays a major role while in type III H. pylori is the 
dominant factor. Consequently, the incidence of AGC could reflect the algebraic sum of these 
two opposing aetiologies.  
The currently accepted etiological factors, thought to be driving the mounting incidence of ACO 
in The Netherlands, are increasing obesity41 and the declining prevalence of H. pylori infection42 
which mediate their effects through the induction of  reflux oesophagitis and Barrett’s 
oesophagus43. Consequently, these factors are likely to be less relevant for AGC. For the factor 
obesity this expectation was confirmed in a recent meta-analysis of overweight as a risk factor for 
gastro-oesophageal reflux disease. In marked contrast to ACO, it found only a marginally 
increased risk of  AGC from obesity 44. Studies on the influence of  H. pylori infection on AGC 
also failed to find significant relationships between the risk of AGC and H. pylori infection45, 46. 
However, another factor, smoking, may well have had a greater influence on AGC than on ACO.  
Lagergren et al.  in a study where by its prospective design the differentiation between ACO and 
AGC was particularly accurate, found AGC to be dose dependently associated with smoking, 
odds ratio=4.2, while the relation with ACO was weak or absent47. 
The contrasting secular changes in Dutch male and female smoking patterns mentioned  
earlier28, very nicely fit the contrasting patterns in the cohort effects observed in males and 
females with AGC (Figure 5) and would therefore tend to support an important role for smoking 
in the aetiology of AGC. In view of the 4:1 male/female ratio, the effect of the declining number 
of male smokers obviously considerably outweighed that of the increase in their female 
counterparts on the net outcome of the AGC incidence rates. 
The conversion of nitrite in saliva by acid into potentially mutagenic substances such as nitrous  
 121
acid, nitrosative species and nitric oxide comprises a less well-established aetiology for 
oesophagus-cardia adenocarcinoma. It has been suggested that the greater use of nitrogenous 
fertilizers after World War II may have increased in importance of this factor48.  In patients with 
Barrett’s oesophagus mutagenic nitrite conversion has recently  
been shown to occur within  the Barrett’s oesophagus segments49. For AGC patients this 
conversion is likely to be localized in the cardia50. Whether this, as yet hypothetical,  
factor is still on the increase or has passed its peak is unknown. However, in the absence of more 
solid evidence on the nitrite issue, we prefer to stay with our previous explanations for the 
downward trend in the incidence rates of AGC. These are the steadily falling number of male 
smokers and the fact that two of the major factors driving the rising incidence of ACO did not 
have a similar effect on the incidence of AGC.  
In conclusion, this study has established the epidemiological inhomogeneity of  
ACO and AGC. In spite of the declining AGC incidence rates there was a 36% rise in the 
incidence rate of oesophagus-cardia adenocarcinoma between 1989 and 2003. This was the result 
of the annual growth in the ACO incidence rates of 7.2% in males and 3.5% in females. This 
two-fold gender difference could be attributed to a substantial fall in the annual rate of increase in 
elderly females, possibly linked to the relatively small number of female smokers in this age 
group and their higher NSAID consumption. The likely explanation for the declining AGC 
incidence rates was found in the combination of the precipitous fall in the number of male 
smokers and the observation that increasing obesity and the decreasing prevalence of H. pylori 
infection, generally considered responsible for the rapidly growing ACO incidence rates, had 
little or no influence on the incidence of AGC.   
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ABSTRACT 
 
Background: The overall incidence of adenocarcinoma of the oesophagus (ACO) is high in 
the Netherlands, but there are considerable regional variations. Case-control studies have 
suggested that colonisation with H. pylori provides protection against adenocarcinoma of the 
oesophagus.  
Aims: To investigate whether a relationship could be shown between the prevalence of H. 
pylori colonisation and the incidence rates of ACO within The Netherlands  
Methods: The prevalence of H. pylori was tested serologically in 1600 blood donors, 400 
from each of four regions, per region divided into 5 equal ten-year age groups. The regions 
differed with respect to ACO incidence rates; two with a low incidence rate(3.4 and 3.7/ 105 
in males, 0.6 and 0.9/105 in females), one with  intermediate (4.9/105 in males and 1.1/105 in 
females), and one with high (6.1/105 in males and 1.4/105 in females) ACO incidence rates. 
Results: There were clear age specific gradients in the prevalence of H. pylori colonisation; 
however, there were no differences in colonisation rates between the four regions. 
Conclusions: This population-based study found no relationship between the contrasting 
incidence rates of ACO and the very constant prevalence of H. pylori in four regions of The 
Netherlands. Although not conclusive, this negative evidence calls into question the presumed 
protective effect of H. pylori colonisation against the incidence of ACO. 
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INTRODUCTION 
The Netherlands, a country of 16 million inhabitants, has one of the highest incidences of 
adenocarcinomas of the oesophagus (ACO)1. Since 1989, nationwide cancer registration in 
this country has been carried out by nine regional registries hosted by Comprehensive Cancer 
Centres (CCC) working to a standard protocol.  In each region all malignancies are reported 
to the CCC by both hospital medical record departments and pathology departments. This 
double case ascertainment ensures a high degree of accuracy. The Netherlands Cancer 
Registry in turn collates the data from all 9 CCCs2. The ascertainment of symptomatic 
oesophageal cancer in The Netherlands is presumed to be high, as the disease practically 
always results in  symptoms that warrant endoscopic and histological diagnosis for curative or 
palliative interventions 3. The country has a high incidence of adenocarcinoma of the 
oesophagus (ACO), yet data from the nine CCC regions have shown there to be considerable 
regional differences, the causes of which are unknown.  
 The relationship between colonisation with H. pylori and gastro-oesophageal reflux disease 
has been the subject of discussion since 1997 when  a  negative relationship between 
colonisation with H. pylori and reflux oesophagitis was first suggested4, 5. Initially, in analogy 
with gastric carcinoma, the carcinogenic effect of the colonisation of Barrett’s oesophagus 
with H. pylori was investigated. However, as this colonisation was only found in gastric type 
oesophageal metaplasia, no conclusions could be drawn 6-8. In 1998 Richter et al. launched 
the hypothesis that colonisation with H. pylori might be protective against the spectrum of 
gastro-oesophageal reflux disease9.  
This study aimed to analyse the regional differences in the incidence rates of ACO and 
adenocarcinoma of the gastric cardia (AGC) and their rates of annual proportional change, 
and to test the hypothesis that the observed regional differences in incidence rates reflect 
regional differences in the prevalence of colonisation with H. pylori. 
MATERIALS AND METHODS  
Cancer data 
The annual number of cases of ACO ( ICD10. C15, 3, 4 and 5) and AGC (ICD10. C16.0)  for 
each of the 9 CCC regions was provided by the Netherlands Cancer Registry for the 15-year 
period 1989-2003. The localisation by CCC region was accurate as all patients were 
registered at their home address, irrespective of the location of the hospital in which their 
cancer had been diagnosed. 
Blood donors. 
In each of the four CCC regions selected for comparison, we requested the regional blood 
banks (Sanquin Blood Banks  South-West, Rotterdam, covering CCC regions West and 
Rotterdam and South-East, Nijmegen, covering CCC regions South and Limburg 
respectively)  to provide us with small aliquots of  plasma from donors living in various areas 
within each of  these 4 CCC regions. From each region, 400 samples were collected, equally 
divided into about 80 samples per 10-year age group between the ages of 18 and 70. The 
samples were anonymous, only the age and gender of the donor and the region where blood 
had been drawn were provided. Consequently, under Dutch law, no informed consent was 
required. The number of 400 in each CCC region was chosen to create a discriminative power 
able to identify differences of ≥10% in the prevalence of H. pylori per region. Dutch blood 
donors are for 98% native born Caucasians.  
 
Serological testing.  
Samples were centrifuged and an aliquot of supernatant plasma kept frozen at -80Co until the 
analyses were performed. H. pylori specific IgG antibodies were determined by a commercial 
ELISA kit (Pyloriset EIA-G-III, Orion Diagnostica).At a cut off titer of ≥ 20 positive and< 20  
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negative, this test achieved a sensitivity of 100 % ( 95% CI95.6 - 100 %) and a specificity of 
94.3 % ( 95% CI 88.6 - 97.7 %).  
Statistics 
Both the age standardised ACO and AGC incidence rates and their trends over the 15-year 
period were calculated by log-linear regression from incidence data provided by the 
Netherlands Cancer Registry for each of the 9 CCC regions, set out against Dutch population 
data for 1998. The H. pylori results were subjected to logistic regression. The regional 
prevalence rates of H. pylori were calculated by a model correcting for age and gender. 
Subsequently the increase of H. pylori prevalence with age was calculated by a model 
describing region-specific linear trends after correcting for gender. This yielded the 
proportional increase in the H. pylori colonisation prevalence for each additional year of age. 
RESULTS 
Table 1 presents the mean ACO and AGC incidence rates and the annual proportional 
changes in percentages for each of the 9 CCC regions over the 15-year period 1989-2003. The 
names of the four CCC regions selected for the comparison of H. pylori colonisation 
prevalence are underlined. The 9 CCC regions, together with their mean15-year male ACO 
incidence rates, projected on a map of the Netherlands, are shown in Figure 1. These mean 
incidence rates varied between 3.4/105 in CCC region Limburg and 6.3/105 in CCC region 
North.The differences between the various region were statistically significant. The highest 
mean ACO incidence rates can be seen to be found in the north-eastern and south-western 
regions, with intermediate values in a large part of the country lying between these two 
regions. The lowest mean incidence rates were localised in the south-eastern region, 
extending into the central part of the country. For females the mean ACO incidence rates 
followed very similar patterns although at very much lower levels (Table 1). Besides these 
regional variations in ACO incidence rates, there were also wide variations in the regional 
proportional changes which in males ranged between 4.6 to 4.7% in Limburg and the 
Amsterdam CCC region to 13.8% in the South CCC region. Both the ACO incidence rates 
over the 15-year period and the trends in the proportional changes for the four CCC regions 
involved in the comparison of H. pylori colonisation prevalence are illustrated in Figure 2. 
Fairly steep parallel trends in ACO incidence rates, although at different levels, were seen in 
the Rotterdam and South regions, as against far less steep trends, again at different levels, in 
the West and Limburg regions. These differences were all significant. 
The spread in the AGC incidence rates was far smaller than in ACO and here there was a 
tendency towards stabilisation or decline, the latter significantly in CCC regions South, 
Middle and Rotterdam (Table1).  
The prevalence of H. pylori serum antibodies in the four compared CCC regions, presented by 
age and gender, are shown in Table 2 and Figure 3. The statistical analyses of the prevalence 
of H. pylori per CCC region and the increases of this prevalence for every extra year of age 
are presented in Table 3. After correction for age and gender there were no statistically 
significant differences in the prevalence of H. pylori between the four CCC regions, p=0.87. 
In addition there were no significant differences between males and females. The proportional 
increase of the H. pylori prevalence for each extra year of age was almost identical for all 
regions, with the exception of CCC West. However, the difference between the latter region 
and the other three was not statistically significant, p=0.14 (Table3). Consequently, in these 
four CCC regions, chosen for comparison, there were neither parallels between the widely 
varying regional incidence rates of ACO and the identical prevalence of  H. pylori 
colonisation, nor between the regional  annual proportional trends in the rising incidence rates  
 
 129
of ACO and the again  identical age-related proportional changes in the prevalence rates of H. 
pylori in these four regions. 
 
  
Table 1.  Mean ACO and AGC Incidence Rates and their Annual Proportional 
Changes per CCC Region 
 ACO AGC 
Mean Incidence
Rates/105 
Annual % 
Change 
Mean Incidence
Rates/105 
Annual % 
Change CCC 
Region 
M F 
 
 
M F M F M F 
 4.6* 5.7   0.4 1.4 Limburg 
95% CI 
3.4 
2.9-3.9 
0.6 
0.5-0.8     
3.5 
3.1-4.0 
1.0 
0.8-1.3    
South 
95% CI 
3.7 
3.4-4.1 
0.9 
0.8-1.0 
 13.8** 9.0**  4.8 
4.5-5.2 
1.3 
1.1-1.4 
 -4.6** -2.4 
   -2.5x 1.9 Middle 
95% CI 
3.8 
3.3-4.2 
1.1 
0.9-1.3  
6.5** 2.1 
 
5.1 
4.6-5.6 
1.2 
1.0-1.4    
East 
95% CI 
4.0 
3.6-4.5 
0.8 
0.7-1.0 
 10.5** 7.2*  4.2 
3.8-4.7 
0.8 
0.6-0.9 
 -0.3 0.3 
 5.4** 2.8   -0.2 -0.6 West 
95% CI 
4.9 
4.5-1.3 
1.1 
1.0-1.3     
5.0 
4.6-5.5 
1.1 
0.9-1.3    
 4.7** 1.4   -1.3 0.6 Amsterdam 
95% CI 
5.3 
5.0-5.7 
1.3 
1.2-1.5     
4.9 
4.6-5.3 
1.0 
0.9-1.2    
 5.5** -0.4   0.5 -1.3 Twente 
95% CI 
5.4 
4.9-5.9 
1.4 
1.2-1.7     
4.4 
3.9-4.8 
1.1 
0.0-1.7    
Rotterdam 
95% CI 
6.1 
5.7-6.5 
1.4 
1.3-1.6 
 8.2** 3.2x  5.1 
4.8-5.5 
1.2 
1.0-1.3 
 -3.2** -4.2* 
North 6.3 1.3  7.5** 6.2**  5.2 0.9 -0.8 -1.3 
95% CI 5.9-6.7 1.2-1.5     4.9-5.6 0.8-1.1 
 
  
Significance of Annual % Change: x p= 0.01-0.05, * p=0.005-0.01, ** p<0.0001 
Table 1 presents the age standardised incidence rates of adenocarcinoma of the 
oesophagus (ACO) and of the cardia (AGC) calculated by log-linear regression for the 
period 1989-2003 for both genders in the 9 Comprehensive Cancer Centre regions of The 
Netherlands. In addition, the annual percentage change in these incidence rates and their 
statistical significance are presented. 
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Table 2                       H. pylori prevalence by CCC Region 
 Age bands 18-28 29-38 39-48 49-58 59-70 18-70 
  
Hp N % Hp N % Hp N % Hp N % Hp N % Hp N % 
CCC Males 7 37 18.9 12 44 27.3 15 43 35 15 44 34.1 18 44 40.9 67 212 31.6
South Females 4 44 9.1 7 37 18.9 13 38 34 17 36 47.2 21 39 53.8 62 194 32 
 Totals 11 81 13.6 19 81 23.5 28 81 35 32 80 40 39 83 47 129 406 31.8
                   
CCC  Males 4 40 10 6 40 15 14 40 35 14 40 35 17 40 42.5 55 200 27.5
Limburg Females 8 40 20 14 39 35.9 17 40 43 17 40 42.5 21 40 52.5 77 199 38.9
 Totals 12 80 15 20 79 25.3 31 80 39 31 80 38.8 38 80 47.5 132 399 33.1
                   
CCC  Males 9 30 30 9 39 23.1 13 48 27 16 56 28.6 18 47 38.3 65 220 29.5
West Females 11 50 22 11 40 27.5 11 32 34 8 23 37.8 15 31 48.4 56 176 31.8
 Totals 20 80 25 20 79 25.3 24 80 30 24 79 30.4 33 78 42.3  121 396 30.6
                   
CCC  Males 3 20 15 5 32 15.6 19 42 45 12 46 26.1 32 52 61.5 71 192 37 
Rotterdam Females 3 38 7.9 9 31 29 11 36 31 9 32 28.1 9 26 34.9 41 163 25.2
 Totals 6 58 10.3 14 63 22.2 30 78 39 21 78 26.9 42 78 53.8 112 355 31.5
Table 2 presents the results of the H. pylori serology in the four compared Comprehensive Cancer Centre (CCC) 
regions. South and Limburg are low adenocarcinoma of the oesophagus incidence regions, West a medium and 
Rotterdam a high incidence region. There are no significant differences between the 4 regions in the prevalence of
H. pylori, p=0.87. N= number of tested donors; Hp= number of donors with positive H. pylori serology;  
% = percentage of tested donors with positive H. pylori serology.             
 
 
Table 3 H. pylori Prevalence and Proportional Annual 
Increases 
CCC 
region 
Odds ratios  
vs. mean 
95% CI Annual  
increase 
95% CI 
Limburg 1.08 0.89 -1.30 3.8% 2.1-5.4 
South 1.01 0.84 - 1.22 4.1% 2.5-5.8 
West 0.97 0.80 - 1.17 2.0% 0.4-3.6 
Rotterdam 0.95 0.78 - 1.16 4.6% 2.7-6.5 
Table 3 presents the odds ratios for the levels of the H. pylori 
prevalence in the four Comprehensive Cancer Centre regions set 
against  the mean value for the 4 regions  of 1.There are no significant 
differences, p= 0.87. The proportional increase for each additional year 
of age is practically the same for all 4 regions, with the exception of 
West, but this difference is not significant, p= 0.14. 
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Figure 1. 
A map of 
The Nethetherlands 
showing the 9 
Comprehensive 
Cancer Centre 
(CCC) regions. The 
grey scale provides 
an indication of the 
mean 
adenocarcinoma of 
the oesophagus 
incidence rates for 
males over the 
period 1989-2003 in 
each region, the 
actual mean 
incidence rates are 
shown in each CCC 
region. Note the 
lower incidence 
rates in the  
South-Eastern regions, extending into the central area and the high incidence rates in the 
North-East and South-West 
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Figure 2 shows the trends in the incidence rates of adenocarcinoma of the oesophagus (ACO) 
from 1989-2003 for the four CCC regions involved in the H. pylori prevalence comparison. 
Rotterdam and South show similar, high annual increases at different levels, while West and 
Limburg share slower growth, again at different levels. In females both overall rates and 
annual growth are far lower but similar in pattern. 
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Figure 3. The percentage of male and female H. pylori serologically positive blood donors found  in 
the 4 Comprehensive Cancer Centre regions. Note that for the total 18-70 year age group the results 
for the 4 regions are practically identical.  
 
DISCUSSION. 
This study shows that there are up to almost two-fold differences in the incidence rates of 
ACO in various parts of The Netherlands. At first sight this was a rather surprising finding as 
it involves a small country with a high standard of living and relatively small differences 
between social classes. The only general factor distinguishing the high and low ACO 
incidence rates was that the former were situated in the formerly predominantly Protestant 
provinces bordering the North Sea and the latter in the inland, formerly predominantly Roman 
Catholic provinces of the South-East. Until the middle of the 20th century the South-East, 
South-West and North-East were less affluent, but these differences have practically 
disappeared over the last 40 years. Nevertheless, only 25 years ago predominant Roman 
Catholic regions were still characterised by excess mortality figures in comparison with other 
parts of the country. This was mainly attributed to a higher prevalence of smoking. Although 
these differences were far smaller than those currently found in ACO and had been declining 
since 1950, these data provided evidence for the influence of the variations in lifestyle within 
our small country on regional health outcomes10. 
Could these different ACO incidence rates be artefacts resulting from differing cancer 
registration policies? All 9 CCCs function according to a centralised protocol and there are 
regular meetings intended to coordinate practices. In addition, there are close national 
contacts between gastroenterologists, pathologists and surgeons involved in treatment of these 
patients, among others guided by national guidelines. Together, this makes it unlikely that the 
observed differences can be explained by registration policies. In addition, Table 1 shows that 
the regional differences for AGC were far smaller than for ACO and for squamous cell 
carcinoma of the oesophagus the differences were even smaller (data not shown). 
One of the factors which has been cited as a cause for the rapidly rising incidence of Barrett’s 
oesophagus and consequently, of ACO in Western industrialised countries, is the declining 
prevalence of colonisation with H. pylori 9, 11. The observation that Eastern European and  
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Asian countries, with far higher colonisation rates of H. pylori than in the West, have 
considerably lower rates of Barrett’s oesophagus and ACO supports this concept12-14. 
However, the comparison between geographically and culturally very diverse countries 
obviously introduces many potential confounding factors.   
Currently there is only one published population based study of the relationship between the 
prevalence of H. pylori colonisation and the ACO incidence rates within a single country15. 
Here the controls consisted of age and gender matched persons randomly selected from the 
Swedish population register. 
We decided to approach our population based study by estimating the prevalence of H. pylori 
colonisation in healthy inhabitants (blood donors) in four Dutch CCC regions with relatively 
low and high incidence rates of ACO in order to establish whether a link could be 
demonstrated between the H. pylori prevalence in the general population of these four regions 
and their varying ACO incidence rates. The results of the H. pylori testing demonstrated a 
significant age specific gradient in the H. pylori prevalence (Table 3), an outcome compatible 
with a birth cohort effect in H. pylori prevalence which has been found  in several European 
countries16-19. However, there were no indications of any relationship between the regional H. 
pylori prevalence and the incidence rates of ACO. The size of the tested groups of blood 
donors was adequate as shown by the confidence intervals of the H. pylori prevalence data, 
which were related to the size of the sample tested in each CCC region (Table3). The choice 
of blood donors as representing the whole population could be criticised on the grounds that 
they are for over 98% recruited from the native Dutch population, while currently about 10% 
of the population consists of firsts and second generation immigrants, in particular from 
Mediterranean, South American and Caribbean origin in whom the H. pylori colonisation 
rates are far higher than in the native Dutch population20. However, perusal of the records of 
the 1088 patients presented to the Rotterdam Oesophageal Cancer Group over the 10-year 
period 1994-2003 revealed only 29 patients born outside The Netherlands (data not 
published). Of these, only two patients with ACO came from Mediterranean countries and 
two from South East Asia. This suggests that, in The Netherlands, ACO is currently still 
predominantly a disease of the native Dutch population and therefore the colonisation 
prevalence of H. pylori as found in blood donors is relevant for the epidemiology of ACO, a 
statement which would obviously not be true for the epidemiology of peptic ulcer or gastric 
cancer. Another potential confounding factor could result from regional variations in the 
number of donors who had undergone H. pylori eradication. However, a general practitioner 
electronic data bank, covering 500 000 patients from all over the country, revealed that the 
number of H. pylori eradication treatments had ranged between about 5/10 000 patient years 
in the 40-year age group to about 18/10 000 patient years in the 60- year age group (E. van 
Soest, data not published), i.e. over the previous 10 years, out of our 1600 tested donors, one 
or two might have undergone H. pylori eradication.  
Our negative results do not come as a complete surprise. The relationship between H. pylori 
infection and reflux oesophagitis and its sequellae has been questioned previously21, 22.  
Vieth et al. claimed to have established this relationship on the basis of the retrospective 
analysis of gastric and oesophageal biopsies obtained from a total of 2,201 patients. They 
found 297 patients with gastro-oesophageal reflux disease, 1054 with Barrett’s oesophagus 
and 138 with Barrett’s neoplasia (high-grade dysplasia or adenocarcinoma). A total of 712 
patients with non-ulcer dyspepsia served as a control group. There were no significant 
differences in H. pylori colonisation between patients with gastro-oesophageal reflux disease 
(51.4%)  Barrett’s oesophagus (53.3%) and Barrett’s neoplasia (47.8%). While these 
percentages were significantly lower than in controls,  the H. pylori prevalence of 65.7% in 
this control group was unacceptably high for a Western European population and does not  
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admit the conclusion that there were significant differences between patients and the general 
population23.  
 Finally, our study provides renewed data on the age specific and overall prevalence of H. 
pylori serum antibodies in our Western population. This prevalence in blood donors was 35% 
overall in 198924 and is currently, in spite of the age cohort effect, still 32% indicating that 
over the foreseeable future H. pylori-related diseases are likely to remain prevalent in The 
Netherlands, not only in immigrants but also in the native Dutch population.   
In conclusion, this study investigating the relationship between the prevalence of H. pylori 
colonisation and the strongly differing incidence rates of ACO in various regions of The 
Netherlands, failed to find the expected inverse relationship between these two factors. This 
lack of positive evidence calls into question the presumed protective effect of H. pylori 
infection against the incidence of ACO. In addition, it clearly indicates that other factors must 
be sought to explain the observed regional differences in ACO incidence rates and their 
proportional changes within this country. In view of the steep rise in the incidence of ACO 
and its precursors in Western countries25-27 research is needed to reveal the factors responsible 
for this rise, which may in the near future also occur in other parts of the world such as Asia28-
30.  
Acknowledgment: this study was made possible by a grant from the Gastrostart Foundation. 
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DISCUSSION 
 
Chapter1.  Introduction. 
The definition limiting Barrett’s oesophagus to metaplastic cylinder cell lined oesophageal 
mucosa containing specialised intestinal metaplasia, is criticised on the grounds that two 
forms of cylinder cell lined oesophagus, one innocent and one progressing to cancer, are both 
implausible and not confirmed by any clinical follow up studies. In fact, both forms often co-
exist1 and a British follow up study found equal numbers of adenocarcinomas of the 
oesophagus in patients with and without specialised intestinal metaplasia at their first 
endoscopy2.  
The historical section is chiefly of interest to the historically minded. However, the section on 
the history of experimental reflux oesophagitis describes studies on the effects of acid, bile 
acids and pancreatic enzymes on the oesophageal mucosa which are still relevant today. In 
addition, the efforts of the pioneers in the analysis of the motility disturbances underlying 
reflux oesophagitis and ultimately, Barrett’s oesophagus, deserve to be recorded. 
Unfortunately, the success of proton pump inhibitors in treating reflux oesophagitis appears to 
have dimmed the interest in its pathophysiology. Although techniques such as ambulatory 24-
hour oesophageal pH, bilirubin and motility monitoring and oesophageal impedance 
measurements of gas and non-acid fluids have added much to our insights into the when and 
where of duodeno-gastric-oesophageal reflux, little more is known about the what, i.e. which 
bile acids or enzymes in what concentrations are present where at any given time of day. The 
relevance of such data is shown by the very considerable overlap between the degree of 
reflux, as measured by pH monitoring and the severity of oesophagitis or presence of 
Barrett’s oesophagus. Although genetical factors may also be at work, it is likely that the 
composition of the refluxate plays an important role in triggering both inflammation and 
carcinogenesis. This lack of clinical interest in pathophysiology stands in stark contrast to the 
impressive developments in the fields of molecular biology. The insights into the steps 
leading to malignancy and the results of genetic profiling, of which some examples are 
discussed, may eventually lead us to the Holy Grail, the ability to effectively predict the 
impending onset of adenocarcinoma from biopsies of Barrett’s oesophagus. 
 
Chapter 2. The Incidence of Adenocarcinoma in Barrett’s Oesophagus in an 
Institutionalized Population.  
Eur J Gastroenterol Hepatol 2004;16: 903-909  
This study combined data from 2 studies previously published by Dr. Clarisse Böhmer who 
had studied the prevalence of gastro-oesophageal reflux disease by 24-hour pH monitoring in 
an age and gender representative randomly selected group of inhabitants of institutions for the 
severely mentally handicapped, here called IDI. 
As expected by the investigator, the prevalence of both gastro-oesophageal reflux disease and 
of gastro-oesophageal reflux oesophagitis and Barrett’s oesophagus, for reasons as yet 
unknown, was extremely high in these IDI3. The second study observed the number of cases 
oesophageal cancer, and specifically that of adenocarcinoma of the oesophagus, in these 
institutions over a period of six years4. The current study, by extrapolating the observed 
prevalence of Barrett’s oesophagus in the randomly selected representative group of IDI, 
estimate of the size of the total IDI population with Barrett’s oesophagus. From this data and 
the observed adenocarcinoma of the oesophagus the incidence rates of adenocarcinoma of the  
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oesophagus calculated for this population with Barrett’s oesophagus. In spite of the relatively 
small IDI population and therefore the limited number of IDI follow up years, the about  
tenfold prevalence of Barrett’s oesophagus did enable the estimation of relevant 
adenocarcinoma of the oesophagus incidence rates which, after correction for age distribution, 
proved to be similar to the adenocarcinoma of the oesophagus incidence rates from the 
Rotterdam Barrett’s oesophagus follow up study group of free living individuals with full 
access to alcohol and tobacco5.  
The study includes several interesting points. Neither the prevalence of gastro-oesophageal 
reflux disease and oesophagitis nor that of Barrett’s oesophagus had ever been surveyed in 
randomly selected patients not expressing any symptoms. Because the IDI do not smoke or 
use alcohol and this fact is guaranteed by their institutionalization, the finding of the “usual” 
10% prevalence of Barrett’s oesophagus in the IDI with gastro-oesophageal reflux disease, 
would tend to exonerate alcohol and tobacco, both from the aetiology of Barrett’s oesophagus 
and that of adenocarcinoma of the oesophagus. The differentiation between adenocarcinoma 
of the oesophagus and of the cardia is always a problem. Involvement of the cardia was 
reported in 4 of 18 adenocarcinomas, however, Barrett’s oesophagus was found in 9 and 
reflux oesophagitis in 14, so that while the number of adenocarcinomas of the oesophagus 
was presumably only 14, it is notable that a ratio of 14:4 for adenocarcinoma of the 
oesophagus to adenocarcinoma of the cardia is remarkably different from the usual 50:50 
ratio, certainly in this period. This observation could support the idea that smoking does play 
a role in the aetiology of adenocarcinoma of the cardia6. 
 
Chapter 3 . Age and sex distribution of the prevalence of Barrett's oesophagus 
found in a primary referral endoscopy center. 
Am J Gastroenterol 2005;100:568-576. 
This study again made use of data published by others, in this case the number of cases of 
Barrett’s oesophagus diagnosed over a 15-year period in patients predominantly referred for 
endoscopy by general practitioners7. By adding in the number of first endoscopies performed 
in each of three five-year periods as a denominator, it was possible to calculate the percentage 
of patients with Barrett’s oesophagus, including those with and without specialised intestinal 
metaplasia, by age and sex for each 5-year period and the full 15 years. Further statistical 
analysis revealed that for Barrett’s oesophagus in general and both histological subtypes, the 
percentage increase in prevalence for each additional year of age was constant in both 
genders, for males until 60 and females until 80 years of age. In addition, a 20-year shift in 
the age of onset of Barrett’s oesophagus between men and women was demonstrated. This 
finding, including the 20-year age shift, was recently confirmed in a study of data from an 
electronic general practitioner’s databank in The Netherlands8 This 20-year age shift, if 
confirmed in further studies, is an extremely important finding.  In the first place it goes a 
long way to explain the 2:1 gender ratio in Barrett’s oesophagus and the even higher gender 
ratio in adenocarcinoma of the oesophagus. The age shift is the result of low incidence rates 
of Barrett’s oesophagus in young, fertile women and obviously suggests hormonal influences 
which would be interesting to explore. The relationship between the prevalence of gastro-
oesophageal reflux oesophagitis and overweight in women9 could suggests that this 
hypothetical hormonal protection for women may disappear with their tendency to gain 
weight around the age of 40. The identical rates of increase in the prevalence of Barrett’s 
oesophagus with age provided further arguments against the concept of two types of Barrett’s 
oesophagus, with and without specialised intestinal metaplasia. 
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Chapter 4. The Incidence of Adenocarcinoma and Squamous Cell Carcinoma of the 
Oesophagus; Barrett's Oesophagus makes a Difference. 
Am J Gastroenterol 2005;100:766-774. 
 
This study again made use of previously published data, this time on the incidence of 
oesophageal cancer, and specifically adenocarcinoma of the oesophagus. in Denmark. A 
strong point of this data was that the distinction between adenocarcinoma of the oesophagus 
and adenocarcinoma of the cardia had been revised by a panel of gastroenterologists, using 
original clinical data10. After adding population data, age and gender specific incidence rates 
were calculated for adenocarcinoma of the oesophagus, adenocarcinoma of the cardia and 
squamous cell carcinoma of the oesophagus. 
The most interesting finding was a declining incidence rate of adenocarcinoma of the 
oesophagus in the oldest age group. The fact that this was not caused by under diagnosis was 
demonstrated by the absence of a similar decline in the incidence rate squamous cell 
carcinoma of the oesophagus. This finding posed the question whether this decline was the 
result of a birth cohort effect, a question which could not be answered as it was impossible to 
exclude the possibilities of it being caused by the extra mortality from adenocarcinoma of the 
oesophagus, to which the population with Barrett’s oesophagus is prone or from a 
hypothetical inferior state of health of this population. 
 
Chapter 5. Moddeling a Population with Barrett’s Oesophagus from Oesophageal 
Adenocarcinoma Incidence Data 
In press, Scand J Gastroenterol 2006, published on-line 26-9-2006  
 
This study forms a companion to that in chapter 4. The finding that the great majority of 
persons with Barrett’s oesophagus are never diagnosed, results in practically all data on the 
prevalence of Barrett’s oesophagus being derived from the small minority who are ascertained 
by clinical endoscopy, mostly performed for reflux symptoms. The population with 
adenocarcinoma of the oesophagus is, however, selected for a completely different symptom 
and consequently, is likely to reflect the composition of the largely hidden Barrett population 
far more accurately than data provided by clinical endoscopy. 
By using Danish adenocarcinoma of the oesophagus incidence rates and a complicated 
statistical technique it was possible to choose between the three hypotheses explaining the 
declining incidence rates of adenocarcinoma of the oesophagus in elderly Danes, resulting in 
a choice for the birth cohort phenomenon. In addition, it was possible to calculate the age 
specific incidence rates of adenocarcinoma of the oesophagus for a hypothetical cohort of 
persons who had acquired Barrett’s oesophagus before the age of 40.  However, the 
limitations of this model meant that it was impossible to extend these incidence rates to the 
whole Danish population with Barrett’s oesophagus. To achieve this goal a new model will 
have to be designed, which will need to encompass the growth of the population with 
Barrett’s oesophagus on the basis of the findings in chapter 3. Simplistic calculations, 
unsupported by any statistician, suggest that this growth tends to neutralize the age specific 
increase in the incidence of adenocarcinoma of the oesophagus, resulting in a fairly constant 
incidence rate of adenocarcinoma of the oesophagus in persons with Barrett’s oesophagus, 
which is in accordance with clinical observations11. 
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Chapter 6. Differential Time Trends in the Incidence of Oesophageal Adenocarcinoma in 
The Netherlands 1989-2003 
 
submitted for publication 
 
This study of the incidence rates of adenocarcinoma of the oesophagus and adenocarcinoma 
of the gastric cardia examined the question whether over the past 15 years the incidence rates 
of both cancers have been increasing at the same rate. The inclusion of age-period-cohort 
analyses both widened the scope of the analyses and guarded against the occurrence of 
diagnostic shift from adenocarcinoma of the gastric cardia to adenocarcinoma of the 
oesophagus. An unequivocal rise in the incidence rates of adenocarcinoma of the oesophagus 
and a somewhat smaller fall in those of adenocarcinoma of the gastric cardia were observed. 
The fact that a clear period effect in the falling incidence rates of adenocarcinoma of the 
gastric cardia was not mirrored by a similar period effect in the rise of the incidence rates of 
adenocarcinoma of the oesophagus made a diagnostic shift from adenocarcinoma of the 
gastric cardia to adenocarcinoma of the oesophagus most unlikely. In adenocarcinoma of the 
oesophagus the age specific percentage rise in incidence rates of women between the ages of 
60 and 84 declined dramatically in comparison with males. It was suggested that this decline 
could have been the result of the higher consumption of NSAIDs in elderly females. These 
declining rates of increase of the adenocarcinoma of the oesophagus incidence may also have 
contributed to the 4:1 gender ratio in the incidence rates of adenocarcinoma of the 
oesophagus; a more intriguing question is whether we can observe the effect of the 20-year 
age shift in the onset of Barrett’s oesophagus. Numerically, a comparison between the number 
of cases of adenocarcinoma of the oesophagus in men between the ages of 25 and 69 and 
women between the ages of 45 and 85+ would tend to explain the larger part of the 4:1 gender 
ratio. However, this hypothesis has not yet been blessed by statistical approval. It is possible 
to  conclude that the steeply rising incidence rates of adenocarcinoma of the oesophagus were 
the cause of the rising incidence rates of oesophageal adenocarcinoma in the 15 years between 
1989 and 2003. The incidence rates of adenocarcinoma of the gastric cardia actually declined, 
possibly as the result of the falling number of male smokers. 
 
Chapter 7. No Relationship between the Regional Prevalence of Helicobacter pylori 
Infection and Adenocarcinoma of the Oesophagus  
 
To be submitted for publication 
 
The large differences in the incidence rates of adenocarcinoma of the oesophagus in males 
and to a lesser extent in females, found in the 9 Comprehensive Cancer Centre regions, 
offered a challenge to explore the aetiological factors involved. There is a fairly extensive 
literature, mainly based on case control studies, that infection with Helicobacter pylori 
provides protection against the incidence of Barrett’s oesophagus and adenocarcinoma of the 
oesophagus. This hypothesis was addressed in this study by measuring the prevalence of 
Helicobacter pylori infection in 4 Comprehensive Cancer Centre regions selected for their 
divergent incidence rates of adenocarcinoma of the oesophagus. The prevalence of 
Helicobacter pylori infection was examined in about 400 blood donors from each of these 4 
regions. To our surprise there were no significant differences between the prevalence of 
Helicobacter pylori infection in the 4 regions and therefore no relationship with the very 
significant differences in the incidence rates of adenocarcinoma of the oesophagus. This study 
therefore calls into question the protective effect of Helicobacter pylori infection against  
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adenocarcinoma of the oesophagus. Possibly further studies could be envisaged comparing 
the prevalence of of Helicobacter pylori in patients with Barrett’s oesophagus and 
adenocarcinoma of the oesophagus with the Helicobacter pylori prevalence in their region. 
  
CONCLUSIONS 
The observations described in this thesis on the epidemiology of Barrett’s oesophagus and its 
final stage, adenocarcinoma of the oesophagus, were not part of a preconceived research plan 
but were inspired by a desire to learn more about the epidemiology of these conditions. 
In researching background information for chapter 2 “the incidence of adenocarcinoma in 
Barrett’s oesophagus in an institutionalised population12” it became clear that epidemiology 
was a rather neglected field in the otherwise richly cultivated landscape of the literature on 
Barrett’s oesophagus, with however, all the opportunities which such relatively uncultivated 
fields afford.  
The problem of the mainly hidden population of Barrett’s oesophagus was now approached 
from two directions. The first was the estimation of the prevalence of Barrett’s oesophagus 
within a large number of patients referred by general practitioners for a wide variety of 
indications in order to avoid patient selection which inevitably occurs in larger centres. By 
converting the originally published Barrett’s oesophagus prevalence data7 into prevalence 
rates per 100 first endoscopies13 it became possible to discover a certain systematic order 
from these data. It revealed that in both genders the prevalence of Barrett’s oesophagus 
increased by a fixed percentage for each additional year of age, be it that in women this 
increase was delayed by 20 years and this delay, or age shift, was responsible for the 2:1 male 
to female ratio in the prevalence of Barrett’s oesophagus. It was a great relief when a study by 
Eva van Soest, using data from a Dutch electronic general practitioners data base, confirmed 
this finding14. The causes of this 20 year period of grace granted to women before acquiring 
Barrett’s oesophagus should be an obvious field for further research. 
The second approach was through adenocarcinoma of the oesophagus which forms the final 
chapter in Barrett’s oesophagus. This tumour has a fairly high ascertainment rate and, in 
contrast to Barrett’s oesophagus, there is no selection bias towards symptoms of reflux 
oesophagitis, in practice there are fairly uniform symptoms and investigations leading to 
diagnosis. By converting Danish adenocarcinoma of the oesophagus incidence data10 to 
incidence rates15 and employing further statistical techniques16 it was possible to demonstrate 
a birth cohort effect in the rising incidence rates of adenocarcinoma of the oesophagus in 
Denmark and fitting to the observed rises after the observation period. A birth cohort effect 
implies that the factors responsible for the rising incidence rates of adenocarcinoma of the 
oesophagus are probably already operational in a large part of the population. This means that 
uncovering these factors is of vital importance if any form of primary prevention is envisaged. 
A current front runner would appear to be obesity which appears responsible for  an 
increasing prevalence and severity of gastro-oesophageal reflux disease 17. In addition the 
mathematical moddeling16 has provided a first step in estimating the total population with 
Barrett’s oesophagus which is for over 90% undetected. Such estimates would be valuable in 
planning secondary prevention. 
 The data on the incidence rates of adenocarcinoma of the oesophagus and adenocarcinoma of 
the gastric cardia, provided by the Association of Comprehensive Cancer Centres and collated 
by the Netherlands Cancer Registry, proved another valuable source. Analysis of these data, 
(see chapter 6) has shown that in The Netherlands the incidence rates of adenocarcinoma of 
the gastric cardia are in decline while those of adenocarcinoma of the oesophagus are rising  
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rapidly. Although some speculations are advanced in chapter 6 to explain these different 
trends, some serious efforts should be made to provide more scientifically based explanations. 
Another interesting finding were the major differences in the incidence rates of 
adenocarcinoma  of the oesophagus in various regions of The Netherlands, differences which 
were far smaller for adenocarcinoma of the gastric cardia.  These regional variations are again 
an obvious target for further analysis. A first attempt, a comparison between the Helicobacter 
pylori colonisation rates in blood donors from regions with low and high incidence rates of 
adenocarcinoma of the oesophagus failed to reveal any differences. 
Finally, having established that the incidence of Barrett’s oesophagus and consequently that 
of adenocarcinoma of the oesophagus is rising rapidly in Western industrialised countries and 
this rise is likely to continue, this raises the question: what can be done? In the first place a 
sense of proportion is essential. A number of studies initiated in Rotterdam by Jan Dees have 
shown that only a small percentage of people with Barrett’s oesophagus actually die from 
adenocarcinoma of the oesophagus5. Although both the diagnostic and therapeutic potentials 
of endoscopic surveillance of patients with Barrett’s oesophagus have undergone 
revolutionary changes, the main problem remains that the ascertainment of Barrett’s 
oesophagus is less than 10% of the population with this condition. Endoscopic screening of 
all males over the age of 50 would not appear to lie within the realm of reality while the 
public acceptance is unlikely to be high. The answer must probably be sought in the field of 
genomics and/or proteomics which can potentially provide simple blood tests to identify 
individuals with Barrett’s oesophagus and for their subsequent treatment.  
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SUMMARIES 
Chapter 1. 
Barrett’s oesophagus is defined and the history of the gradually emerging relationship 
between reflux oesophagitis, Barrett’s oesophagus, and adenocarcinoma of the oesophagus, is 
sketched in the historical section. This leads on to the attempts made over several decades to 
unravel the pathophysiology of reflux oesophagitis. A brief overview is presented of the 
clinical tests and classic balloon and manometric studies which revealed the importance of the 
failure of lower oesophageal sphincter function and of oesophageal motility in the aetiology 
of reflux oesophagitis. The experimental studies on the effects of various substances in the 
refluxate on the oesophageal mucosa are described in some detail as their outcome are still 
relevant today. In the present state a brief outline is given of the modern insights into the 
genetic changes occurring during the progress from reflux oesophagitis to Barrett’s 
oesophagus and adenocarcinoma of the oesophagus. The current thinking on the aetiology of 
reflux oesophagitis are discussed in the light of the effects of strong acid inhibition by proton 
pump inhibitors. 
Chapter 2.  
A study designed to ascertain the incidence rate of adenocarcinoma in Barrett’s oesophagus 
(ACO) in a stable population of 28 000 institutionalised intellectually disabled individuals 
(IDI) in whom the prevalence rate of Barrett’s oesophagus (BO) was previously estimated in a 
representative sample by 24-hr pH monitoring and endoscopy.  In this population all cases of 
ACO were ascertained over a 6 year period. These IDI do not smoke or drink alcohol and 
were known to have exceptionally high prevalence rates of gastro-oesophageal reflux disease 
(GORD) and consequently of BO. 
The six year observation of the IDI population comprised 52 038 person years, within this 
period all cases of cancer of the oesophagus were ascertained and the histological diagnosis 
established from medical records. On the basis of the representative sample, the percentage of 
this population with BO was estimated to be 10.8%. ACO incidence rates could then be 
estimated and compared to those found in a free living population with BO, after correction 
for age and gender. In IDI an incidence rate of ACO of 2.5/1000 person years was found 
against 6.3/1000 person years in the free living population. However, the age distributions of 
the IDI and of the free living population were very different, and after correction for this 
factor there was no significantly lower incidence rate of ACO in the IDI (relative risk : 0.79; 
p= 0.61). This is the first reported incidence study of ACO in a stable, well defined population 
in which the ascertainment of BO was not based on endoscopy for symptoms but on random 
selection. In contrast to squamous cell carcinoma, the similar ACO incidence rate of this 
abstemious population to that of a free living population suggest only a minor role for 
smoking and alcohol in the aetiology of ACO.  
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Chapter 3. 
 
Both the demographics underlying the sex ratio in the prevalence of Barrett’s oesophagus 
(BO) and the status of BO without intestinal metaplasia (IM) are unclear.   
This study set out to establish the demographics of histologically proven BO, both IM+ and 
IM-, as observed over a 15 year period at a primary referral, endoscopy unit.  
 For all BO patients aged 20-89 and identified between1982-96, BO IM+ or IM-, prevalence 
rates per 100 first endoscopies were calculated.   
 492 cases of BO, 320 (248 IM+) in males, 172 (127 IM+) in females were identified in 
21,899 first endoscopies (10,939 males, 10,960 females) Between ages 20-59 in males and 
20-79 in females, both IM+, IM- BO and all BO prevalence rates rose by ±7.36% for each 
additional year of age (p=0.92) with however, a 20 year age shift between the sexes, resulting 
in a male/female O.R. 4.15, 95%CI 2.99-5.77. A declining rate of increase in over 59 males 
finally resulted in an overall male/female O.R. 2.14, 95%C.I. 1.77-2.58. Over the age of 79, 
BO prevalence rates/100 first endoscopies fell from a maximum of 5.1 in males and 3.65 in 
females to 3.38 and 2.53 respectively. 
We concluded that the 4:1 sex ratio and 20 year age shift between males and females in the 
prevalence of BO, both IM+ and IM- BO, found in younger age groups, was the main cause 
of the overall BO 2:1 sex ratio. The very similar demographics of IM- and IM+ BO suggest 
they may well be 2 consecutive stages in the same metaplastic process.  
  
Chapter 4. 
Adenocarcinoma limited to the oesophagus (ACO) arises in Barrett’s oesophagus (BO).The 
incidence of ACO is therefore restricted to this BO sub-population, whose size is unknown 
and which is for 95% unidentified. 
We set out to determine the age and gender specific incidence rates of ACO, limited to the 
BO sub-population, within a defined geographical area and to compare them with those of 
squamous cell carcinoma of the oesophagus (SCC), which can affect the entire population.    
The age and gender specific incidence rates for ACO and adenocarcinoma of the cardia 
(AGC) were calculated after an expert panel classified 87% of all cases of adenocarcinoma of 
the oesophagus, reported to the Danish Cancer Registry over a six year period, as ACO or 
AGC.  
The age specific incidence rates of ACO for males rose from 0.09/105 (30-34 yr) to 14.14/105 
(80-84 yr), falling to 7.2/105 (85+ yr), for females from 0.19/105 (45-49 yr) to 2.79/105 (80-84 
yr) , falling to 2.43/105 (85+ yr) and yielding a gender ratio of 5.9:1; AGC demonstrated a 
similar pattern and a gender ratio of 4.26:1.  However, the incidence rates of SCC continued 
rising after age-80, with a gender ratio of 2.5:1.  
The continuing rise in the SCC incidence rates in the elderly demonstrated that the 
unexpected decline and fall in the incidence rates of ACO over age-80 did not result from 
under diagnosis but were most probably caused by a declining prevalence rate of BO, 
restricting the elderly BO sub-population at risk of developing ACO.  
The difference between the 6:1 gender ratio in ACO and 2.5:1 in SCC was ascribed to  
the 2:1 or greater gender ratio in BO. 
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Chapter 5.  
 
The study described in the previous chapter, analysing the adenocarcinoma of the oesophagus 
(ACO) incidence rates in Denmark, revealed a steep fall in the over-80  
population, interpreted as the result of a declining prevalence of Barrett’s oesophagus (BO) in 
this age group for which three hypotheses were advanced: the specific mortality from ACO 
and, superimposed, either excess mortality from causes of death unrelated to ACO or a birth 
cohort effect.  
On the basis of the observed ACO incidence rates, we attempted to create statistical models 
estimating the BO population fitting each of these 3 hypotheses and, by selecting the most 
plausible hypothesis, to gain insight into the composition of the Danish BO population. 
The models which were designed for three hypotheses conformed to the generally accepted 
0.4-0.5% annual ACO incidence in BO patients. These models employed expectation-
maximization algorithms, Danish life tables and the observed ACO incidence rates. The 
models enabled the estimation of a BO population for each hypothesis. 
After testing against previously set criteria, the most plausible model was found to be that 
describing a birth cohort effect, which was found to predicted a ± 5% annual rise in the 
prevalence of BO and consequently, in the incidence rate of ACO in Denmark. This 
prediction was borne out over the decade following on the ACO observation period. 
This rising ACO incidence rate is likely to continue into the foreseeable future. The use of 
EM algorithms enabled a first estimate of the BO population at risk of ACO  although, owing 
to the limitations imposed by  the models, the age and gender specific ACO risk for the entire 
Danish BO population could not as yet be ascertained, this will require a more complicated 
model. 
 
Chapter 6.  
  
: In common with other industrialized countries, The Netherlands has experienced a rising 
incidence of oesophagus-cardia adenocarcinoma, raising the question of the respective roles 
of the two constituent tumours, i.e., adenocarcinoma of the oesophagus (ACO) and 
adenocarcinoma of the gastric cardia (AGC) in this rise. 
We set out to answer this question by comparing time trends for the incidence of ACO and 
AGC in The Netherlands while also controlling for registration artefacts.  
The trends in the 1989 to 2003 annual incidence rates by 3-year age classes and gender for 
ACO and AGC, as provided by the Netherlands Cancer Registry, were compared. In addition, 
these data were analyzed for age-period-cohort patterns which also provided a check on 
diagnostic drift from AGC to ACO. Over the 15-year period, the annual rise in the incidence 
rate of oesophagus-cardia adenocarcinoma was 2.6% for males and 1.2% for females. This 
was the net outcome of annual increases in ACO incidence (7.2% for males and 3.5% for 
females) and annual rate of decline in AGC incidence of over 1% for both genders. For ACO 
and AGC, both genders exhibited a non-linear cohort pattern, whereas a non-linear period 
pattern was only observed for males with AGC.    
We concluded that the divergent time trends and age, period and cohort patterns observed 
between ACO and AGC clearly establish their epidemiological  
heterogeneity. The declining AGC incidence probably resulted from both the secular decline 
in the number of male smokers and that the two main aetiological factors,  
considered to be driving the rising ACO incidence, do not affect the incidence of AGC. 
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Chapter 7 
The overall incidence of adenocarcinoma of the oesophagus is high in the Netherlands, but 
there are considerable regional variations. Case-control studies have suggested that 
colonisation with H. pylori provides protection against adenocarcinoma of the oesophagus. 
These regional variations led us to investigate whether a relationship exists between the 
prevalence of H. pylori colonisation and the incidence rates of adenocarcinoma of the 
oesophagus within The Netherlands. 
The prevalence of H. pylori was tested serologically in 1600 blood donors, 400 from each of 
four regions, per region divided into 5 equal ten-year age groups. The regions differed with 
respect to adenocarcinoma of the oesophagus incidence rates; two with low incidence rates 
(3.4 and 3.7/ 105 in males, 0.6 and 0.9/105 in females), one with intermediate (4.9/105 in males 
and 1.1/105 in females), and one with  high (6.1/105 in males and 1.4/105 in females) 
adenocarcinoma of the oesophagus incidence rates. 
There were clear age specific gradients in the prevalence of H. pylori colonisation; however, 
there were no differences in colonisation rates between the four regions. 
This population-based study showed no relation between the prevalence rates of H. pylori and 
the incidence rates of adenocarcinoma of the oesophagus. This  observation calls into question 
the presumed protective effect of H. pylori colonisation against the incidence of 
adenocarcinoma of the oesophagus. 
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  SAMENVATTING 
 
Hoofdstuk 1.  Inleiding. 
De beperking van de definitie van de Barrett oesophagus tot metaplastisch cylinder epitheel 
van de oesophagus dat gespecialiseerd intestinale metaplasie heeft ondergaan wordt 
bekritiseerd op grond van het feit dat het onwaarschijnlijk lijkt dat er twee soorten 
metaplastisch cylinder epitheel bestaan, de een onschuldige afwijking, de andere een 
voorbode van kanker. Er zijn bovendien geen klinische vervolg studies die dit concept 
ondersteunen. In de praktijk komen beide soorten vaak samen voor1 en een Britse vervolg 
studie2 heeft aangetoond dat er evenveel adenocarcinomen van de oesophagus werden 
gevonden bij patiënten met en zonder gespecialiseerde intestinale metaplasie bij hun eerste 
endoscopie. 
De historische sectie is vooral interessant voor mensen met gevoel voor geschiedenis. De 
sectie over de geschiedenis van de experimentele reflux oesophagitis beschrijft echter 
onderzoek na de invloed van zuur, galzuren en pancreas enzymen voor het slijmvlies van de 
oesophagus die momenteel nog steeds relevant zijn. Bovendien is het de moeite waard om de 
pogingen van de pioniers om de motiliteitsstoornissen te analyseren die te grondslag liggen 
aan het ontstaan van reflux oesophagitis, en uiteindelijk de Barrett oesophagus, vast te leggen. 
Helaas heeft het succes van de proton-pomp remmers in het behandelen van de reflux 
oesophagitis de belangstelling voor de pathofysiologie van deze aandoening sterk doen 
verminderen. Hoewel technieken zoals de 24-uurs mobiele oesophageale metingen van pH, 
bilirubine en motiliteit en de oesophageale impedantie metingen van gas en niet-zure 
vloeistoffen onze inzichten in het wanneer en waar van de duodeno-gastrische-oesophageale 
reflux hebben vergroot, is er nog steeds weinig bekend over wat. Bedoeld wordt welke 
galzuren en enzymen er in welke concentraties waar aanwezig zijn op ieder gegeven ogenblik 
van de dag. De relevantie van dergelijke gegevens wordt aangetoond door de zeer 
aanzienlijke overlap tussende mate van reflux, zoals gemeten door pH registratie en de ernst 
van de reflux oesophagitis of de aanwezigheid van een Barrett oesophagus. Hoewel het zeer 
wel denkbaar is dat er genetische factoren in het spel zijn is het toch waarschijnlijk dat de 
samenstelling van het refluxaat een belangrijke rol speelt bij de aanzet tot de ontstaan van 
zowel ontsteking als kanker.  
Dit gebrek aan belangstelling voor pathofysiologie staat in schrille tegenstelling tot de 
indrukwekkende ontwikkelingen op het gebied van de moleculaire biologie. Het inzicht in de 
stadia die uiteindelijk uitmonden in maligniteit en de resultaten van genetische profileringen, 
waarvan enkele voorbeelden besproken worden,. zouden ons uiteindelijk kunnen brengen tot 
de Heilige Graal, het vermogen om met succes het op handen zijnde ontstaan van een  
adenocarcinomen van de oesophagus te kunnen voorspellen. 
  
Hoofdstuk 2.  
In dit onderzoek werden de gegevens gecombineerd van twee eerder gepubliceerd studies die 
door Dr Clarisse Böhmer waren verricht naar het voorkomen van gastro-oesophageale reflux 
ziekte door middel van 24-uur ambulante pH meting in een representatieve steekproef van 
willekeurig geselecteerde bewoners van tehuizen voor zeer ernstig geestelijk gehandicapte 
individuen, verder aangeduid als IDI. Zoals de onderzoekster had verwacht vond zij, om 
alsnog onbekende redenen, een zeer hoge prevalentie van zowel gastro-oesophageale reflux 
ziekte als van reflux oesophagitis en van Barrett oesophagus bij de IDI3. In haar tweede 
onderzoek had zij het aantal gevallen van oesophagus carcinoom, en specifiek dat van 
adenocarcinomen van de oesophagus onderzocht in deze tehuizen gedurende een periode van 
zes jaar4.  Het huidige onderzoek had door het extrapoleren van de in de representatieve  
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steekproef waargenomen prevalentie van Barrett oesophagus naar de totale IDI populatie een 
schatting gemaakt van de omvang van de gehele IDI populatie in alle instellingen.  De 
combinatie van deze gegevens met het aantal waargenomen adenocarcinomen van de 
oesophagus leverde de incidentie rate van adenocarcinomen van de oesophagus in deze 
populatie met Barrett oesophagus op. Deze incidentie bleek, na correctie voor 
leeftijdsverdeling, overeen te komen met de incidentie rate in een groep in de normale 
samenleving verkerende  patiënten met Barrett oesophagus die al jarenlang vervolgd werden 
in Rotterdam5. Het verschil tussen de twee groepen was echter dat de IDI niet roken en geen 
alcohol gebruiken. Opvallende aspecten van dit onderzoek waren dat hier voor het eerst het 
voorkomen van gastro-oesophageale reflux ziekte, reflux oesophagitis en  Barrett oesophagus 
waren onderzocht bij willekeurig geselecteerde personen zonder specifieke klachten. Ook viel 
op dat er in vergelijking met het aantal adenocarcinomen van de oesophagus relatief weinig 
adenocarcinomen van de cardia  waren gevonden, dit zou kunnen duiden op het feit dat roken 
wellcht een grotere rol speelt bij de laatst genoemde tumor. 
 
Hoofdstuk 3. 
Dit onderzoek naar het patroon van het voorkomen van de Barrett oesophagus wat betreft 
leeftijd en geslacht maakte weer gebruik van reeds gepubliceerde gegevens over het aantal 
waargenomen patiënten in een endoscopie afdeling die vooral onderzoekingen verrichtte voor 
huisartsen zodat het een zo min mogelijk op bepaalde klachten geselecteerde groep betrof 7. 
Door nu het aantal patiënten met Barrett oesophagus per 100 eerste scopieën te berekenen kon 
nu het patroon ontrafeld worden. Het bleek dat met de stijging van de leeftijd per jaar het 
voorkomen van Barrett oesophagus met een vast percentage toenam, met dien verstande dat 
deze stijging bij vrouwen 20 jaar later inzette dan bij mannen. Hierdoor werd ook de 2:1 
verhouding tussen het voorkomen van Barrett oesophagus bij mannen en vrouwen verklaard, 
waarom dit verschil optrad blijft echter nog onverklaard, een hormonale invloed lijkt 
aanemelijk. Deze uitkomst werd onlangs door de Rotterdamse groep aan de hand van 
gegevens uit Nederlandse huisartsenpraktijken bevestigd14. 
 
Hoofdstuk 4. 
 
Aan de hand van reeds gepubliceerde gegevens over het voorkomen van adenocarcinomen 
van de oesophagus in Denemarken10  kon door toevoeging van bevolkingsgegevens de 
incidentie rates van de drie soorten carcinoom van de oesophagus worden bepaald. Het betrof 
het adenocarcinomen van de oesophagus het adenocarcinomen van de cardia en het 
plaveiselcel carcinoom van de oesophagus.  
Hierbij bleek dat de incidentie rate van de adenocarcinomen van de oesophagus in de  
bevolking boven 80 plotseling daalde, uit het feit dat deze daling niet optrad bij patiënten 
boven de 80 met het plaveiselcel carcinoom van de oesophagus kon de conclusie worden 
getrokken dat er geen sprake was van een verminderde diagnostiek bij deze hoogbejaarden. 
De verklaring werd gezocht in een kleiner aantal personen met Barrett oesophagus in de 
oudere leeftijdsgroepen wat zou kunnen duiden op een geleidelijke toename van het aantal 
mensen met Barrett oesophagus over de afgelopen 50 jaar, een zogenaamd geboorte cohort 
fenomeen. 
 
Hoofdstuk 5. 
In aansluiting op het onderzoek beschreven in het vorige hoofdstuk werd nu met behulp van 
een mathematische techniek per 10 jaar leeftijd de omvang van de Deense bevolking 
geconstrueerd waaruit de patiënten met adenocarcinomen van de oesophagus beschreven in 
hoofdstuk 4 afkomstig waren. Hiermee werd een aanzet gegeven tot berekeningen van de  
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gehele populatie met Barrett oesophagus die momenteel slechts voor minder dan 10% bekend 
is. Bovendien kon nu de verklaring worden gevonden voor de daling van het voorkomen van 
adenocarcinomen van de oesophagus in de leeftijdsgroep boven de 80 jaar. Dit bleek 
inderdaad het cohort fenomeen te zijn. De door dit fenomeen voorspelde verder ontwikkeling 
van het aantal adenocarcinomen van de oesophagus bleek in de volgende 7 jaren uit te komen 
en dit betekent dat het aantal adenocarcinomen van de oesophagus jaarlijks blijft stijgen, iets 
dat ook al voorspeld werd door de in hoofdstuk 3 aangegeven stijging in het aantal gevallen 
van Barrett oesophagus. 
 
Hoofdstuk 6. 
Deze keer werd gebruik gemaakt van oorspronkelijke gegevens van de Nederlandse 
kankerregistratie over het voorkomen van het adenocarcinoom van de oesophagus en het 
adenocarcinoom van de cardia tussen 1989 en 2003. De groei in het aantal adenocarcinomen 
van de oesophagus en oesophagus–maag overgang bleek geheel te zijn veroorzaakt door een 
sterke jaarlijkse stijging van het aantal adenocarcinomen van de oesophagus, het aantal 
adenocarcinomen van de cardia liep zelfs geleidelijk terug. Door een statistische bewerking 
kon aangetoond worden dat er geen sprake was van een verschuiving van diagnose 
adenocarcinoom van de cardia naar die van het mogelijk meer populair geworden  
adenocarcinoom van de oesophagus. Een nog niet beantwoorde vraag is of de 4:1 man-vrouw 
verhouding bij beide tumoren verklaard kon worden door het 20 jaar uitstel in het voorkomen 
van Barrett oesophagus bij vrouwen.  
 
Hoofdstuk 7. 
Uit de gegevens over het voorkomen van het adenocarcinoom van de oesophagus in 
Nederland, vermeld in het vorige hoofdstuk, bleek dat de incidentie rates  van deze tumor 
sterke verschillen vertoonden tussen diverse delen van het land. Met name kwam het 
adenocarcinoom van de oesophagus relatief weinig voor in de oorspronkelijk Rooms 
Katholieke gebieden in het zuid-oosten en juist veel in de oorspronkelijk meer Protestante 
gebieden Rotterdam, Zeeland, Groningen, Friesland en Drente. Teneinde een meer 
wetenschappelijke verklaring voor deze verschillen te vinden werd de theorie getoetst dat een 
infectie met de Helicobacter pylori, de bacterie die verantwoordelijk is voor het ontstaan van 
maag- en twaalfvingerigedarm- zweren, zou beschermen tegen het ontstaan van het 
adenocarcinoom van de oesophagus. 
Hiervoor werd het voorkomen van deze infectie onderzocht bij bloeddonors uit vier 
verschillende gebieden waarin meer of minder adenocarcinomen van de oesophagus waren 
gevonden. Er bleken echter geen verschillen te bestaan zodat er sterk getwijfeld moet worden 
aan deze veronderstelde beschermende werking van de Helicobacter pylori. 
 
Hoofdstuk 8. 
Dit hoofdstuk omvat onder anderen deze samenvatting en conclusies. De belangrijkste 
conclusie is dat door de gestage toename van het aantal mensen met een Barrett oesophagus 
ook het aantal adenocarcinomen van de oesophagus zal toenemen waarbij wel overwogen 
moet worden dat slechts een klein percentage van deze mensen aan deze tumor zullen 
overlijden. Onderzoek naar de factoren die blijkens dit proefschrift invloed kunnen hebben op 
het al dan niet ontstaan van Barrett oesophagus en het daaruit voortkomende 
adenocarcinomen van de oesophagus lijkt aangewezen. De huidige opsporingsmethoden van 
mensen met Barrett oesophagus door middel van endoscopieën is waarschijnlijk ongeschikt 
om de grote onbekende groep van mensen met Barrett oesophagus op te sporen en hiervoor 
zal gezocht moeten worden naar bloedtests waarmee de veranderde expressie van genen die 
actief zijn in de Barrett oesophagus kunnen worden opgespoord. 
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Dankwoord. 
 
De normale promovendus is uiteraard vooral dank verschuldigd aan zijn of haar medewerkers 
die zijn asociale levenshouding aanvaarden, hem bijstaan in zijn wanhoop en hebben leren 
leven met zijn humeurigheid. In het geval van een promotie van achter de geraniums is er 
echter sprake van een heel andere medewerker en wel mijn vrouw Ursula die al deze 
ongemakken niet alleen in kantooruren maar 24 uur per dag heeft moeten dragen. Aan haar 
dus in de eerste plaats veel dank. 
Het is goed te zien hoe de oude “GE centrale” zich heeft ontwikkeld tot een van de top, zo 
niet dé top MDL afdeling in Nederland. Dit is het werk geweest van mijn promotor, Professor 
Dr. Ernst Kuipers.  
Beste Ernst, ik ben jou dank verschuldigd dat jij mij ondanks mijn wijsneuzerigheid toch hebt 
toegelaten op jouw afdeling en je bovendien hebt ingezet om deze onconventionele promotie 
mogelijk te maken. Daarbij hebben jouw aanmoedigingen en geloof in de goede afloop een 
grote rol gespeeld. Bovendien heeft jouw enorme ervaring als reviewer mij al voor menig 
medisch-literaire misstap behoed. Voor dit alles mijn dank. 
Deze geranium reeks was nooit op gang gekomen zonder de deskundige statistische hulp van 
Dr.Wim Hop die zich indertijd ook belangeloos heeft gebogen over de andere artikelen van 
Clarisse Böhmer die de basis vormen van hoofdstuk 2. Bovendien wees jij mij de weg naar 
collega statisticus Ir.Caspar Looman. Voor dit alles mijn dank. 
Caspar, zonder jouw bijzondere kennis en vaardigheden zouden niet alleen dit proefschrift, 
maar een kast vol proefschriften nooit zijn ontstaan. Het is niet overdreven te stellen dat ik jou 
de getallen aandraag, dat jij er vervolgens wetenschap uit distilleert en ik vervolgens als ghost 
writer het verhaal opschrijf, want schrijven is het enige waar jij geen zin in hebt. Caspar, het 
is onmogelijk jou afdoende te bedanken voor wat je hebt gedaan, niet alleen voor dit boekje 
maar ook voor mijn wetenschappelijke ontwikkeling. 
Een belangrijke prikkel voor het wekelijkse bezoek aan de afdeling is de Barrett club van    
Dr. Peter Siersema. Peter, wij kennen elkaar al heel lang en hoewel de rollen nu zijn 
omgekeerd blijven onze literaire relaties intact. Ik ben erg trots op de manier waarop jij 
gedurende het interregnum de gastroenterologische wetenschap draaiend wist te houden en 
erg blij dat het mogelijk is gebleken jouw aandacht van de porphyrie naar de Barrett 
oesophagus te verplaatsen. Als co-promotor heb jij jouw rol als bad cop zeer beschaafd 
ingevuld. Voor dit alles dank. 
Dankzij de uitvinding van de PC heeft de leescommissie het niet makkelijk gehad. 
In de eerste plaats wil ik Professor Dr. Guido Tytgat danken. Guido, jouw aanwezigheid als 
gastroenterologische wereldster op mijn promotie is alleen al een hoogtepunt. Nadat je de 
Nederlandse gastroenterologie op de kaart hebt gezet heb jij mij, om nog steeds 
onbegrijpelijke redenen, voorzitter van de door jou tot wasdom gekomen Nederlandse 
Vereniging voor Gastroenterologie  benoemd  en daarmee een van de aangenaamste perioden 
van mijn leven ingeluid. Mijn dank voor jouw huidige en vroegere inspanningen. 
Professor Dr. Huug Tilanus, beste Huug, jij bent  de huidige vertegenwoordiger van de reeks 
van Rotterdamse hoogleraren in de chirurgie die ik als kleine ondernemer  binnen het 
academisch ziekenhuis altijd  tot mijn beschermheren heb mogen rekenen. Ik heb altijd diepe 
bewondering gehad voor jouw fantastische chirurgische vaardigheden gekoppeld aan een zeer 
onchirurgische bescheidenheid. Jouw magistrale boek over de Barrett oesophagus was voor 
mij steeds een vruchtbare bron voor op z’n minst geestelijk plagiaat. Ook hiervoor  mijn dank 
Professor Dr. Jan Willem Coebergh, beste Jan Willem, zelden zal een zeer vreemde eend zo 
goed in een bijt ontvangen zijn. Jouw inspirerende stroom van totaal anders gerichte 
conclusies en denkrichtingen heeft mij geleerd dat de epidemiology nog veel ingewikkelder is 
dan ik al vreesde en dat ik nog veel moet bijleren voordat ik de door jou in het vooruitzicht  
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gestelde titel van Epidemioloog  posthuum  zal kunnen aanvaarden. Mijn dank voor je inzet 
en wijze lessen. 
Zelfs een amateur epidemioloog heeft een laboratorium nodig, dankzij de deskundige inzet 
van Dr. Hanneke van Vuuren en de ijver van Martine Ouwendijk konden de soms slordig en 
onduidelijk benoemde plasma monsters uit diverse bloedbanken toch tot ordentelijke lijst 
Helicobacter pylori serologie uitslagen worden omgetoverd. 
Tenslotte de Barrett club. Deze groep jonge enthousiaste onderzoekers, post-docs, AIOs en 
studenten werd opeens met en opa-figuur geconfronteerd die bovendien iets met Peter had. 
Alle reden voor wantrouwen, maar integendeel, ik mag mij nu hopelijk als lid beschouwen 
van deze elite groep. Zo ja, mijn hartelijke dank.  
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